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Abstract
Visceral leishmaniasis is the second largest parasitic killer in the world (after 
malaria) with 59,000 deaths annually. The parasite resides in macrophages, within a 
compartment called the parasitophorous vacuole, but many anti-leishmanial drugs are 
toxic and poorly effective due to the low concentrations attained in this compartment. 
Therefore, the aim o f this study was to establish the basis for design o f N-(2- 
hydroxypropyl)methacrylamide (HPMA) copolymer-drug conjugates that would target 
the parasitophorous vacuole, with potential to deliver improved treatments for 
leishmaniasis. Mannose was selected as a ligand for macrophage targeting and 
amphotericin B as a model drug.
First, in vitro macrophage models (RAW 264.7 and THP-1 cells) were established 
that displayed mannose receptor expression and uptake o f mannosylated 
macromolecular ligands. A library o f HPMA copolymer-mannose conjugates containing 
Oregon Green (OG) were then synthesised to define the optimal mannose loading 
needed for targeting. To define the fate o f internalised conjugates a density gradient 
subcellular fractionation method was developed for THP-1 cells. Finally HPMA 
copolymer-amphotericin B ± mannose conjugates were synthesised and their cell 
uptake, intracellular fate and preliminary haemolytic and cytoxicity profiles established.
HPMA copolymer-OG-Man conjugates with a mannose loading 2* 4 mol % 
showed significantly higher uptake by THP-1 cells. The subcellular fractionation and 
confocal fluorescence microscopy confirmed time-dependent trafficking o f such 
conjugates to late endosomes/lysosomes. Release o f free OG (as a drug model) from 
the biodegradable polymer-OG linker was seen. HPMA copolymer-amphotericin B- 
mannose conjugates were taken up 5-fold faster than the control and accumulated in the 
late endosome/lysosomal compartment. HPMA copolymer-amphotericin B- mannose 
conjugates displayed reduced haemolysis and cytotoxicity against the THP-1 cells.
This study has established methods to investigate the intracellular trafficking o f 
polymer-drug conjugates, and has demonstrated the potential o f mannose-targeted 
HPMA copolymer conjugates for effective targeting o f anti-leishmanial drugs to 
macrophages.
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LDL Low density liposomes
LPG Lipophosphoglycan
LPS Lipopolysaccharide
MA Methacrylic acid
MHC Major histocompatibility complex
MLV M ultilameller vesicles
MR Mannose receptor
MSF Medecins Sans Frontieres
MTD Maximum tolerated dose
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium
Mw M olecular weight
NADH Reduced nicotinomide adenine dinucleotide
xix
NADPH 13-nicotinamide adenine dinucleotide reduced disodium salt
NO Nitric oxide
OG Oregon green
ONp P-nitrophenol
OPM O-palmitoyl mannan
PBS Phosphate buffered saline
PEG Polyethylene glycol
PGA Polyglutamic acid
PNS Post nuclear supernatant
PAM P-aminophenyl-mannopyranoside
RBC Red blood cell
PKC Protein kinase C
PKDL Post Kala Azar Dermal Leishmaniasis
PMA Phorbol 12-myristate 13-acetate
PV Parasitophorous vacuole
RES Reticuloendothelial system
SCF Subcellular fractionation
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis
SD Standard deviation
SEM Standard error o f the mean
TBS Tris-buffered saline
TEMED N,N,N ,N’-tetra-methyl-ethylenediamine
Th- T cell helper cell type
TIF Tagged image file
TLC Thin layer chromatography
TN F-a Tumour necrosis factor-a
Tris-Base T ris(hydroxy methy l)aminomethane
Tris HC1 Tris(hydroxymethyl)aminomethane hydrochloride
Tf-TxR Transferrin Texas red
TDR Tropical Diseases Research Programme
UV Ultraviolet
VL Visceral Leishmaniasis
WHO World Health Orghanisation
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1.1 Introduction
The aim o f this study was to design and characterise targeted polymer-drug 
conjugates active against the parasitic disease leishmaniasis. Visceral 
leishmaniasis (VL) belongs to a group o f diseases broad in distribution and 
phenotype. They are known by an equally broad group o f names such as Baghdad 
Boil, Valley Sickness, Espundia, White Leprosy, Dum-Dum Fever, and most 
commonly Kala Azar. Leishmaniasis was officially named after the Scottish 
pathologist William Boog Leishman in 1901 (Herwaldt, 1999), and it falls into a 
category o f what have been termed ‘neglected diseases’, i.e. those prevalent in 
developing countries that receive little research funding (Beyrer et al., 2007). 
Combined with problems such as poor diagnosis, co-infection with HIV and 
increasing resistance to current therapies, VL is becoming an increasing threat. It 
is the second largest parasitic killer in the world (after malaria) with 59,000 deaths 
annually. This leads the World Health Organisation (WHO) to classify it as a 
Class 1 disease, emerging and uncontrolled (W HO, 2001).
Leishmaniasis results from the bite o f a sandfly that transmits the 
Leishmania parasite. The parasite then infects, and resides within, the host 
macrophage cells (Alexander et al., 1999). After uptake into the macrophage, it 
lives and multiplies within a specialised vesicle called the parasitophorous 
vacuole (PV) (Courret et al., 2002). The fact that the parasite resides within such a 
protected environment presents a major obstacle to therapy. Current drugs used in 
the treatment o f VL include, as first line, long course treatments o f pentavalent 
antimonials (Pentostam, Glucantime). These are highly toxic and have shown 
growing resistance in endemic areas (Murray, 2000; Sundar et al., 2000). Second 
line treatments include pentamidine and amphotericin B (Fungizone), which have 
also shown growing resistance and high toxicity. The problems o f systemic 
toxicity and resistance have led to an interest in methods for targeted delivery of 
anti-leishmanial drugs to the macrophage.
Liposomal formulations have been explored as a means o f improving drug 
delivery, particularly for Amphotericin B (AmB) (Lopez-Berestein, 1988). 
Liposomes show increased uptake by macrophages and are the most common
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method studied for macrophage drug delivery (Ahsan et al., 2002). The liposomal 
Ambisome* has been approved for treatment o f VL and shows decreased AmB- 
related toxicity (Bern et al., 2006), however it is also the most expensive and least 
cost effective drug for VL, even where preferential pricing occurs (Vanlerberghe 
et al., 2007).
In addition to liposomes, polymers are being increasingly explored as drug 
delivery agents. A few studies have investigated poly mer-drug conjugates as an 
alternative delivery system for targeted delivery o f anti-leishmanials (discussed in 
further detail in section 1.5.3). There are several advantages o f using polymer 
conjugates for delivering anti-leishmanial agents. By targeting high drug 
concentration in vicinity o f the parasite, they can reduce non-specific toxicity and 
possibly overcome drug resistance. The polymer-drug linker can also be tailored 
to give a controlled rate o f release in the specific target cell/compartment. 
Therefore, it is hypothesised that polymers are potentially an ideal way to target 
anti-leishmanial drugs to the PV of the macrophage. To understand the scope of 
this project, it is important to understand the pathology o f Leishmania and the 
limitations to its treatment, as well as the background to drug targeting and 
polymer therapeutics. These areas will be discussed in the following sections.
1.2 Leishmaniasis
When designing a drug delivery system it is important to consider the 
various disease characteristics as these factors may affect the design. The 
following sections discuss the parasitic life cycle o f Leishmania, the disease 
complex in general and then specifically VL.
7.2.7 Epidemiology
An estimated 350 million people are at risk worldwide o f leishmaniasis 
with 12 million currently affected (Desjeux, 2001). This includes both overt 
disease and symptom-less disease. There are an estimated 1 . 5 - 2  million new 
cases o f  leishmaniasis annually, though only 600,000 are declared. Located 
mainly in tropics and sub-tropics, the disease is endemic in 88 countries on 5 
continents - Africa, Asia, Europe, North America and South America (Figure 1.1). 
The severity o f disease is highly dependent on the location and the species o f
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Figure 1.1 D istribution of Leishmaniasis worldwide and its co-infection with HIV 
(taken from  w w w .w ho.int/tdr/tropical_diseases/databases/im agelib.pl (2003).
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infecting parasite (Table 1.1). O f the 2 million new cases o f leishmaniasis 
annually, the fatal visceral form of the disease makes up 500 000, and o f these 
90% are located in only 5 countries - Bangladesh, Brazil, India, Nepal and Sudan. 
Severe epidemics periodically occur, for example in Sudan in the 1990's and 
Afghanistan in 2002.
It is accepted that the actual disease burden has been underestimated for 
many years, either due to misdiagnosis or to cases simply going unrecorded 
(Desjeux, 2001). Only in 32 o f the 88 endemic countries is it compulsory to 
declare this disease. Despite this, evidence suggests that the incidence of 
leishmaniasis may be increasing, even taking previous underestimations into 
account (Desjeux, 2001). Until now, spread o f the sandfly has been limited by its 
susceptibility to cold climates, its tendency to take blood from humans or animals 
only and its ability to support the internal development o f only specific species of 
Leishmania. The recent spread is related to increasing urbanisation and large 
population movements, as well as other environmental changes. Co-infection with 
HIV increases the risk o f infected individuals developing visceral disease, and 
therefore the mortality rate, and is a growing concern (Tremblay et al., 1996). 
Again, the spread o f co-infection is mainly restricted to developing countries. 
Therefore it is imperative that effective, safe and affordable drugs be available in 
these regions.
1.2.2 Life cycle
The complex life cycle o f Leishmania means that drug access to the 
parasite is limited, and treatment without systemic toxicity a major obstacle. 
Leishmania are parasitic protozoa with a life cycle involving two distinct 
morphological forms o f the parasite, the promastigote in the vector, and the 
amastigote in the vertebrate or mammalian host (Figure 1.2) (Alexander et al., 
1999). The promastigote is an extracellular, elongated, motile flagellate form, 
about 10-20 pm long. The amastigote is a round, non-motile, predominantly 
intracellular form, about 3-7 pm in diameter. The chang in morphology, as well as 
the various locations inhabited, impacts on the susceptibility o f the parasite to 
therapy.
The female phlebotomine sand fly acts as a vector, becoming infected 
when feeding on the blood o f an infected human or animal reservoir (Bates,
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Table 1.1 Species, geographical distribution and disease type of Leishmania parasite1.
Subgenus Complex Subspecies Geographical Distribution Disease Type
Leishmania Leishmania donovani L. donovani China, India, Iran, Sudan, Kenya, Ethiopia Visceral
L. infantum Mediterranean Basin, Central and West Asia Visceral
L. chagasi Brazil, Columbia, Venezuela, Argentina Visceral
Leishmania Leishmania tropica L. minor Mediterranean Basin, Afganistan Cutaneous
L. major Central and West Asia, W. N. and Central 
Africa
Cutaneous
Cutaneous
L.aethipica Ethiopia, Kenya
Leishmania Leishmania mexicana L. mexicana Mexico, Honduras, Guatemala Cutaneous
L. amazonensis Amazon Basin Cutaneous
L.pifanoi Venezuela Cutaneous
Vianna Leishmania L. braziliensis Brazil, Peru, Ecuador, Columbia, Venezuela Cutaneous/mucocutaneous
hraziliensis L.guyanensis Guyana, Brazil, Venezuela Cutaneous
L.panamensis Panama, Columbia Cutaneous
L.peruviana Peru Cutaneous
A dap ted  from ‘Bates et al., 2007’
The sandfly ingests parasites  
w hen taking a blood meal 
from reservoir host e .g  
human, rodent, dog.
>
The am astigote transforms 
rapidly to prom astigote form 
and attaches to gutwall of 
sandly.
"N
Inside the m acrophage, the 
parasites transform into 
am astigtes, replicate inside the 
PV until the cell ruptures and 
they are released  into 
bloodstream .
* _________________
W hen bitten by the sandfly, 
the promastigote is
transferred to the host, and 
rapily taken up by the 
m acrophages.
 J
Figure 1.2 The dimorphic life cycle of the Leishmania parasite. Stages include 
infection o f its reservoir host and transmission via the sandfly to the human host. 
Photos were reproduced from www.who.int/tdr/tropical_diseases/databases/imagelib.pl 
(2003), (a) Phlebotomus sandfly WHO/TDR/Stammers, (b) promastigotes
WHO/TDR/Pasteur Inst., and (c) macrophage infected with amastigotes
WHO/TDR/Behin.
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2007). It ingests either infected macrophages, or released amastigotes in the 
circulation. Once released in the stomach o f the insect, the amastigotes almost 
immediately transform into the non-infective procyclic promastigote form. They 
then migrate to the alimentary tract, where they live extracellularly and multiply 
by binary fission, avoiding expulsion from the midgut by attaching themselves to 
the gut wall. After a period o f 4-25 days the parasite transforms from the dividing 
non-infective procyclic promastigote to a non-dividing infective metacyclic stage. 
This process is known as metacyclogenesis (Sacks, 1989). The metacyclic form is 
unable to attach to the gut wall and so migrates to the mouthparts (proboscis). 
Maximum infectivity coincides with the sandfly taking its next blood meal. It 
regurgitates between 1-1000 promastigotes with saliva into the haemorrhagic pool 
formed by lacerated blood vessels and saliva hyaluronidase. The short length o f 
the proboscis determines that only the superficial vessels o f the dermis, at the 
dermal-epidermal interface, can be reached.
Promastigotes rapidly parasitise the reticulo-endothelial system (RES) o f 
the host. They are phagocytosed by host macrophages, inside which they revert to 
the amastigote form. Here they replicate by binary fission until the macrophage is 
ruptured and the amastigotes are released. Once in the blood stream they can then 
infect other macrophages, and are also available for vector uptake and 
transmission, thus completing the cycle (Amer & Swanson, 2002). The different 
forms o f  the parasite have different susceptibilities to drugs, which often work on 
the promastigote or amastigote only. If we are to effectively design drug 
conjugates targeted to the intracellular compartments o f the macrophage, we need 
to ensure they are effective against the amastigote form primarily.
1.2.3 Pathology
The various species o f Leishmania produce very different phenotypes, which 
are likely to necessitate specific therapies, as drugs may be active against only 
certain species and require targeting to different sites. The phenotype varies from 
the very mild cutaneous form to the fatal visceral form (Murray et al., 2005). The 
manifestations and outcome depend not only on the infecting species, but is also 
modulated by the host immune response. There are over 30 species o f 
Leishmania, categorised into two subgenera that infect mammals, Leishmania 
leishmania and Leishmania vianna (Banuls et al., 2007). The L. leishmania group
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are primarily located in the Old World and transmitted by Phlebotomus sand fly 
species, whereas L. vianna is predominantly in the New World, transmitted by the 
Lutzomyia species. The disease complex can be broadly categorised into three 
types.
Cutaneous leishmaniasis is the most common form (Figure 1.3a). It is confined to 
the dermis, usually involving a self-healing lesion, although it can present as a 
relapsing ulcer, or spread to other cutaneous areas of the body. The 
mucocutaneous form initially appears as a single dermal lesion then multiple 
lesions that undergo extensive ulceration (Figure 1.3b). After a variable period it 
will spread to the cartilage and other connective tissues o f the nasopharynx, 
causing extensive tissue destruction and disfiguration. The more serious cases are 
often fatal.
Visceral leishmaniasis is the most serious form, most commonly known as 
‘kala a za r\ This is where treatment is most clearly needed, and where a targeted 
therapy could be most effective (Figure 1.3c). Subspecies o f the Leishmania 
donovani complex cause systemic infections, resulting in intermittent fever and 
dysfunction o f the liver, spleen, bone marrow and lymph nodes. The 
manifestations usually appear within 3 months o f infection. Fever is the most 
common symptom, accompanied by tachycardia, and frequently by diarrhoea and 
cough. The spleen and liver enlargement is dramatic, and there is often immune 
complex glomerulonephritis and interstitial nephritis. The later manifestation o f 
hyperpigmentation gives the name 'kala azar' or 'black fever' in Hindi. The 
fatality rate o f untreated cases exceeds 80%, but the response to available drugs in 
non-resistant cases is relatively good. Later relapse occurs in ~ 3 - 10% o f 
patients, presenting as the cutaneous form 'post kala-azar dermal leishamaniasis' 
(PKDL). This then acts as a readily accessible infection source for the vector.
As VL is caused primarily by the subspecies o f Leishmania donovani it 
was therefore decided here to concentrate on this species. Each species has 
different survival strategies and mechanisms within the host, which may be 
relevant to choice o f therapy. Therefore the following section will concentrate on 
studies on the L. donovani species.
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(a) C utaneous leishm aniasis  
- single lesion
(b) M ucocutaneous leishm aniasis  
- nasopharangeal t issue  distruction
(c) Visceral leishm aniasis  
- sp len om ega ly
Figure 13  The three m ajor clinical manifestations of leishmaniasis. Photos 
were reproduced from www.who.int/tdr/tropical_diseases/databases/imagelib.pl 
(2003), (a) WHO/TDR, (b) WHO/TDR/Crump, (c) WHO/TDR/Crump.
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1.3 Parasite invasion and survival
Leishmania parasites have evolved to both evade and take advantage o f the 
immune response o f the host (Cunningham, 2002). The parasite evades and/or 
survives the humoral response by living in the macrophage, and also survives the 
cellular response o f the macrophage phagosome (Awasthi et al., 2004). The 
activity o f the polymer conjugate will, in part, depend on its intracellular 
trafficking in relation to the parasite.
1.3.1 Extracellular survival
Unique parasite membrane glycoconjugates are key to survival both inside 
and outside the macrophage cell (Ilg, 2000). Promastigotes have a unique 
lipophosphoglycan (LPG) molecule on their cell surface. They express large 
amounts o f LPG as well as other gly coconjugates, such as gp63, on their surface, 
thought to protect the parasite from hydrolytic enzymes in the sandfly gut. In 
order to avoid being excreted after digestion o f the blood meal, procyclic 
amastigotes attach to the midgut epithelium through binding interactions 
involving LPG with lectins in the gut. As it differentiates into the metacyclic 
form, extensive structural modifications, involving its size and the expression o f 
terminally exposed sugars, are made to the LPG molecule, reducing the binding 
affinity for lectins. This leads to detachment from the gut wall, and migration to 
the pharynx.
Once transmitted to the vertebrate host, the parasite must avoid destruction 
by the immune system while transiently in the bloodstream. The first attack is by 
complement. Metacyclic promastigotes not only resist lysis by complement but 
also use it to gain entry into the macrophage. L. donovani metalloprotease gp63 
helps prevent complement-mediated lysis and enhances promastigote uptake by 
cleaving C3b to C3bi, an opsonin that binds the macrophage complement receptor 
CR3 (Brittingham et al., 1995). Also, sandfly saliva contains a peptide called 
maxadilan. This has been suggested to inhibit the lipopolysaccharide (LPS) 
stimulated macrophage from producing tumour necrosis factor-a (TN F-a) and 
nitric oxide to kill the parasite (Morris et al., 2001). Once inside the macrophage, 
a variety o f protection mechanisms are employed to keep the parasite hidden from
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the immune system, and protected from destruction.
1.3.2 The Macrophage
To develop a rationale for the design o f macrophage targeted polymer-drug 
conjugates it is important to review the current knowledge o f macrophage biology 
and the relationship with the L. donovani parasite. Life within the macrophage 
enables Leishmania to remain hidden from the host immune system, and 
consequently also results in protection from any drug given systemically. The 
macrophage plays a very important role in the innate immune system and this role 
is what has enabled its parasitism (Amer & Swanson, 2002; Berman et al., 1979; 
Gordon et al., 1992). Macrophages are phagocytes responsible for removing 
senescent, dead and damaged cells, and are unique in being able to ingest large 
microorganisms such as protozoa. They also act as antigen presenting cells, 
signalling and activating other immune cells.
The tissue macrophages form a network called the reticuloendothelial 
system found in a number o f organs. They exhibit a large degree o f phenotypic 
heterogeneity and include the Kupffer cells in the liver, the intraglomerula 
mesangium o f the kidney, the alveolar macrophages in the lung, the serosal 
macrophages, the brain microglia, the spleen sinus macrophages and the lymph 
node sinus macrophages. Macrophages, as part o f the innate immune system, are 
professional phagocytes. The size o f the phagosome is determined by the size of 
the ingested particle and can be almost as large as the cell itself. To initiate 
phagocytosis by resident macrophages (constitutively in the tissue) or recruited 
macrophages (monocytes recruited from circulation that are then triggered to 
differentiate), the cell must be 'triggered' by ligation o f its receptors (Aderem & 
Underhill, 1999b). The mechanisms o f uptake and the resulting vacuole are 
discussed in sections 1.3.4 and 1.3.5.
Numerous receptors are involved in macrophage phagocytosis, recognising 
both endogenous and exogenous ligands. Altered host cells, apoptotic or infected, 
are recognised by scavenger-type receptors, which suppress or induce 
inflammatory responses, though by incompletely understood mechanisms 
(Pluddemann et al., 2007). Endogenous ligands recognised by macrophage
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receptors include modified lipoproteins, lysosomal hydrolases, heat-shock 
proteins, and proteinase complexes, therefore playing a major role in tissue 
homeostasis. Exogenous ligands, such as those on micro-organisms, are 
recognised by receptors that either recognise opsonins that coat the molecule, such 
as antibody, complement and LPS-binding protein; or that directly recognise 
ligands such as carbohydrates, proteins, lipids and nucleic acids (Linehan et al., 
2000); or both. These receptors include the Fc receptor, complement receptors 
(CR), and the mannose receptor; which bind ligands such as immunoglobulin, 
complement and glycoproteins (Table 1.2).
1.3.3 The mannose receptor
The mannose receptor (MR) is a promising target for macrophage delivery, 
and certainly the most widely used. It is also an important method o f entry for the 
Leishmania parasite into the macrophage. The MR is one o f the best characterised 
o f the macrophage receptors, first discovered in macrophages (Pontow et al., 
1992), then dendritic cells (Sallusto et al., 1995). It is a 165 kD type 1 
transmembrane glycoprotein with 8 C-type lectin carbohydrate-recognition 
domains (CRDs), a fibronectin-like domain, and a cysteine-rich domain (Figure 
1.4) (Stahl, 1992). The long cysteine rich ‘tail’ binds calcium and is known to be 
critical for MR-mediated endocytosis and sorting in the endosome (Schweizer et 
al., 2000). The CRDs bind sugar residues with varying affinities: L-fucose > D- 
mannose > N-acetyl-D-glucosamine » >  D-galactose (Kery et al., 1992; Stahl, 
1992). Leishmanial membranes express all o f these sugars, in particular mannose- 
rich glycoconjugates. The high binding affinity for oligosaccharides is generated 
by cooperative binding o f several CRDs, although CDR4 is the only one able to 
mediate mannose binding alone (Linehan et al., 2000).
The MR is expressed almost exclusively by macrophages, plus dendritic 
cells (which can also be infected by Leishmania) and selected endothelial cells, 
but not by their precursor monocytes or other immune cells such as neutrophils. 
Binding o f the receptor mediates endocytosis and phagocytosis o f mannosylated 
ligands, including microbial ligands and endogenous ligands such as lysosomal 
hydrolases, tissue plasminogen activator, myeloperoxidase, thyroglobulin 
(Gordon, 2003). The receptor binds ligand at the cell surface in a Ca++ dependent
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Table 1.2 Receptors expressed on human macrophage cells.
Receptor Expression Specificity Reference
p-Glucan Macrophage p-Glucan (fungal cell walls) Adachi et al., 2004
/ Dectin-1 Neutrophil, dendritic cell
CR3 / MAC-1 Monocyte/macrophage p-Glucan, some mannose and N-acetyl-glucosamine Ehlers, 2000
Natural Killer, neutrophil containing oligosaccharides
Galectin-3 Monocyte/macrophage Galactose bearing oligosaccharides Sano et al., 2003
Epithelial
Mannose Macrophage Mannose, fucose and N-acetyl-glucosamine Wileman et al., 1986
Dendritic containing oligosaccharides
Lymphatic and Synusoidal endothelium
NKCL Monocyte /macrophage Mannose Fernandes et al.,
Neutrophils 1999
Sialoadhesin Tissue macrophage Oligosaccharides terminating in sialic acid Hartnell et al., 2001
Collectin / C 1 q Leukocytes C lq , mannose binding protein, SP-A, conglutinin Malhotra, 1993
Platelets
Endothelium
Cystein-rich domain
Fibronectin Type II 
domain
C-Type Lectin domain with 8 
carbohydrate recognition 
dom ains (CRDs)
Plasm a m em brane
8 Cnrmmnn
5
7
Figure 1.4 D iagram  of the structure of the m annose receptor.
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manner, and becomes uncoupled from the receptor in the sorting endosome, the 
receptor being recycled back to the surface. Ligands are directed to the lysosome 
for degradation. The newly synthesised receptor has a half-life o f 33 h and is 
recycled hundreds o f times before being degraded (Lennartz et al., 1989).
The normal level o f cell surface expression is in the region o f 100,000 MR 
per cell, plus an additional 400,000 intracellularly (Shepherd et al., 1990). MR 
expression is mediated by a number o f factors. It is not present on freshly isolated 
blood monocytes but starts appearing after 3 days o f cell culture. The Leishmania 
infection rate increases with days o f incubation with a differentiation promoter 
(phorbol myristate acetete (PMA)) (Rouleux-Bonnin et al., 1995). This correlated 
with increasing expression o f receptors involved in Leishmania phagocytosis, 
such as MR.
Expression is increased by drugs such as dexamethasone, and by vitamin 
D. MR mediated endocytosis is induced by the cytokines interleukin (IL) -4 and 
IL-13, and downregulated by interferon-y (IFNy) and IL -10 (Stahl, 1992). 
However, cytokine-mediated effects on MR expression are complex. A study by 
Raveh and colleagues showed an increase in M R-dependent phagocytosis in THP- 
1 macrophage cells by the cooperative effect o f  IFNy and IL4, despite opposing 
effects on surface expression (Raveh et al., 1998).
Though activation by microorganisms is thought to decrease expression o f 
the MR, the relationship is complicated. Rabinovitch et al. (1985) found no 
difference in MR-mediated uptake between L. mexicana amazonensis infected and 
non-infected macrophages in vitro. However, in a second study, L. donovani 
infection o f macrophages resulted in a 50% reduction in surface receptors (Basu et 
al., 1991). This appeared to have a direct correlation with the parasite burden, as 
expression decreased with time o f infection. However, it has also been shown that 
when MR expression was reduced by IFNy, MR-mediated phagocytosis was 
conversely upregulated (Marodi et al., 1993). The picture is complicated by the 
fact that MR cannot mediate phagocytosis alone, requiring co-receptors (Le Cabec 
et al., 2005). Downstream effects o f ligation depend on the differentiation stage o f 
the macrophage, and the type o f ligand. This may have implications for targeting. 
MR uptake is dissociated from macrophage activation and therefore could be
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considered a ‘safe’ method o f entry for Leishmania and a suitable receptor for 
drug targeting.
1.3.4 Endocytosis
The Leishmania parasite enters the macrophage by receptor-mediated 
phagocytosis, one route being via the MR (Handman & Bullen, 2002). The 
polymer-drug conjugate can also be targeted to the MR, however once 
internalised it may or may not localise to the same intracellular compartment as 
the parasite. It is therefore essential to understand the complexities o f the 
endocytic process, and it will be important to study the trafficking o f the polymer- 
drug conjugates. Endocytosis is a general term used to describe the internalisation 
o f plasma membrane with extracellular material and/or extracellular fluid 
enclosed in a vesicle (Mukherjee et al., 1997). The process is complex but can be 
divided into two categories: pinocytosis and phagocytosis (Figure 1.5).
Pinocytosis literally translates as 'cell drinking' and describes the uptake o f 
soluble material and extracellular fluid that occurs in all cell types. Pinocytosis 
rates vary hugely with cell type and include fluid-phase uptake o f molecules in 
solution, adsorptive uptake involving molecules binding non-specifically to the 
cell membrane e.g. polar molecules; as well as specific receptor-mediated uptake 
e.g. transferrin by the transferrin receptor. It is actin independent. Polymer 
conjugates have been shown to be primarily taken up by pinocytosis, either fluid- 
phase, non-specific absorptive or receptor-mediated if  a targeting residue is used 
(Duncan et al., 1981).
Phagocytosis means 'cell eating' and describes the internalisation o f 
particulate matter carried out by specialised cells, principally monocytes, 
macrophages and neutrophils (Aderem & Underhill, 1999). It is characteristically 
receptor mediated and usually occurs for particles more than 0.75 p,m in diameter. 
Phagocytosis is generally described by the ‘zipper’ analogy (Swanson & Baer, 
1995). After initial particle binding, phagocytosis requires sequential recruitment 
o f cell-surface receptors to bind the rest o f the particle surface. This results in the 
formation o f closely opposed pseudopodia extending along the particle, the 
resulting phagosome conforming to the shape o f the particle. Initiation is triggered
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N ucleus
i. Early en d o so m e - 
sorting/recycling
ii. Late en d o so m e  
iii. L ysosom e
1. P h agocytosis  of pathogen  
via pseudopodia  
2. P h agosom e  
3. P h ago lysosom e
Figure 1.5 Illustration of phagocytosis (1-3) and pinocytosis (i-iii) in the m acrophage.
The blue arrow indicates traffic between vesicles and golgi, the red arrow indicates fusion 
of lysosmes and phagosomal vesicles.
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by signals arising from receptor-ligand interaction, and is actin dependent. Altered 
host cells and microorganisms, including Leishmania parasites, are taken up by 
phagocytosis (Rittig & Bogdan, 2000).
The endocytic pathway, for simplicity, is divided into three stages; the early 
endosome, the late endosome and the lysosome, each being characterised by 
expression o f a particular set o f cell surface molecules, pH range and function. In 
reality, these vesicles form a continuous and dynamic network throughout the cell 
and defining characteristics are not absolute. Though not identical, the pathway is 
similar for pinocytosis and phagocytosis (Henry et al., 2004). In any case the 
phagocytosis and trafficking o f Leishmania is thought to be unique, and therefore 
any differences will be discussed in relation to phagocytosis o f Leishmania in the 
next section.
The early endosomal network is primarily a sorting station, either directing 
contents back to the plasma membrane, as is primarily the case for receptors; to 
the golgi, for use within the cell; or downwards along the endocytic pathway for 
degradation. Early endosomes are characterised by a pH o f ~ 5.9 - 6, reduced by 
ATP dependent H+ pumps, which causes the receptors to dissociate from their 
ligand, and the presence o f markers such as the early endosomal antigen (EE A -1), 
and Rab proteins 4 and 5 (a family o f small GTPases) (Geisow & Evans, 1984).
Transition from early endosome to the late endosome occurs via fusion 
events and acquisition o f various proteins, orchestrated by the Rab proteins. 
Maturation is accompanied by a decrease in pH to ~ 5.5 -  6, accumulation o f Rab 
7, and a loss o f ability to fuse with vesicles from the surface or other sorting 
endosomes.
Transition to the lysosome, which maintains a pH o f ~ 4.5 - 5, occurs by 
similar maturation as well as fusion with existing (dense core) lysosomes. There is 
some debate over whether these fusion events are ‘kiss and run’ events (transient 
membrane attachment for transfer) or complete fusion resulting in hybrid 
oraganelles (Luzio et al., 2007). Lysosomes contain about 40 types o f hydrolytic 
enzymes including proteinases, nucleases, glycosidases, lipases, phospholipases, 
phosphatases and sulphatases. All are acid hydrolases, i.e. work optimally in acid 
environment, and would do little damage in the neutral cytosol (pH 7.2).
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The lysosome is responsible for the degradation o f macromolecules, after 
which the final products e.g. amino acids, sugars, and nucleotides are transported 
to the cytosol, excreted or released by the cell. Undegradable particles are retained 
in lysosomes forming residual bodies. It is important that drug conjugates 
delivered to the lysosome are not retained, which could lead to the development o f 
lysosomal storage disease. There is, as yet, no evidence o f this with any polymer 
drug conjugates, though none have been clinically tested for chronic 
administration.
Whether the conjugate ends up in the same compartment as the parasite will 
depend on the specific route o f entry and the trafficking pathway taken inside the 
cell. Therefore, it is important to carefully investigate the intracellular trafficking 
o f the conjugate in relation to the parasite.
1.3.5 The parasitophorous vacuole
The Leishmania-containing phagolysosome, or PV, has a distinct set o f 
characteristics in part determined by the parasite (Russell et al., 1992). Polymer 
delivery o f the drug to the PV will depend on the intracellular trafficking in 
infected macrophages and the enzyme content o f the PV. Leishmania 
promastigotes are 1 0 - 2 0  pm in diameter and are phagocytosed by the 
macrophage at the site o f infection, as well as by dendritic cells and fibroblasts. 
Released amastigotes (3-7 pm) are also phagocytosed by macrophages after the 
initial infection. Both are phagocytosed via either opsonic or non-opsonic 
receptors on the macrophage surface. Opsonisation with C3b and C3bi, which 
bind to macrophage receptors CR1 and CR3, is the predominant method by which 
the promastigote enters the macrophage (W ilson & Pearson, 1986). CR1 and CR3 
ligation promote phagocytosis without eliciting oxidative burst, and CR3 
mediated uptake inhibits IL -12 induced cell-mediated immunity. L. donovani also 
use the Fc receptor after opsonisation with immunoglobulin (Blackwell, 1985), 
and the MR, as discussed earlier.
To design a therapeutic that can target the PV, it is important to better 
understand its nature and composition. The parasite-infected phagosome generally
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matures into a phagolysosome (or PV). However, L. donovani infection delays 
maturation o f the vesicle and alters its properties, causing it to arrest in a late 
endosomal-like state. It exhibits both late endosomal and lysosomal 
characteristics. The pH is ~ 4.7 -  5.2, and it contains the lysosomal hydrolases 
cathepsins D, B, H and L, and the lysosome-associated membrane proteins 
LAMP-1 and LAMP-2, ATPase and major histocompatibility complex (MHC) 
class II (Antoine et al., 1998; Courret et al., 2002; Henry et al., 2004).
The Leishmania-containing PV exhibits a number o f features that enable 
and enhance survival. L. donovani is thought to delay phagosome-endosome 
fusion by reducing fusogenic properties o f the membranes to allow time for 
amastigote differentiation. The PV accumulates an F-actin coat instead o f 
shedding it which may physically block vesicle fusion (Lodge & Descoteaux, 
2005a). However, this appears to be transient or limited as transfer o f lysosomal 
contents has been shown in numerous studies (Berman et al., 1979; Berman et al., 
1981; Weldon et al., 1983) The parasite is also able to either withstand or inhibit 
the enzymes present in phagosomes (Lewis & Peters, 1977). The Gp63 protease 
on the Leishmania membrane exhibits optimal activity under acidic conditions 
and can actually degrade lysosomal enzymes (Chaudhuri et al., 1989; Lewis & 
Peters, 1977). LPG may act as barrier as it is highly anionic and has unique 
galactose-P 1,4-mannose linkages within the repeating units, rendering it resistant 
to lysosomal enzyme (Lodge & Descoteaux, 2005b; Lodge et al., 2006). LPG can 
also bind calcium and impairs signal transduction (protein kinase C (PKC) 
activation) and hence may prevent activation o f the macrophage. As the 
parasitophorous vacuole has the characteristics o f a late endosomal vacuole it 
would be expected to allow MHC class II presentation. MHC class II is expressed 
but presentation by infected macrophages decreases rapidly with time post­
infection with L. donovani and correlates with transformation to the amastigote 
form (Lang et al., 1994). It also suppresses expression o f B7-1 co-stimulatory 
molecule.
The overall clinical outcome o f Leishmania infection is highly dependent 
on the cytokine response (Awasthi et al., 2004). IL -12 production stimulates a T 
helper cell type 1 (T h l) response and induces nitric oxide killing o f  the parasite.
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However, if  IL-4 is produced a Th2 response is elicited and the host is left 
susceptible to infection (Miralles et al., 1994). The principle mechanism for 
killing the Leishmania parasite is nitric oxide (NO). Although there are 
differences in response between infecting species, the requirement for IFNy is a 
constant. If IFNy is present before infection, macrophages are stimulated to 
produce NO, but if  infection occurs first, NO production is inhibited. The 
microbicidal oxidative burst has also been shown to be suppressed by LPG 
(Lodge & Descoteaux, 2005b; Lodge et al., 2006). As stated earlier, the response 
is dependent on both host genetic factors and the infecting species, though the 
exact mechanisms are not wholly elucidated. Amastigotes have been shown to 
downregulate macrophage IL-12 production (Carrera et al., 1996). L.donovani 
also induces IL -10, which suppresses macrophage activation, cytokine production 
and expression o f co-stimulatory molecules (Bhattacharya et al., 2001). A 
diagrammatic view o f the uptake into the PV and subsequent modulation o f the 
immune response is shown in Figure 1.6.
Combined, these strategies enable Leishmania  to parasitise the host 
successfully and establish disease. To successfully treat leishmaniasis, new 
therapies, whether small molecules, liposomes or polymer-drug conjugates, must 
be taken up by macrophages, gain access to the PV and be active against the 
amastigote form. Current therapies and new strategies that have informed this 
work will be discussed below.
1.4 Anti-leishmanial therapy
The limitations o f current therapies highlight the need for new therapies, 
and the potential importance o f drug targeting to reduce toxicity and potentially 
overcome resistance. The following section describes commercially available 
drugs, those in pre-clinical development, and the most promising drug or drug 
combinations for delivery using polymer-drug conjugates.
1.4.1 Diagnosis and prevention
Early diagnosis is essential in the control o f leishmaniasis. Diagnosis is 
laboratory based and therefore often impractical and unreliable in rural areas. The 
gold standard is parasite diagnosis from a biopsy (e.g. bone marrow) though PCR
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based techniques are increasingly prevalent (WHO, 2001). Vector and reservoir 
control have also been tried with some success (Kishore et al., 2006). Insecticide 
impregnated bednets can be effective and efforts to improve these strategies are 
underway.
Traditionally, in hyper-endemic areas, pus from lesions has been used to 
inoculate susceptible young children against future infection, indicating the 
potential o f an anti-leishmanial vaccine. Both killed and subunit recombinant 
vaccines have been tried with limited success. As a Thl response has been shown 
to be protective in animal models (M iralles et al., 1994), addition o f Thl-driving 
adjuvants such as leishmanial antigens, or cytokines such as IL -12 may boost a 
vaccine (Skeiky et al., 1998). Recently, a chimeric vaccine made o f a fusion 
protein o f these three recombinant leishmanial antigens (LelF, LmSTI-1 and 
TSA) combined with monophosphoryl lipid A has undergone successful phase I 
clinical trials (Fujiwara et al., 2005). Leishmune is the first licensed vaccine 
against canine VL (an important reservoir for VL), and contains the L. donovani 
MR ligand (Saraiva et al., 2006). However, the number o f different 
species/subspecies may mean development o f a ‘universal’ vaccine could be 
difficult to achieve. At the moment, there is no human vaccine available, so 
chemotherapy remains the main defence strategy (Chappuis et al., 2007).
1.4.2 Currently used anti-leishmanial therapies
Table 1.3 shows the drugs, their mechanism o f action and their 
recommended dosages, and Figure 1.7 shows their chemical structure. The first 
successful treatment o f  leishmaniasis was by Vianna in 1912 (Mishra et al., 2007). 
He employed the toxic antimony compound, potassium antimonyl tartrate ('tartar 
emetic') in mucocutaneous leishmaniasis cases. Subsequently this compound was 
used against the more dangerous visceral form and controlled the extensive 
epidemics in Assam in 1915 (Dye & Wolpert, 1988). Antimonials are still the 
main treatment for leishmaniasis, with sodium stibogluconate (pentostam) and 
meglumine antimonate (glucantime) being first line treatments. However, 
resistance is now widespread in some areas.
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Table 1.3 Current anti-leishmanial drugs, their mechanism of action and suggested dosage7.
Drug Mechanism of action Dosage
Meglumine antimoniate Acivated in amastigote by conversion to trivalent form. MoA 20 m g/kg '/day’1 IV/IM
Sodium stibogluconate unknown. 20 -  28 days
Amphotericin B Complexes with ergosterol in parasite membrane, causing pore 1-3 mg/kg*'/day'1 IV
formation leading to ion imbalance and death. 20 days
Ambisome As above, plus enhanced uptake into macrophages and 2 m g/kg''/day'1 IV
intracellular release. 3 days
Pentamidine Uncertain but can bind to kinetoplast DNA 2 - 4 m g/kg '/day '1 IV/IM
Alternate days for 15 days
Paromoycin (phase III) Thought to bind to 30S subunit o f ribosomes, causing misreading 15 m g/kg''/day'1 IM
and termination o f protein synthesis. 21 days
Miltefosine (phase IV; Possible inhibition o f phospatidylcholine biosynthesis, signal 2.5 mg/kg’ '/day*' orally
registered in India) transduction and calcium homeostasis. 28 days
A d ap ted  from ‘Mishra et al., 2007
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Figure 1.7 Chemical structure of current anti-leishmanial drugs.
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The diamidines have reasonable tolerability, the preferred drug being 
pentamidine, and are generally used as second line treatment. Unfortunately 
pentamidine has greater toxicity, common side effects and resistance has 
developed in parts o f  India, leading to its abandonment in this area (Jha, 1983).
Most recently, the polyene macrolide antibiotics have been employed, 
amphotericin B (AmB) being most predominant (Giri, 1994). AmB consists o f a 
glycosidic molecule containing a large lactone ring linked to an amino sugar, 
mycosamine. Its mechanism o f action involves increasing cell membrane 
permeability leading to loss by leakage, first o f ions, then other cellular contents. 
It binds to ergosterol in the parasite membrane, forming pores, and leading to cell 
death. However, use is limited by the drugs systemic toxicity (it is the most toxic 
antibiotic available for clinical use) to those cases that are refractory to both the 
antimonials and pentamidine.
Paromomycin is an aminoglycoside antibiotic, and acts by binding to 
ribosomes, inhibiting protein synthesis and causing misreading and premature 
termination o f  mRNA translation. It is used as an affective alternative to, or in 
combination with, antimonials, as a topical ointment for treatment o f cutaneous 
disease. It was approved in India for injectable treatment o f VL in 2006 (Sundar et 
al., 2007). However it is less active against VL than AmB and pentamidine 
(Thakur et al., 2000).
An orally administered drug, miltefosine, is in advanced clinical trials, 
with promising results, and was registered in India in 2002 (Sundar et al., 2006; 
Sundar et al., 1998). However, it has a small therapeutic window and there are 
implications in women o f childbearing age due to teratogenic effects (Murray,
2000). It has a long half life (~ 150 h) and resistance is easily induced in vitro 
(Perez-Victoria et al., 2006).
Successful chemotherapy cannot be guaranteed for any form of 
leishmaniasis with the present limited range o f available drugs. All are toxic, and 
most have the disadvantage o f requiring parenteral administration and 
hospitalisation. There is no evidence o f clinical resistance to AmB as yet, however
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resistance to the other anti-leishmanials is on the increase, particularly the 
antimonials and pentamidine, as well as concerns over miltefosine (Ouellette et 
al., 2004). The response to these drugs is again dependent mainly on the strain o f 
the infecting parasite but also the degree o f host susceptibility and immune 
response. Recently there has been development o f several new drugs, and drug 
delivery strategies in an attempt to overcome these difficulties.
1.4.3 New anti-leishmanial therapies
Improved anti-leishmanial therapies. These must be non-toxic, highly 
effective drugs preferably administered by the oral route or as a single or low dose 
parenteral. The search has been largely unsuccessful. One exception is the 
increased activity o f AmB seen when delivered within a liposome (vesicle 
composed o f phospolipid bilayers surrounding an aqueous compartment) 
(Davidson et al., 1991; New et al., 1981; Yardley & Croft, 2000). Ambisome® is 
highly active and is well tolerated (Dupont, 2002; Yardley & Croft, 2000).
In Ambisome® AmB is intercalated into a unilamelar bilayer membrane 
consisting o f phospholipids with saturated fatty acid side chains o f hydrogenated 
soy phosphatidylcholine, distearoylphosphatidylglycerol, and cholesterol. The 
incorporation o f cholesterol stabilizes the liposome and has been postulated to 
bind to the AmB, minimising the interaction with mammalian cell membrane 
(Adler-Moore & Proffitt, 2002). It has shown no acute or chronic toxicity up to 15 
mg/ml and has a 90-100 % efficacy. However, infusion related toxicity and 
leakage o f  drugs from such systems could be problematic with AmB’s high 
toxicity. The main problem is that it is prohibitively expensive. Its increased 
efficacy and tolerance, is matched by its increase in cost. It is widely used in 
Europe but not available for most o f Asia and Africa where disease burden is 
highest. Recent cost analysis studies o f drugs for VL found Ambisome® to be the 
least cost effective treatment (Sundar & Chatterjee, 2006; Vanlerberghe et al., 
2007). A course o f conventional AmB was the most effective and costs around 
US$ 70, whereas Ambisome® costs USS 1500 (Kshirsagar et al., 2005). The 
success o f the liposomal therapy does, however, suggest a method o f reducing 
systemic toxicity by cell targeting.
Recent work has brought knowledge o f a number o f potential parasite
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specific enzyme or metabolites that could be targeted, e.g. inhibitors o f 
dihydrofolate reductase (Gilbert, 2002). Such compounds have shown activity 
against the cell-free amastigotes, but lower activity against the intracellular 
amastigotes.
A second option is to combine chemotherapy with cytokine therapy. IFNy is 
sometimes used in combination with antimonials and does increase the cure rate, 
but the cost o f such treatments is prohibitive for use in undeveloped nations (Li et 
al., 1997). Another factor to be taken into consideration is HIV co-infection. In 
co-infected individuals, cure rates drop to around 60-70 % for antimonials, AmB 
and its lipid complexes (Laguna, 2003) and also for miltefosine (Sindermann et 
al., 2004), increasing the need for new drugs.
1.5 Drug delivery strategies
It is important to bear in mind that new drug molecules will have little effect 
if they are unable to penetrate the PV. One way to ensure that drugs will cross 
host cell membrane barriers is to use a drug delivery agent that will constitutively 
enter via endocytosis rather than diffusion into the cytoplasm. The benefits o f 
using drug delivery strategies, for example liposomal encapsulation, are well 
known, including the possibility o f enhanced specificity and reduced toxicity. 
This is how Ambisome® exerts its effect and avoids systemic toxicity. Studies 
have demonstrated successful treatment o f multidrug resistant patients with 
Ambisome® (Davidson et al., 1991).
There have been several studies on drug delivery o f anti-leishmanial drugs 
(Table 1.4). Liposomes have been the most common delivery method employed, 
particularly for macrophage delivery, though other studies have included protein- 
and polysaccharide drug conjugates. The ease o f formulation and high drug 
encapsulation into liposomes has allowed a wide variety o f drugs to be delivered 
in this manner. The first studies mainly used antimonials (Black et al., 1977; New 
et al., 1978), but also, as discussed in the previous section, liposomal AmB that 
has since proved very effective (Berman et al., 1986b; New et al., 1981). Specific 
targeting has been shown to further increase uptake o f liposomes, using such 
targeting residues as parasite specific antibody (Mukherjee et al., 2004) and
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Table 1.4 Anti-cancer polymer-drug conjugates in clinical trials, their status and indication. 
Compound Clinical Status (Phase) Reference
Polyglutamate-paclitaxel (Xyotax) III Li et al., 1998
Polyglutamate-camptothecin I Bhatt et al., 2003
HPMA copolymer-doxirubicin (PK1) III Vasey et al., 1999
HPMA-copolymer-dox-galactosamine I/II Duncan etal., 1983; 1986
(PK2)
HPMA-copolymer-paclitaxel I Meerum-Terwogt et al., 2001
HPMA-copolymer-camptothecin I Caiolfa et al., 2000
HPMA-copolymercarboplatin platinate I/II Rademaker-Lakhai et al., 2004
HPMA-copolymer-DACH platinate I/II Lin et al., 2004
Dextran-doxorubicin I Danhauser-Riedl et al., 1993
Modified dextran-camptothecin I Inoue et al., 2003
PEG-camptothecin (Prothecan|) II Posey et al., 2005
DACH, diaminocyclohexane; HPMA, N-(2-hydroxypropyl)methacrylamide; PEG, poly(ethyleneglycol).
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phosphatidylserine (Tempone et al., 2004). Banerjee and colleagues tested sugar 
grafted liposomes in vivo and found mannose-grafted liposomes were the most 
efficient in comparison with either glucose or galactose-grafted ones, in reducing 
spleen parasite load (Banerjee et al., 1996). However, the combined problems of 
poor stability and high cost o f preparation mean liposomes are less than ideal as a 
drug delivery method. Also, the drugs are not covalently bound; therefore the 
release kinetics cannot be customised for specific needs.
There are now more sophisticated delivery methods being developed, and 
polymer conjugates have many advantages over liposomes, as discussed in the 
next section.
1.5.1 Polymer therapeutics
Polymer therapeutics offer great flexibility in terms o f architecture and 
loading. There is large scope for different combinations o f drugs, targeting 
residues and linkages. This enables controlled pharmacokinetics with the design 
o f agents with specific size, charge, body distribution and drug release patterns. 
This section will concentrate on polymer therapeutics, their background, 
applications and potential for anti-leishmanial therapies.
Polymers are already widely used biomedical materials in medicine, for 
example, hip prostheses, contact lenses, vascular grafts and as scaffolds for tissue 
engineering. Pharmaceutical uses include excipients in oral formulations 
(alginates, celluloses, dextrin, dextran or synthetic polymers), solubilisers in 
parenteral formulations and in controlled release products. Such polymers are 
considered inert, they are simply carriers without being covalently bound to a 
drug or exerting any biological effect themselves.
A more recent approach to the use o f polymers in pharmaceuticals has 
been to exploit the properties o f natural or synthetic water-soluble polymers for 
use as drugs or pro-drugs themselves. The idea stemmed from Christian de 
Duve’s realisation in the 70’s that drug delivery might make use o f the endocytic 
pathway (de Duve et al., 1974), termed ‘lysosomotropic drug delivery’. In 1975, 
R ingsdorf introduced the concept o f the targeted drug carrier in which water- 
soluble polymers, modified with both targeting agents and drugs, could be used to 
deliver the drugs to appropriate disease sites (Ringsdorf, 1975). The term
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‘polymer therapeutics’, coined by Duncan (Duncan, 2003), is used to distinguish 
this new class.
Defining properties o f these polymers are that they are water soluble, 
biologically active and/or covalently bound to a drug, and are usually 
administered either by intravenous or subcutaneous injection. The term ‘polymer 
therapeutics’ includes polymeric drugs, polymer-protein conjugates, polymer-drug 
conjugates, block polymeric micelles (to which drug is covalently bound) and 
multi-component polyplexes that are being developed as non-viral gene delivery 
systems (Figure 1.8). Most are designed for intracellular drug delivery, either 
lysosomotropic, diffusing out o f the lysosome, or endosomotropic, diffusing out 
o f the endosome before it reaches the lysosomal compartments, though some may 
be designed to act on the surface. Recent developments in the design o f polymer 
therapeutics have focused on increasingly complex architectures to give 
multivalent multibranched structures such as graft and block copolymers, 
dendrimers and star polymers. These new structures provide multivalent surfaces 
for attaching drugs as well as imaging agents, targeting molecules and peptide 
epitopes. However most polymer-drug conjugates have, to date, been based on 
linear polymers.
1.5.2 Polymer-drug conjugates
Although considered drug delivery agents, polymer-drug conjugates are 
defined as macromolecular drugs or pro-drugs in their own right as they are 
chemically conjugated to the drug and therefore new chemical entities. Polymer 
conjugates can be used to deliver nucleic acids, proteins and drugs. The basic 
principle is to reduce the immunogenicity or toxicity, increase the stability and 
solubility, and prevent the rapid clearance from the circulation by the RES or the 
kidney. They can also enhance targeting and site-specific delivery.
Despite a growing number o f polymer-drug conjugates now in clinical 
trials, there are none yet on the market (Table 1.5). The first polymer drug 
conjugates, developed in the early 1980’s by Duncan and colleagues, went into 
clinical trial in 1994 (Duncan, 2005; Duncan et al., 1998; Vasey et al., 1999). The 
conjugates were based on N-(2-hydroxypropyl)methacrylamide (HPMA) 
copolymers bound to the anti-cancer drug doxorubicin. The simplified structure o f
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Figure 1.8 Simplified diagram  of polym er therapeutics. Adapted from 
Duncan R., 2003 .
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Table 1.5 Examples of liposomes and polymer therapeutics for treatment of leishmaniasis reported in the literature
Type of carrier Component Targeting residue Drug Reference
Liposome - Antimonials Black et al., 1977, New et al., 1978
- Amphotericin B New et al., 1981, Berman et al., 1986
- Sodium stibogluconate Hunter et al., 1988
Mannose Piperine Raay et al., 1999
- Doxorubicin Mukherjee et al., 2004
Phosphatidylserine Sodium stibogluconate Tempone et al., 2004
Microsphere PLGA: Poly(D,L-lactide-co- 
glycolide)
• Amphotericin B Vemier-Julienne et al., 1985
Protein Maleylated BSA Maleic anhydride Methotrexate Chaudhuri et al., 1989
Mannosylated HSA Mannose Doxorubicin Sett et al., 1993
Polysaccharide Mannose substituted poly-L-lysine Mannose Allopurinol riboside Negre et al., 1992
Arabinogalactan Amphotericin B Golenser et al., 1999
Polycationic branched poly-L-lysine - Methotrexate Koczan et al., 2002
Carboxymethyldextran Mannose Pyrimethamine De Carvaho et al., 2003
Synthetic polymer Polymethacrylate Pentamidine Paul et al., 1998
Mannosylated HPMA copolymer Mannose NPC1161 Nan et al., 2001; 2004
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a targeted HPMA copolymer-drug conjugate showing the polymer backbone 
covalently bound to a drug or targeting residue via a linker, is shown 
schematically in Figure 1.9.
As the First polymer therapeutics, HPMA copolymer drug conjugates have 
been widely studied. HPMA copolymer is a synthetic water soluble polymer, first 
developed in Czekoslovakia as a plasma expander (Sterba et al., 1976). There has 
been no evidence o f accumulation with HPMA below 40 kD and it is considered 
non-toxic. It increases the water solubility o f hydrophobic drugs such as 
doxorubicin (Dox). The plasma half-life is increased leading to higher 
accumulation in target sites and reduced side effects and toxicity. The first 
polymer-drug conjugates to enter clinical trial were Dox conjugates, PK1, and the 
second PK2, which also contains a liver-targeting residue. Dox was linked via a 
peptide linker, designed to be cleaved by lysosomal enzymes.
PK1 has activity against non-small-cell lung cancer and anthracycline 
resistant breast cancer. No immunogenicity or polymer-related toxicity was seen, 
the dose-limiting toxicity being the same as that o f Dox alone. PK2 has a 
galactosamine molecule bound to the backbone, which targets liver cells by 
binding the asialoglycoprotein receptor (ASGPR) (Duncan et al., 1983; Duncan et 
al., 1986). It has proved effective against liver cancer, and is the first polymer 
therapeutic designed for receptor-mediated uptake to be tested clinically. 
Hepatoma concentrations were significantly higher than could be achieved with 
Dox alone (Seymour et al., 2002).
Most polymer-drug conjugates to date have been anticancer agents. The 
first generation were mainly anthracyclines, the second generation now entering 
clinical trials are paclitaxel and camptothecin, which are normally poorly water 
soluble and lead to hypersensitivity reactions. The HPMA-camptothecin 
conjugates produced side effects and have poor drug loading, but a polyethelene 
glycol (PEG) conjugate has provided more promising results (Caiolfa et al., 2000; 
Posey et al., 2005). PEG has not been widely used for drug conjugates as it has 
only two terminal end groups with which to bind drug, polymers with higher 
loading capacities are normally required. HPMA copolymer-paclitaxel has also 
shown dose limiting toxicity similar to paclitaxel alone (Meerum Terwogt et al.,
2001). These results likely result from the ester linkage used, which, unlike the
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Figure 1.9 Simplified structure of a polym er-drug conjugate. The diagram 
shows a linear HPMA copolymer with drug and targeting residue attached via a 
peptide linker (GFLG).
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peptide linkers designed for lysosomotropic delivery, is cleaved in the 
bloodstream. HPMA copolymer-platinates have shown good activity and reduced 
toxicity as with the Dox conjugates (Lin et al., 2004; Rademaker-Lakhai et al., 
2004). The first anti-angiogenic drug conjugate, HPMA copolymer conjugated to 
TNP-470, is now being tested in vivo (Satchi-Fainaro et al., 2004). Also, HPMA 
copolymer conjugated adriamycin has been shown to overcome multi drug 
resistance in adriamycin resistant cell lines (Minko et al., 1998).
Biodegradable polymers have also been used, for example polyglutamic 
acid (PGA), o f which there are two in clinical trial, PGA-paclitaxel and PGA- 
camptothecin (Bhatt et al., 2003; Li et al., 1998). The paclitaxel conjugate has a 
very high drug loading (37 wt %) and has shown activity against several cancers 
including paclitaxel-resistant ovarian carcinoma. Interestingly, it has shown 
greater efficacy in women. Dextran conjugates o f Dox and camptothecin have 
unfortunately shown higher toxicity than the HPMA copolymer conjugates 
(Danhauser-Riedl et al., 1993; Inoue et al., 2003).
The design o f biodegradable linkers allows the selective release o f drug 
where the therapeutic effect is required, reducing toxicity elsewhere (Duncan et 
al., 1982; Ulbrich & Subr, 2004). Linkers used should be bioresponsive, i.e. stable 
during transport through the plasma, but preferentially degraded at the target site. 
The drug must also be released in its native/active form, as any chemical 
modification o f the structure may result in loss or change o f therapeutic activity. 
There are two main types o f linkers used. Acid labile or pH sensitive linkers make 
use o f the decreasing pH o f the endosome, or the low pH associated with tumour 
tissue (the hydrazone or the N-cis-aconityl linker). Peptide linkers have been 
developed to be enzyme degradable, making use o f tumour associated enzymes, 
or lysosomal hydrolases and proteases (Duncan et al., 1980). HPMA copolymer 
conjugates are taken up by endocytosis, and trafficked to the lysosome (Duncan et 
al., 1981). PK1 and PK2 have an endocyticly cleaved linker, Gly-Phe-Leu-Gly 
(GFLG). The choice o f  linker will depend primarily on the intracellular trafficking 
o f the conjugates in the macrophage.
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1.5.3 Targeting o f  polymer-drug conjugates
Polymer conjugation allows targeting o f the drug to its site o f action, 
either by an active or passive mechanism. Passive mechanisms use 
pathophysiological properties o f the intended site; the most well documented 
being the properties o f tumour tissues. Conjugates are easily able to access the 
tumour tissue due to leaky vasculature, and are retained longer due to lack o f 
lymphatic drainage. This is termed the enhanced permeability and retention (EPR) 
effect and leads to accumulation o f drug in the tumour tissue (Matsumura & 
Maeda, 1986).
Other potentially useful properties o f tumour tissue or other pathologies 
include reduced pH or secreted enzymes. However, most disease sites do not have 
such easily exploited properties, hence most polymer therapeutics to date have 
been anti-cancer agents. Intracellular infections, such as leishmaniasis, are likely 
to require active targeting. This usually involves conjugation o f a targeting moiety 
that will bind a specific receptor on a particular cell type or tissue. If conjugates 
lack a targeting ligand they are usually internalised slowly as a solute by fluid 
phase pinocytosis, though hydrophobic polymers may interact with the plasma 
membrane in some cell types, leading to non-specific adsorptive uptake. A high 
loading o f a hydrophobic drug could increase this non-specific binding. If a ligand 
with low specificity is used, cross-reactivity o f the targeting moiety with other 
tissue may result in severe side effects. Therefore targeting to any particular site 
requires careful verification, to ensure non-specific toxicity is reduced and that 
there is no unexpected targeting to other sites.
Targeting can be achieved using a virtually infinite number o f molecules, 
but the two types that have shown most promise are antibodies and sugars, for 
example the MR discussed in section 1.3.3. PK2 has had success in clinical trials 
and is a good model for sugar targeting. Using this method o f targeting it may be 
possible to achieve higher drug concentrations in the macrophage.
1.5.4 Polymer-drug conjugates -  applications fo r  anti-leishmanial therapies
A number o f  polymers have been studied for anti-leishmanial drug delivery 
including proteins, polysaccharides and synthetic polymers including HPMA 
(Table 1.5). Those that have had most success have included mannose as a 
targeting residue. Previous studies using this sugar have shown it can selectively
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localise polymers to macrophages. Duncan and colleagues demonstrated the 
targeting effect o f  mannose conjugated to HPMA, and the concentration o f these 
conjugates in cells o f the RES in the liver and spleen (Duncan et al., 1983). They 
also showed that the increasing sugar content resulted in increased uptake 
(Duncan et al., 1986).
Most recently, Ghandehari’s group have used HPMA with mannose 
targeting residues conjugated to anti-leishmanial 8-aminoquinoline analogues 
(Nan et al., 2004; Nan et al., 2001). Though the cytotoxicity was halved compared 
to that o f free drug, the conjugates were toxic to KB cells at levels required to 
match the efficacy o f free drug. The conjugates were, however, significantly more 
effective against Leishmania in vivo compared to free drug in mice models. These 
studies demonstrate the potential o f HPMA copolymer-drug conjugates as anti- 
leishmanial therapeutics. The uptake o f polymers by endocytosis, the selectivity 
o f targeted conjugates for macrophages and the delivery o f the drug to the PV are 
o f prime importance in the design o f such therapeutics.
In summary, there are several advantages o f polymer therapeutics that make them 
a good prospect for treating leishmaniasis:
• Solubilise poorly soluble anti-leishmanial compounds.
• Can incorporate multiple drugs for combination therapy.
• Allow targeting o f macrophages, where the parasite resides.
• Enter the macrophage by endocytosis delivering a high drug
concentration in the vicinity o f the parasite.
• Could potentially overcome resistance mechanisms.
• Release kinetics can be tailored depending on the drug/drugs used and
the trafficking.
1.6 Aims of the project
There is a pressing need for new anti-leishmanial therapies, the essential 
criteria o f any new agent being the ability to gain access to the PV. One way to 
achieve this is using targeted polymer-drug conjugates. The main aim o f the work 
described in this thesis was therefore to synthesise and characterise HPMA 
copoly mer-drug conjugates with mannose as targeting residues for macrophage- 
specific endocytic anti-leishmanial drug delivery. An important part o f this work
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was to set up both the macrophage models for the targeting studies, and the 
methods necessary to study the trafficking o f the conjugates in these models.
1.7 Summary of the project
First, suitable in vitro macrophage cell models were established (Chapter 3). 
A library o f HPMA copolymer conjugates with a range o f mannose loadings were 
synthesised in order to ascertain the optimal loading for significant receptor- 
mediated uptake (Chapter 4). It was next important to investigate the intracellular 
trafficking o f the conjugates. A novel subcellullar fractionation method was 
optimised for the THP-1 macrophage cell line to study the localisation o f the 
HPMA copolymer-Man conjugates in these cells. Confocal fluorescent 
microscopy was used to support these studies and confirm the intracellular fate o f 
the conjugates (Chapter 5). To the selected conjugate the chosen model drug was 
conjugated to the polymer backbone. AmB was chosen as it has near 100% cure 
rate and resistance is rare. Though it has very high toxicity, studies have shown 
this can be overcome using drug delivery vehicles such as liposomes 
(Ambisome®). In vitro cytotoxiciy and activity in infected macrophages was 
performed (Chapter 6) with the aim o f providing candidates for further testing in 
vivo and eventually for clinical trial.
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2.1 Equipment
2.1.1 Equipment fo r  cell culture
Costar cell culture consumables (sterile flasks and plates) were supplied by 
Corning Inc, USA. Serological pipettes, Bijoux and universal containers were from 
Elkay, Ireland. Galaxy S incubators and a Procell incubator were from Wolf 
laboratories and Jencons-PLS, UK respectively. Bioair and Microflow class II 
laminar flow hoods were from Bioair, Italy and Servicecare, UK. Routine cell culture 
and counting was performed using a silver stained Neubauer haemocytometer, 
Germany, on an inverted DM IL Leica bright field microscope (Leica, Germany). 
Cell scrapers (1.8 cm swivel blade) were from Fisher Scientific, UK. A Varifuge 3.0 
RS with swing out rotor buckets (type 8080, rmax 21.1 cm) and Eppendorf 5417 R 
bench-top centrifuge with standard fixed angle rotor (model 5417 C/R) were from 
Heraeus Instruments and Eppendorf, Germany respectively. The Mr. Frosty cryovial 
container was from Wessington Cryogenics, UK.
2.1.2 General analytical equipment
Ultraviolet (UV) absorbance was measured with a sunrise UV absorbance 
plate reader from Tecan, Austria, and a Cary 1G UV-visible spectrophotom eter from 
Varian, Australia, using Cary Win UV software package for data acquisition and 
analysis. Fluorescence was measured using a Fluostar optima fluorescent plate reader 
from BMG Labtechnologies, Germany, and an Aminco-Bowman Series 2 
luminescence spectrophotometer from Spectronic instruments, USA. Thin layer 
chromatography (TLC) silica plates coated with Alugram SIL-G/UV254 were from 
Macherey-Nagel, Germany and visualised under a multiband UV lamp (254/365 nm) 
from Upland, USA.
Polymer conjugates were freeze dried before analysis using a Flexi Dry FD- 
1.540 freeze-dryer from FTS Systems, USA, connected to a DD75 double stage, high 
vacuum pump from Javac, Australia. Gravitational gel permeation chromatography 
(GPC) was performed with sephadex G25 PD10 columns that were supplied by 
Amersham Biosciences, Sweden.
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2.1.3 Flow cytometry and fluorescent microscopy equipment
Images were acquired by fluorescence microscopy using an inverted Leica 
TCS SP5 confocal microscope equipped with 40 x oil immersion objective and 
Argon (488 nm), GHe/Ne (543 nm) and blue diode (405 nm) lasers. Images were 
processed with LAS (Leica, Germany) software.
Flow cytometry data was collected on a Becton Dickenson FACScalibur flow 
cytometer equipped with an argon laser (excitation wavelength 488 nm) using 
manufacturers instructions. Logarithmic-transformed data was acquired in 1024 
channels with band pass filters FL-1 (530 ± 30 nm) and FL-2 (585 nm ± 42 nm) and 
subsequently processed with Cell Quest software (version 3.3).
2.1.4 Subcellular fractionation equipment
The automated gradient maker and piston fractionator were from Biocomp 
instruments (Canada). The samples were spun on a Beckman SW 41 TI rota 
ultracentrifuge. The refractometer was from Abbe 60/DR, Bellingham and Stanley 
Ltd. The cells were homogenised using the cell cracker from the European Molecular 
Biology Laboratory (EMBL, Germany). Ultracentrifugation was performed with a 
Beckman SW 41 TI rota on an Optima LE-80K centrifuge from Beckman Coulter, 
USA. Polyclear™ (14 x 89 mm) ultracentrifuge tubes were from Seton Scientific, 
CA, USA.
2.1.5 Western and dot blotting
All electrophoresis equipment was from Bio-Rad, UK. Protan® 0.45 p.m 
nitrocellulose membrane was from Schleicher and Schuell Biosciences, Germany. 
The Bellydancer automated shaker was from Stovall Life Science, USA.
2.2 Materials
2.2.1 General chemicals and reagents
Ethanol, methanol, acetone, ethyl acetate, hydrochloric acid, triethylamine, 
sodium hydroxide pellets, sodium chloride, disodium hydrogen orthophosphate, 
sodium dihydrate orthophosphate, citric acid monohydrate and trisodium citrate 
dihydrate were from Fisher Chemicals, UK. Dimethylsulphoxide (DMSO), triton X- 
100, ninhidrin, 4 % w/v copper (II) sulphate solution, 3-am ino-1 -propanol (AP),
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citric acid monohydrate, N-2-hydroxyethylpiperazine-N’-ethanesulphonic acid 
(HEPES), ethylenediaminetetraacetic acid (EDTA),
tris(hydroxymethyl)aminomethane (Tris-Base), p-nitrophenyl phosphate, sodium 
borate, B-nicotinamide adenine dinucleotide reduced disodium salt (NADPH), 
leupeptin, bovine serum albumin (BSA) and glycine were from Sigma Aldrich, UK. 
All other general chemicals, unless otherwise specified, were from Sigma Aldrich, 
UK.
2.2.2 Cells and tissue culture reagents
RAW 264.7, a mouse monocyte macrophage cell line (established from an 
ascites o f a tumour induced in a male mouse by intraperitoneal injection of Abselon 
Leukaemia Virus) and THP-1, a human monocytic cell line (established from an 
acute monocytic leukaemia o f a male ly r infant), were obtained in frozen ampules 
from European Collection o f Cell Cultures (ECACC) and American Type Culture 
Collection (ATCC) respectively. Dutch modified Eagles medium (DMEM) with 
glutamax (with and without phenol red pH indicator) and RPMI 1640 with glutamax 
(with and without phenol red), and foetal bovine serum (FBS) were from Invitrogen, 
UK. Medical grade CO2, N2 (95 % v/v) and liquid nitrogen were supplied by BOC, 
UK. Trypan Blue reagent, tissue culture grade DMSO, 3-(4,5-dimethylthiazol-2-yl)- 
2,5-diphenyl-2H-tetrazolium (MTT) and phorbol 12-myristate 13-acetate (PMA) 
were obtained from Sigma Aldrich, UK.
2.2.3 Chemicals and reagents fo r  flow  cytometry and fluorescent microscopy
Mannan (Saccharomyces Cerevisiae) was obtained from Sigma Aldrich, UK. 
FACS Flow, Clean and Rinse formulations and falcon FACS tubes were from 
Becton Dickenson, UK. FITC-labelled bovine serum albumin (FITC-BSA) and 
mannosylated FITC-BSA (FITC-BSA-Man) were obtained from Sigma Aldrich, UK 
and DQ-ovalbumin from Molecular Probes, UK. Mouse anti-EEA-1 antibody was 
from BD Biosciences, UK and mouse anti-transferin and anti-LAMP-1 antibody 
were from DSHB, USA. Alexa Fluor 488- and Cy5- labelled anti-mouse antibodies 
were from Molecular Probes, UK. Frosted microscope slides and 16 mm coverslips 
were purchased from Chance Propper, UK. Vectashield was obtained from Vector,
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USA and clear nail varnish from Rimmel, UK. Immersion oil was obtained from 
Leica, Germany.
2.2.4 Reagents fo r  subcell ular fractionation
Optiprep™ was from Axis-Sheild Diagnostics, UK. The protease inhibitor 
complex tablets were from Roche Diagnostics, UK. Texas Red-labelled Transferrin 
was from Molecular Probes, UK. Sucrose was from Sigma Aldrich, UK.
The following reagents for the biochemical assays; N-Acetyl-p- 
glucosaminidase (Hex A), 2-p-iodonitrotetrazolium violet (INT), 
tris(hydroxymethyl)aminomethane hydrochloride (Tris-HCl), succinic acid 
tris(hydroxymethyl)aminomethane (Tris base), p-nicotinomide adenine dinucleotide 
reduced disodium salt (NADH), pyruvic acid (crystallised monosodium salt), sodium 
citrate, citric acid, 4-methylumbelliferyl, 4-methylumbelliferyl-N-acetamido-P-D- 
glucosaminide, sodium hydroxide pellets, p-nitrophenol phosphate (aq.), sodium 
borate and magnesium chloride were from Sigma Aldrich, UK.
2.2.5 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS PAGE), 
Western and dot blot reagents
Prestained SDS-PAGE standards, broad range (7,331 -  211,806 g/mol) were 
obtained from Bio-Rad, USA. Acrylamide / Bis-acrylamide (30 % solution), 
ammonia persulphate (APS), dithiothreitol (DTT), bicinchoninic acid (BCA) 
solution, copper (II) sulfate and glycerol were purchased from Sigma Aldrich, UK. 
Coomassie brilliant blue (CB), bromophenol blue, 2-mercaptoethanol, sodium 
dodecyl sulphate and N,N,N,N’-tetra-methyl-ethylenediamine (TEMED) were 
supplied by Bio-Rad, USA. Glycine (electrophoresis grade) was from ICN 
Biomedicals, USA. Mouse anti-EEA-1 antibody was from BD Biosciences, UK and 
mouse anti-LAMP-1 antibody was from DSHB, USA. Alexa Fluor 488- and Cy5- 
labelled anti-mouse antibodies were from Molecular Probes, UK. HRP-conjugated 
anti-mouse and anti-rabbit antibodies were from Dakocytomation, UK. The 
enhanced chemiluminescence detection reagent kit was from Pierce, USA.
2.2.6 Polymers and reagents used in conjugation o f HPMA copolymer
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Batches of HPMA copolymer-GFLG-ONp containing 9.03 mol % side chains 
terminating in p-nitrophenoxy (ONp) (Batch PP10/22/277 Mw 37,427 Mw/Mn 1.58) 
were obtained from Polymer Laboratories Ltd., UK. Oregon Green (OG) 488 
cadaverine was from Molecular probes, UK. Dry triethylamine and dry DMSO were 
obtained from Sigma Aldrich, UK in sure-sealed bottles. All other reagents and 
solvents were from Sigma Aldrich, UK. Spectra/Pore 7-regenerated cellulose dialysis 
membrane (Mw cut-off 2000 g/mol) was obtained from Spectrum Laboratories Inc, 
USA.
2.3 General methods
All the general methods used in these studies are described below, however, 
where necessary, specific methods and steps taken to tailor details of the methods, 
are given in the related experimental chapters. Where the development of a method is 
considered an important part of the results, such as the synthesis of HPMA 
copolymer-OG ± Man and HPMA copolymer-Man ± AmB conjugates, the method is 
detailed in the respective chapter. All buffers were made up in double distilled water 
as detailed in the Data for Biochemical Research reference book (Dawson et al., 
1986).
2.3.1 General cell culture
2.3.1.1 Maintenance o f  cell lines
Routine cell culture was performed in a laminar flow hood under sterile 
conditions. RAW 264.7 cells were maintained in DMEM with glutamax and phenol 
red pH indicator supplemented with 10 % foetal bovine serum (complete medium) 
at 37 °C and 5 % CO2. Sub-confluent subcultures (~ 80 %) were split and passaged, 
as described below, approximately every 3-4 days. This cell line is semi-adherent 
i.e. some adhere strongly, some loosely and some grow in suspension. Therefore, 
adherent cells were removed mechanically by scraping, and then the suspension 
spun down to collect all cells. All cells were resuspended in fresh complete medium, 
counted and seeded at a density o f 105 cells per ml.
THP-1 cells were maintained in RPMI 1640 medium with glutamax and 
phenol red supplemented with 10% foetal bovine serum (complete medium) at 37
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°C and 5 % CO2. These cells grow in suspension and so were subcultured by 
replacement o f medium. This was done either by removing medium from flask and 
topping up with fresh complete medium or by centrifugation, and resuspension in 
fresh complete medium after counting. Cells were maintained between 5 x 104 and 
106 cells per ml and passaged approximately every 3 - 4  days.
Suspension cells were differentiated using PMA into adherent macrophage 
cells. PMA (stock solution o f 2 mM in DMSO) was added to the cell suspension 
when seeding to give a final concentration o f 20 nM. Cells were incubated for 48 h 
at 37 °C, at 5 % CO2 before changing for fresh complete medium. Cell adherence 
(differentiated) was confirmed visually by light microscopy.
2.3.1.2 Cell counting and viability assessment using trypan blue
Trypan blue is a dye that does not penetrate the membrane o f living cells but 
is taken up into dead cells, and is therefore used to assess viability. After 
centrifugation, cells were resuspended to give a homogeneous suspension. 100 pi of 
this solution in a bijou bottle was mixed with an equal amount o f trypan blue 
solution added (sterile filtered and diluted 1:1 in phosphate buffered saline (PBS)). 
Cell counting was performed microscopically using a haemocytometer slide. The 
slide has a grid o f 9 large squares with an area o f 1 mm2, and a depth o f 0.1 mm. 
Therefore, when 10 pi o f cell suspension was added, the total volume o f fluid over 
each square is lO'4 ml. The non-blue cells were counted in 5 squares and the mean 
number obtained multiplied by 2 x 104 to obtain the number o f cells per ml of 
solution. The percentage o f cells that had taken up blue dye was used to calculate cell 
viability.
2.3.1.3 Evaluation o f  cell growth using the M TT assay
The MTT assay was first introduced by Mosmann as a means o f measuring 
cell viability (Mosmann, 1983). MTT is a yellow solution that is reduced in viable 
cells by mitochondrial dehydrogenase enzymes. It then forms insoluble blue crystals 
o f formazan salt, which can be solubilised in a solvent. The absorbance at 550 nm is 
proportional to cell number. Cells were seeded in a 96 well plate at a density o f 103 
(RAW 264.7) or 104 (THP-1) cells per well (100 pi) in triplicate and left to adhere
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for 24 h or differentiated as above. Every day for 10 days, the MTT assay was 
performed to obtain a growth curve for each cell line.
MTT (20 pi o f a sterile filtered solution (5 mg/ml) in PBS) was added to each 
well, and incubated with the cells for 5 h at 37 °C and 5 % C 0 2. The plates were then 
centrifuged and the supernatant removed, carefully avoiding the precipitated crystals. 
The crystals were left to dissolve in 100 pi o f sterile DMSO for 30 min at 37°C and 
5% C 0 2 and absorbance was read using a plate reader at 550 nm. The growth curves 
are shown in Figure 2.1.
2.3.1.4 Freezing, thawing and storage o f  viable cells
To preserve the cell lines long-term, cells taken from the log phase growth of 
early passages were frozen and stored in liquid nitrogen. DMSO was used for 
freezing as a cryoprotectant to allow a slower cooling rate and thus preventing the 
formation o f ice crystals that can damage the cell. Cells were resuspended in freezing 
medium (106 — 108 cells/ml in medium containing 20 % FBS plus 10 % DMSO) in 2 
ml cryovials. The vials were placed in a Mr Frosty overnight at -7 0  °C, then into the 
liquid nitrogen storage container. When required, ampules were thawed rapidly, 10 
ml warmed complete medium added, centrifuged and supernatant discarded as 
quickly as possible to remove DMSO. Cells were resuspended in warmed complete 
medium and cultured as previously described.
2.3.2 Fluorescence characterisation o f fluorophores and fluorescent 
conjugates!probes
The absorbance and emmision spectra for each probe or fluorophore were 
measured to determine the peak maxima and degree of overlap. FITC-BSA, FITC- 
BSA-Man and DQ Ovalbumin and OG were dissolved in phosphate buffer (pH 7.4).
1 ml of a 0.1 mg/ml solution was placed in a polystyrene cuvette. Emission and 
absorbance curves were obtained using the Amico Bowman series 2 fluorescence 
spectrophotometer. To assess the effect of pH on fluorescence output, samples of 
each fluorescent probe/fluorophore were dissolved in buffers at three physiological 
pH (0 .1M sodium citrate buffer at pH 5.5 and 6.2, and 0.1 M sodium phosphate 
buffer at pH 7.4). Concentration curves were prepared at each condition (0.001 to 1 
[xg/ml of probe/fl uorophore) in a black 96 well plate. Fluorescence was measured
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49
Chapter 2 Materials and General Methods
using a Fluostar optima fluorescence plate reader using filters for 492/520 nm. The 
degree of fluorescence labelling was calculated using the UV absorbance at 494 nm.
2.3.3 General flow  cytometry protocol to assess binding and endocytosis in RAW
246.7 and THP-1 cells
Cell-associated fluorescence at both 4 °C and 37 °C over time was measured 
to assess binding only, and binding plus uptake respectively. Cells were seeded at a 
concentration o f 5 x 105 cells per ml in complete clear media in 6 well plates. RAW
264.7 cells were incubated at 37 °C, at 5 % CO2 for 24 h to adhere. THP-1 cells were 
differentiated using PMA as described in section 2.3.1, and then incubated for 24 h 
in clear complete media. After experimental procedures (described in the respective 
chapters), incubations were stopped by adding ice cold PBS and putting the plates on 
ice. RAW 264.7 cells were scraped using a rubber policeman, pipetted into FACS 
tubes and centrifuged at 500 r.c.f. for 5 min at 4 °C. They were then washed in PBS 
and centrifuged twice more before re-suspending the cell pellet in a final volume of 
200 pi ice cold PBS. Using THP-1 cells the experiment was performed as above 
except the cells were washed three times with ice cold PBS in the plates and 
collected into FACS tubes as above. For the binding experiments conducted at 4 °C 
plates were pre-incubated on ice in the cold room for 30 min before the experiment.
20,000 counts (cells) per sample were collected. Cells were gated on the 
forward scatter/side scatter plot to exclude the non-viable cells (Figure 2.2 (a)) and 
fluorescence measured on FL1 channel (520 nm) (Figure 2.2 (b)). The geometric 
mean was used to establish the degree o f fluorescence, which equates to the median 
o f the original data (as log-transformed data was acquired). The fluorescent plot was 
arbitrarily gated for positive (M2) and negative cells (M l), negative being the viable 
control cells. The percentage positive takes account o f the autofluorescence o f the 
control cells, as well as the degree o f exogenous cell-associated fluorescence. The 
term ‘derived cell-associated fluorescence’ will be used to describe the binding and 
uptake and was determined by the following equation:
Derived cell-associated fluorescence = (% cells that are positive x geometric mean o f
the fluorescence)/!00
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Figure 2.2 Typical flow cytom etry plots of THP-1 cells. Panels show a) gating of 
viable cells (circled) and b) autofluorescence of control cells and gating of negative (M l) 
and positive cells (M2).
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2.3.4 Bradford assay fo r  protein (Bradford, 1976)
Samples (30 pi) were added to 200 pi Bradford reagent in a 96 well plate and 
incubated at room temperature for 5 min. Absorbance was measured at 595 nm on 
Tecan Sunrise plate reader. Protein concentration was calculated from the BSA 
standard curve in the relevant buffer (0 -  20 pg/ml) (Figure 2.3).
2.3.5 Enzyme assays for markers o f intracellular organelles
2.3.5.1 Cytosol marker (lactate dehydrogenase) assay (Vassault, 1983)
Lactate dehydrogenase catalyses the oxidation o f NADH to NAD+ by 
converting pyruvate to lactate. The reaction is followed by the reduction of NADH 
absorbance at 339 nm. Sample (50 pi) was added to 2.5 ml o f a solution containing 
81 mM Tris-NaOH (pH 7.2), 203 mM NaCl and 244 pM NADH (equilibrated to 30 
°C in cuvette). To this 0.5 ml o f pyruvate (10 mM) was added and the decrease in 
absorbance at 339 nm measured over 1 min.
2.3.5.2 Plasma membrane marker (alkaline phosphatase) assay (Graham, 1993) 
Nitrophenyl phosphate is hydrolysed at alkaline pH to nitrophenol, which has
a UV absorbance at 410 nm. Sample (25 pi) was added to 200 pi o f a solution 
containing 16 mM p-nitrophenyl phosphate and 50 mM sodium borate-NaOH (pH 
9.8) plus 0.8 pi 1M M gCh, and incubated at 37 °C for 30 min. The reaction was 
stopped with 1 ml o f 250 mM NaOH and the absorbance measured. The amount of 
nitrophenol produced was calculated using the calibration curve (Figure 2.4).
2.3.5.3 Lysosomal enzyme (N-acetyl-(3-glucosaminidase) assay (Klemm et al., 1998) 
4-methylumbelliferyl-N-acetamido-ft-D-glucosaminide is hydrolysed by the
lysosomal enzyme to yield the fluorescent product, 4-methylumbelliferone. Samples 
(50 pi) was added to 250 pi o f sodium citrate buffer (200 mM; pH 5), plus 75 pi o f 
1250 mM sucrose containing 0.1 % TX-100. The substrate (100 pi) was then added 
and the reaction incubated at 37 °C for exactly 1 min. The reaction was terminated 
by addition o f 2.5 ml o f glycine-NaOH (250 mM; pH 10.4). The concentration o f 
liberated product (methylumbelliferone) was determined on the fluorimeter 
(absorbance 357 nm, emission 444 nm) using a calibration curve o f 4-
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methylumbelliferone (Figure 2.5). Blanks contained either no biological material or 
no substrate.
2.3.6 SDS-PAGE to separate proteins by size
A 10% SDS-PAGE gel was prepared (Table 2.1) in the gel apparatus 
assembled according to manufacturers instructions (Bio-Rad, UK). The running gel 
was first prepared, pippetted into the space between the glass plates with a layer o f 
isopropanol on top o f the gel and left to set for 30 min. The stacking gel was made 
up, the isopropanol discarded, and applied carefully to the top o f the running gel. An 
appropiate comb was then pushed into the stacking gel and left to set for 
approximately 30 min. Samples (50 pi) were diluted 6:1 in sample buffer (6x to give 
a final concentration o f 62.5 mM Tris-HCl, pH 6.8 containing 2 % SDS, 100 mM 
DTT, 10 % glycerol and 0.001 % bromophenol blue) and boiled for 5 mins (100 °C). 
Samples (30 pi or protein concentration specified in specific chapter) were then 
placed in each well and run in Tris running buffer (25 mM Tris (pH 8.3), 192 mM 
glycine, 0.1 % SDS) for ~ 1 h at 200 V.
2.3.7 General Western blotting protocol
The proteins were wet transferred from the gel onto nitrocellulose membranes 
in cold transfer buffer (25 mM Tris (pH 8.3), 192 mM glycine plus 20 % MeOH) at 
350mA for 1 h. Transfer apparatus was assembled according to the manufacturer’s 
instructions (Bio-Rad, UK). Confirmation o f transfer was performed using Ponceau 
Red stain (0.2%) for 5 min then washed with water until the membrane is clean but 
bands are clear. Membranes were destained by washing extensively with TBS-T 
(Tris buffered saline (TBS) 20 mM Tris-HCl, 150 mM NaCl, adjusted to pH 7.5 plus 
0.1 % Tween-20). The gel was stained with Coomassie stain (25 % MeOH, 10 % 
acetic acid plus 0.18 % w/v CB) for 30 min, then de-stained with a weak solution o f 
acetic acid and methanol solution (25 % MeOH 10 % acetic acid) to confirm 
transfer.
Non-specific binding sites were blocked by incubation with 10 % skimmed 
milk in TBS for 1 h at room temperature. The membranes were the incubated with 
the appropriate primary antibody in TBS-T for 2 hrs at room temperature. Enough
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Figure 2.5 Lysosomal enzyme marker N-acetyl-b-glucosaminidase assay. Panel 
(a) enzyme reaction and (b) calibration curve o f product 4-methylumbelliferone. 
Data represents average ± standard deviation (n = 3).
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Table 2.1 Composition of polyacrylamide gels for SDS PAGE
R eagent R unning Gel 
(ml)
S tacking Gel 
(ml)
ddH 20 9.69 5.85
Tris HC1 5(1 .5  M) 2.5 (0.5 M)
10%  SDS 0.2 0.1
40 % Acryl/Bis 5 1
10%  APS 0.1 0.05
TEMED 0.01 0.005
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solution was prepared to completely cover the membrane so as not to dry out and 
was gently agitated on an orbital shaker (bellydancer). Membranes were washed 
three times with TBS-T before incubation with the appropriate secondary antibody, 
conjugated with either horseradish peroxidase (HRP) or Alexa Fluor 488, for 1 h at 
room temperature. The membranes were washed as above and either fluorescent 
bands visualised directly on the Typhoon or, to detect HRP activity, the membrane 
bands were developed using enhanced chemiluminescence (ECL) reagent and 
exposed to X-ray film in the dark room for various lengths o f exposure (10 s -  5 
min).
2.3.8 Dot blot protocol
A grid was drawn in pencil on the nitrocellulose membrane, to indicate the 
region to blot. Using a narrow-mouth pipette tip, 2 pi o f samples was spotted slowly 
onto the nitrocellulose membrane at the centre o f the grid and left to dry. Non­
specific sites were blocked by soaking in 5% BSA in TBS-T (1 h, RT). Membranes 
were incubated with primary antibody (1:100) dissolved in BSA/TBS-Tween for 1 h 
at RT, then washed three times with TBS-T ( 3 x 5  min). Incubation with secondary 
antibody conjugated with HRP (1:5000) was for 1 h at room temperature, before 
washing three times with TBS-T (15 min x 1, 5 min x 2), then once with TBS (5 
min). Membranes were then incubated with ECL reagent for 1 min, and exposed to 
X-ray film in the dark room for various lengths o f  exposure (10 s -  5 min).
2.3.9 Fixation o f cells for confocal microscopy
Cells were seeded at 5 x 105 cells/well on coverslips (ethanol immersed and 
washed in sterile PBS) in 6 well plates. Cells were placed on ice and washed 3 x with 
ice cold PBS, fixed either by immersion in methanol (20 °C for 5 min) or 20 min in 
3% w/v paraformaldehyde in PBS, washed 3 times in PBS before being 
permeabilized with Triton extraction buffer for 5 min at 25°C (0.2% v/v TX-100 and 
50 mM glycine in PBS pH 7.2). After washing in PBS the coverslips were mounted 
on slides with 40 pi Vectashield, the edges sealed with clear nail varnish, and stored 
at 4 °C for imaging within 72 h.
2.3.10 Immunolabeling o f cells for confocal microscopy
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When cells were to be immunolabeled, after fixation and washing with PBS 
above slides were incubated for 1 h in blocking buffer (2% goat serum in PBS). The 
cells were then incubated at room temperature with mouse anti-EEA 1 (1: 600) or 
anti-LAMP 1 (1: 300) antibodies in blocking buffer for 1 h. Following further 3 x 5  
min washes in PBS, the cells were incubated for 1 h with either Alexa Fluor 488 or 
534 anti-mouse antibodies in blocking buffer. After washing in PBS the coverslips 
were mounted on slides with 40 pi Vectashield, the edges sealed with clear nail 
varnish, and stored at 4 °C for imaging within 72 h.
2.3.11 Fluorescence confocal microscopy o f macrophage cells
Confocal microscopy was performed on a Leica SP5 system. Data was 
collected using dedicated software supplied by the manufacturers and exported as 
tagged image files (TIF); at least three representative images were obtained for each 
sample. Every effort was made to control for the false positives that may be 
associated with “bleed” from one channel to another. This was done by switching off 
the appropriate laser and adjusting the gain settings and laser power until no signal 
was visible in the corresponding photodetection channel. Images in separate channels 
were also acquired sequentially.
2.3.12 Statistical Analysis
Samples were analysed in a minimum of three replicates where possible and 
the error calculated as either standard deviation (SD) or standard error of the mean 
(SEM) where appropriate. Typically, either a students t-test, or a one way analysis of 
variance (ANOVA) followed by a Bonferroni post hoc test, were used to analyse the 
statistical significance of the results where appropriate. Unless otherwise stated, 
probability (p) of < 0.05 was deemed to indicate significance.
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Chapter 3
Characterisation of the in vitro models used to evaluate 
macrophage targeting using mannosylated probes
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3.1 Introduction
To design polymer drug conjugates suitable for macrophage-specific targeting 
o f anti-leishmanial drugs, it was first necessary to set up the in vitro models. There 
were two important considerations when choosing the macrophage models. First, it 
was essential that the cell line was susceptible to infection by the Leishmania parasite 
so that it could later be used to test the conjugates activity. Second, it was important 
that the cell express MR in sufficient number to enable targeting. The murine RAW
264.7 macrophage-monocyte and the human THP-1 cell lines were chosen for these 
studies. The rationale for their choice and the fluorescent probes used is discussed 
below.
3.1.1 The mannose receptor
The MR structure, characteristics and physiological function have been 
described in detail in section 1.6. MR expression is an indicator o f macrophage 
maturity as the MR is not expressed on monocyte precursors. Many cell lines e.g. 
J774-2, J774-B10 and P338-D1 do not seem to express the M R or express low 
receptor levels (Stahl & Gordon, 1982). Therefore it was considered important to 
ensure the cell lines chosen here expressed the MR, and would be able to endocytose 
mannosylated polymer conjugates.
3.1.2 The RAW 264.7 cell line
The RAW 264.7 murine monocyte-macrophage cell line was used in part 
because planned later in vivo studies were going be performed in a murine model. 
This cell line has been shown to exhibit similar characteristics to normal macrophages 
including the phagocytosis o f bacteria and antibody-coated red blood cells 
(Frankenberg et al., 2008; Henry et al., 2004) and secretion o f lysozyme (Raschke et 
al., 1978). It has been shown to be a good model o f inflammatory macrophages, 
capable o f Fc-yR mediated phagocytosis, respiratory burst and cytokine secretion 
(Loegering & Lennartz, 2004). Importantly, RAW 264.7 cells are able to phagocytose 
and maintain Leismania donovani infections (St-Denis et al., 1999).
This cell line has been used to study the pharmacological activity o f anti- 
leishmanials (Kayser & Kiderlen, 2003; Radtke et al., 2003) and literature on RAW
264.7 cell lines indirectly suggests some level o f MR expression as HPMA copolymer 
conjugates containing mannose were taken up to a higher degree than those without
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(Nan et al., 2004). However, the level o f MR expression in this cell line had not been 
extensively studied.
3.1.3 The THP-1 cell line
The TH P-1 cell line is a human cell line. It resembles the blood monocyte, in 
that it has no MR expression and these cells do not phagocytose parasites. Treatment 
o f THP-1 monocytes with the phorbol ester PMA results in a differentiated phenotype 
displaying macrophage characteristics (Schwende et al., 1996). These include 
adherence, loss o f proliferation, phagocytosis o f latex beads, expression o f CR3 and 
CD 14 (LPS receptor), and release o f superoxide anions and TN F-a (Tsuchiya et al., 
1980). PMA is an analogue o f diacylglycerol, an activator o f PKC, therefore its 
actions are thought to be mediated by PKC. It should also be noted that Korho and 
colleagues (2004) found that although many morphological and other characteristics 
are similar to macrophages, there are many differences at the transcriptional level.
Therefore it was considered important to characterise these cells carefully for 
MR expression. Some studies have suggested MR expression in THP-1 cells, for 
example Raveh et al. (1998) studied the effect o f cytokines on MR-dependent 
phagocytosis. They found that the prototypical Th2 cytokine, IL-4, increases both 
surface expression and MR-mediated endocytosis; whereas the T hl cytokine, IFN-y, 
decreases them both. However, both alone and together, these same cytokines act to 
increase MR-mediated phagocytosis. The expression o f the MR is complicated and 
depends on the inflammatory state o f the macrophage. In addition, THP-1 cells have 
been shown to phagocytose and maintain Leishmania infection in vitro (Croft et al., 
2006; Dasgupta et al., 2003; Ogunkolade et al., 1990) and this cell line has been used 
as an in vitro model for screening the pharmacological activity o f anti-leishmanial 
drugs (Gebre-Hiwot et al., 1992).
3.1.4 Choice o f  fluorescent probes
To study endocytosis via the MR it was necessary to choose suitable 
fluorescent probes. The structures o f the proteins (BSA and ovalbumin) used as 
probes are shown in Figure 3.1, and the chemical structures o f the fluorophores used 
in Figure 3.2. FITC-labelled BSA was primarily used in these experiments. Albumin 
is the most abundant protein in blood plasma, being chiefly responsible for
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(a) (b)
Figure 3.1 S tructures of the protein probes. Panel (a) bovine serum albumin (taken from 
Schreiber, 2004) and panel (b) ovalbumin (taken from Yamasaki, 2003).
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(b)
Figure 3.2 Chemical structure of the fluorophores. Panel (a) FITC and (b) 
BOD1PY.
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maintaining blood pH. It is not rapidly degraded in the circulation, and although there 
are macrophage receptors for albumin, such as the scavenger receptors gp l8  and 
gp30, these primarily recognise modified albumins and only weakly bind the native 
form (Schnitzer and Bravo, 1993). However, when conjugated to mannose residues 
albumin can be used as a marker o f mannose receptor-mediated uptake (Monsigny et 
al., 1984). Thus, FITC-labelled BSA was used here to indicate the degree o f targeting 
achievable using the MR in THP-1 and RAW 264.7 cells, and to compare the specific 
and non-specific binding/uptake.
A second probe was also chosen for these studies, DQ-ovalbumin. 
Fluorescently-labelled ovalbumin is commercially available and has been used by 
others to study MR-mediated uptake in mycobacterium-infected macrophages 
(Teitelbaum et al., 1999). DQ-ovalbumin is another albumin protein, derived from 
egg protein (45 kDa) with an inherently high degree o f mannosylation. DQ ovalbumin 
is labelled with a BODIPY fluorophore that has the advantage o f being highly 
quenched at neutral pH, and therefore relatively non-fluorescent. However, once it is 
endocytosed and transported to endosomal compartments containing lysosomal 
enzymes the protein is degraded and the released BODIPY begins to fluoresce. 
Therefore this probe can be used to assess whether MR delivers its payload to the late 
endosomal/lysosomal compartment.
3.1,5 Techniques used to study cellular uptake and binding
Flow cytometry
Flow cytometry was used to measure the cellular binding and uptake o f the 
probes, being a rapid, reliable and widely used technique. It is possible to measure 
both the physical and chemical characteristics o f the cells, examining the scatter 
properties and the fluorescent emission without fixation. Also large cell numbers can 
be analysed. Fluorescence is proportional to the amount o f probe bound and/or 
internalised, provided it is within the linear range o f concentration and at a defined 
pH.
Cell-surface binding o f probes to the THP-1 cells was assessed by incubation 
at 4 °C, as endocytosis is largely inhibited at this temperature. At 37 °C, both binding 
and endocytosis occur, and the fluorescence measured was used to indicate uptake 
into the cells. Receptor-specificity was also investigated by assessing the 
concentration dependence o f the binding and the effect o f competitors. Mannan (yeast
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poly-mannose) can be used as competitor o f mannose receptor mediated binding, and 
therefore endocytosis (Stahl et al. 1980). Competition experiments have co-incubated 
unlabelled mannan and FITC-BSA-Man to determine whether the uptake is 
specifically mannose receptor-mediated.
Fluorescence microscopy
Once taken up into the macrophage, it was considered important to ascertain 
the intracellular trafficking o f the probes and whether they accumulate in late 
endosomal and/or lysosomal compartments. The disadvantage o f flow cytometry is 
that it gives no indication as to where in the cell the compound is localised. 
Fluorescence microscopy has frequently been used to determine cell accumulation 
and localisation o f fluorescently labelled compounds though it is not quantitative and 
care must be taken in interpreting such images (North, 2006; Zwier et al., 2004). Also, 
it allows any changes in cell morphology to be visualised. Macrophage cells were 
observed, by both light and fluorescence microscopy, after incubation with the above 
fluorescent probes, then by confocal fluorescence microscopy, using antibodies to 
label o f the early endosomes and late endosome/lysosome.
Western blotting
The above techniques use indirect methods to investigate MR-dependent 
uptake and provide no direct evidence o f receptor expression. To directly determine 
MR expression in these cell lines, a specific MR antibody was used. Western blotting 
is the most common method used to study expression o f a receptor, and was used here 
to establish comparative levels o f the mannose receptor on theTHP-1 cell line. 
However, it should be noted that this technique can only measure the total cell MR 
content and does not demonstrate either surface expression or functionality o f the 
receptor.
3.1.6 Summary o f  aims
The aim o f this study is to establish macrophage models suitable to investigate 
MR-mediated uptake. The specific technical aims were as follows:
• Characterise the pH-dependence o f the fluorescence output o f the probes.
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• Establish flow cytometry protocols to study the binding (4 °C) and uptake 
(37 °C) o f various fluorescent probes ± Man in THP-1 and RAW 264.7 cell 
lines.
• Use MR competitor (mannan) to investigate specific and non-specific 
uptake.
• Use fluorescence microscopy to visualise the distribution o f the 
fluorescent probes within the macrophage models.
• Use western blotting with an MR specific antibody, as well as microscopy 
o f the TH P-1 cells to visualise total MR expression in the cell lines.
3.2 Methods
The general methods used in these studies have already been described in 
chapter 2. The RAW 264.7 and THP-1 cells were maintained as in section 2.3.1.1. 
SDS-PAGE and Western blotting was performed using the general protocol described 
in sections 2.3.6 and 2.3.7, and the MR antibody was used at a dilution 1:10.
32.1  Fluorescence characterisation o f FITC-BSA, FITC-BSA-Man and DQ 
ovalbumin probes
The absorbance and emmision spectra, the pH and concentration dependence 
of fluorescence of FITC-BSA, FITC-BSA-Man and DQ Ovalbumin was measured 
using the protocols outlined in section 2.3.2.
3 2 2  Binding and endocytosis of probes into RAW 246.7 and THP-1 cells using 
flow cytometry
Derived cell-associated fluorescence was measured with time using flow 
cytometry to assess binding at 4 °C, and binding plus uptake at 37 °C. The flow 
cytometry protocol is described in section 2.3.3. Cells were seeded at 5 x 105 cells per 
ml in clear media in 6 well plates overnight. They were then incubated with FITC- 
BSA, FITC-BSA-Man or DQ ovalbumin in clear media (at either 0.1 mg/ml of 
protein or 10 //g/ml of fluorophore) and cell-associated fluorescence was measured 
every 10 min for 60 min. 10 000 cells were counted, and data expressed as (the % of 
positive cells x geometric mean of the fluorescence)/100.
Flow cytometry experiments were carried also out using a competitive ligand, 
unlabelled yeast mannan (poly-mannose) to determine the degree of specific mannose
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receptor-mediated uptake and to establish the number of receptors present. Cells were 
incubated with mannan (2 mg/ml) 30 min prior to the addition of FITC-BSA or FITC- 
BSA-Man (10 //g/ml FITC equivalent). The cells incubated in the dark at 37 °C, 5 % 
COzfor a further 60 min. Mannan alone was also incubated with the cells as a control.
3 2 3  Live-cell imaging o f binding and endocytosis o f probes in THP-1 cells using 
fluorescent microscopy
THP-1 cells were plated at a seeding density of 5 x 105 cells per ml in clear 
media into small optical petri dishes. After incubation with the fluorescent probes at 
equivalent fluorophore concentration (10 (Lig/ml of FITC) at 37 °C the cells were 
washed with ice cold PBS three times, then 1 ml ice cold PBS was left covering the 
cells in the dish. Dishes were covered and taken directly to the microscope. Phase 
contrast and fluorescent images of samples were captured using a Leica DMIRB at x 
40 using filters set for FITC or BODIPY dyes.
3 2 .4  Fixed-cell imaging o f binding and endocytosis o f probes in THP-1 cells using 
confocal fluorescent microscopy
THP-1 cells were at a seeding density of 5 x 105 cells per ml in 6 well plates, 
each with a sterile coverslip on the bottom of the well, and incubated with fluorescent 
probes as for live cell imaging (section 3.2.3). After washing, cells were fixed and 
labelled with EEA-1 and LAMP-1 antibodies as described in section 2.3.9, 2.3.10 and 
2.3.11.
3.3 Results
33.1  Absorbance and fluorescence characteristics o f FITC-BSA, FITC-BSA-Man 
and DQ-ovalbumin probes
The absorbance and emission peaks of the fluorescence spectra were measured 
at pH 7.4. The FITC-BSA conjugates have a wide absorbance range, consisting of 
three separate peaks, but a single emission peak. The absorption maxima were at 492 
nm and the emission 521 nm (Figure 3.3a,b). In contrast, DQ-ovalbumin had broad 
absorbance and emission peaks, but had absorption maxima of 505 nm and emission 
maxima of 517 nm (Figure 3.3c). These wavelengths were then used to monitor the 
probes fluorescence output.
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When the effect of pH on the fluorescence emission was examined, it was 
found that as the pH decreased from 7.4 to 6.5 to 5.5, the fluorescence of the FITC 
conjugates decreased markedly at all concentrations (Figure 3.4a,b). The fluorescence 
output of FITC also exhibited concentration-dependent quenching and it was 
quenched at concentrations > 0.02 mg/ml FITC-equivalent. This equates to 
approximately 0.6 mg/ml of FITC-BSA and 0.2 mg/ml of FITC-BSA-Man. DQ- 
ovalbumin, conjugated to the fluorophore BODIPY, exhibited a linear increase in 
fluorescence with concentration up to 0.6 mg/ml (Figure 3.4c). Only a small decrease 
in fluorescence output was seen at the lower pH. It was decided, in the following flow 
cytometry experiments comparing the FITC-BSA ± Man probes, that the 
concentration of each probes would be standardised to the same FITC concentration 
(calculated using the UV absorbance readings), rather than concentration of protein. 
All subsequent uptake experiments were conducted using low concentrations of FITC 
(i.e. 10 p,g/ml).
3 3 2  Binding and cellular uptake o f uptake o f fluorescent probes using flow  
cytometry
When the derived cell-associated fluorescence was measured large differences 
were seen for the different cell lines and probes. Both the number of cells that were 
gated positive and the mean fluorescence intensity were significantly increased when 
the RAW 264.7 cells were incubated with FITC-BSA-Man compared to FITC-BSA, 
at both 4 °C and 37 °C (Figures 3.5 and 3.6). The increase in derived cell-associated 
fluorescence of RAW 264.7 cells incubated with FITC-BSA was linear over 60 min at 
37 °C, whereas at 4 °C it remained level (Figure 3.7a). However, RAW 264.7 cells 
incubated with FITC-BSA-Man exhibited derived cell-associated fluorescence at 37 
°C that levelled off at 40 min (Figure 3.7b). The comparison between the two albumin 
probes at 37 °C, and a 4  °C (Figure 3.8a, b), shows the manosylated probe had 
significantly higher derived cell-associated fluorescence than FITC-BSA (p < 0.05, 
students t-test). There was a 4-fold increase at 37 °C and a 5-fold increase at 4 °C.
Similar patterns were found in the THP-1 cell line. Both the number of cells 
that were gated positive and the mean fluorescence intensity were significantly 
increased when the THP-1 cells were incubated with FITC-BSA-Man compared to 
FITC-BSA, at both 4 °C and 37 °C (Figures 3.9 and 3.10). THP-1 cells incubated with
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both FITC-BSA and FITC-BSA-Man showed a low level of derived cell-associated 
fluorescence at 4  °C that did not significantly increase over time (Figure 3.11). Again 
FITC-BSA-Man displayed a very slight increase at 4 °C. FITC-BSA-incubated cells 
showed a linear increase in cell associated fluorescence with time whilst the increase 
with FITC-BSA-Man began to level out after 10 min and had reached a plateau by 50 
min. Comparison of the patterns of uptake of both albumin probes demonstrates that 
the mannosylated probe shows significantly higher cell associated fluorescence over 
FITC-BSA, a 5-fold increase at 37 °C and a 10-fold increase at 4  °C (p < 0.05, 
ANOVA plus Bonferoni post hoc test) (Figure 3.12).
Derived cell-associated fluorescence at 37 °C increased rapidly over 60 min 
for both cell lines when incubated with DQ Ovalbumin. In THP-1 cells, there was a 
maximum increase of 8-fold over the 4 °C derived cell-associated fluorescence at 60 
min and the uptake was linear (Figure 3.13 and Figure 3.14a). The rate of increase in 
derived cell-associated fluorescence in RAW 264.7 cells increased with time, with a 
maximum increase of 6-fold over that at 4  °C (Figure 3.14b). At both temperatures 
the derived cell-associated fluorescence of FITC-BSA-Man was significantly greater 
than FITC-BSA at all time points (p < 0.05, ANOVA with Bonferroni post hoc test). 
It should also be noted that the RAW cells have almost double the derived cell- 
associated fluorescence at 60 min, with all three probes, compared with THP-1 cells.
The derived cell-associated fluorescence of THP-1 cells incubated with FITC- 
BSA-Man at 37 °C was significantly decreased when co-incubated with an excess of 
unlabelled mannan (p < 0.05, students t-test) (Figure 3.15). Derived cell-associated 
fluorescence of cells incubated with mannan alone was equivalent to control cells. At 
4 °C little effect was seen but at 37 °C there was a 44 % decrease in fluorescence.
3 3 3  Imaging o f binding and uptake of probes by fluorescence microscopy
Fluorescence images of RAW 264.7 cells incubated with BSA-FITC, man- 
BSA-FITC and DQ-ovalbumin show the distribution of probes after 60 min at 37 °C 
(Figure 3.16). Each panel compares the standard widefield light microscope image 
with the fluorescent image of the same cells. Probes have clearly been taken up into 
numerous small vesicles throughout the cytoplasm whereas the nuclei are not stained. 
DQ ovalbumin (Panel c) shows the brightest vesicles in the perinuclear region,
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Figure 3.11 T im e-dependent up take o f fluorescent probes in THP-1 cells. Panel (a) FITC- 
BSA and (b) FITC-BSA-Man at 37 °C and 4  °C. The data represent the mean ± SD (n = 3 (4 
°C), n = 9 (37 °C» and where the error bars are not visible they fall within the data points. 
Statistical significance (*) between 37 and 4 °C was determined at p < 0.05 for all data points 
(ANOVA with Bonferroni post hoc test).
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Figure 3.13 Typical raw data obtained from  flow cytometry of RAW 264.7 and THP-1 
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Phase contrast Fluorescence
(a)
Figure 3.16 Phase contrast and  fluorescent microscope images of THP-1 
cells incubated for 1 h with fluorescent probes. Panel (a) FITC-BSA (b) 
FITC-BSA-Man and (c) DQ-Ovalbumin.
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whereas the BSA probes are more diffuse (Panels a,b). There is some hazy 
fluorescence throughout the cell, and vesicles can be more clearly seen in the fixed 
cells.
To identify the intracellular localisation of the fluorescent probes cells were 
labelled with EEA-1 and LAMP-1 (Figures 3.17, 3.18 and 3.19). FITC-BSA and 
FITC-BSA-Man were seen in distinct vesicular structures. After a 1 h pulse and 3 h 
chase FITC-BSA or FITC-BSA-Man fluorescence co-localised with LAMP-1 but not 
with EEA-1. No evidence of plasma membrane, nuclear or cytosolic labelling was 
seen.
3 3 .4  Direct visualisation o f MR in THP-1 cells
Analysis of total MR by western blotting showed specific MR staining in 
THP-1 cells (Figure 3.20a). Further direct visualisation of expression and distribution 
as observed by confocal microscopy showed the MR was distributed throughout the 
macrophage cell, with a small proportion being located on the periphery (cell 
membrane) (Figure 3.20b).
3.4 Discussion
The results presented here indicate the two cell lines chosen, THP-1 and RAW
264.7 macrophages, express functional receptors for mannose and are suitable in vitro 
models for MR targeting studies.
The fluorescent probes chosen show reasonably narrow excitation and 
emission spectra. However, it was found that a reduction in pH, mimicking the 
transition from the neutral extracellular environment, through the early 
endosomal/phagosomal vesicle to the lysosomal/phagolysosomal vesicle radically 
altered the fluorescence characteristics. The FITC fluorescence was highly quenched 
below pH 7.4. Though commonly used in fluorescent studies of uptake, these results 
indicate the poor suitability of FITC as an endocytosis marker. A decrease in pH may 
be due to reduced uptake or simply the acidic environment of the endosomal vesicle. 
In addition, the fluorescence of FITC exhibited concentration-dependent quenching. 
However, as BSA is rapidly degraded once taken up into the endosome, it may no 
longer be quenched (Stahl et al. 1980). Also, though the fluorescence values measured
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(a) EEA-1
(b) LAMP-1
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Figure 3.17 Confocal fluorescent microscope images of THP-1 cells incubated for 
a 1 h pulse and a 3 h chase with FITC-BSA. Panels represent cells co-stained with 
(a) anti-EEA-1 antibody and (b) anti-LAMP-1 antibody. Examples of co-localisation 
between compartment marker and BSA-TxR are indicated using white arrows.
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(a) EEA-1
(b) LAMP-1
Figure 3.18 Confocal fluorescent microscope images of THP-1 cells incubated for 
a 1 h pulse and a 3 h chase with FITC-BSA-M an. Panels represent cells co-stained 
with (a) anti-EEA-1 antibody and (b) anti-LAMP-1 antibody. Examples o f co­
localisation between compartment marker and BSA-TxR are indicated using white 
arrows.
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(a) EEA-1
(b) LAMP-1
Figure 3.19 Confocal fluorescent microscope images THP-1 cells incubated for a 
1 h pulse and a 3 h chase with DQ-ovalbum in. Panels represent cells co-stained 
with (a) anti-EEA-1 antibody and (b) anti-LAMP-1 antibody. Examples o f co­
localisation between compartment marker and BSA-TxR are indicated using white 
arrows.
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Figure 3.20 Expression of the mannose receptor in THP-1 cells. Panel a) western 
blotting for mannose receptor and panel b) staining of cells using an anti-mannose 
receptor antibody (clone 19.2) (trans-golgi anti-TGN46 staining in red).
89
Chapter 3
cannot be taken as absolute values, FTTC-BSA and FITC-BSA-Man uptake was still 
comparable as long as the amount of FITC in the incubation medium was equivalent.
The DQ Ovalbumin probe takes advantage of this rapid degradation in the 
endocytic pathway. In contrast to FITC, the fluorophore BODIPY exhibited the 
advantage of a linear increase in fluorescence with concentration, and little pH 
quenching. The requirement of enzymatic degradation for full fluorescence was 
demonstrated by the low fluorescence exhibited in comparison to the other probes.
When flow cytometry was used to investigate the degree of binding and 
uptake, it was shown that both probes exhibited a fairly low rate of increase in derived 
cell-associated fluorescence over time at 4  °C, correlating with binding only. The 
manosylated probe shows significantly higher (p = < 0.05) derived cell-associated 
fluorescence. The apparent plateau seen may also be due to the rapid degradation of 
FITC-BSA-Man once it reaches the lysosome. Stahl and colleagues (1980) first 
demonstrated the uptake of FITC-BSA. They showed that although the apparent rate 
of uptake levels off after 1 0 - 1 5  min, when the rate of degradation was taken into 
account the rate was effectively linear. However, the rate of degradation would be 
expected to be the same for the FITC-BSA, which shows no plateau over the 60 min. 
Although, the degree of uptake of FITC-BSA-Man is much greater than FITC-BSA, 
and therefore the effect of concentration-dependent quenching as well as degradation 
may contribute to this effect. Also the manosylated FITC-BSA had reached ~ 100 % 
positive cells before 60 min, whereas the FITC-BSA had not. Saturation studies with 
increasing concentrations of probe would have given more information on the 
receptor binding specificity, however due to time constraints, it was decided to do 
these studies using the mannose targeted polymers in the next chapter.
Derived cell-associated fluorescence of THP-1 cells and RAW 264.7 cells 
with DQ Ovalbumin demonstrated similar binding kinetics at 4 °C to the BSA probes, 
though a more rapid rate at 37 °C. It is likely to be due to the low fluorescence on 
binding and initial uptake, and a correlation with the rate of degradation of the probe 
and release of fluorescence as it reaches the lysosome. It does, however, support the
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hypothesis that the probe is taken up by the endocytic pathway and delivered to the 
lysosome.
Comparison between THP-1 and RAW 264.7 cells shows that, although the 
RAW cells have almost double the apparent uptake of all probes compared with THP- 
1 cells, the difference between FITC-BSA and FITC-BSA-Man is greater in the THP- 
1 cells. These results may indicate differences in MR expression or any number of 
differences between the cell lines such as differing levels of non-specific uptake or 
rate of degradation of albumin. The RAW 264.7 cells showed double peaks when 
incubated with the FITC-BSA ± Man probes, whereas the THP-1 cells were more 
uniform in uptake. This is most likely to be due to the fact that they are a uniform cell 
population, whereas the RAW cells are heterogeneous. The adherent and suspension 
cells are likely to exhibit different characteristics, including possibly MR expression. 
Although the THP-1 cells could display different characteristics due to the degree of 
differentiation. There was a longer tail on the THP-1 cell peak, particularly with the 
Man probe, and there was a spike of fluorescence at the highest point measured, 
although this could be an artefact of the way the fluorescence is measured. The initial 
(time zero) derived cell-associated fluorescence is significantly lower in THP-1 cells 
than in RAW 264.7 cells. Time zero refers to the first time point to be measured after 
addition of probe and immediate removal and washing, and therefore is not strictly 
zero but the earliest time point it was possible to measure. Using the RAW 264.7 cells 
this was longer as it required scraping the cells before spinning down and washing in 
fresh PBS rather than removal of the solution immediately as with the THP-1 cells. 
This may explain the higher fluorescence values. These factors make the THP-1 cells 
both easier and more accurate to use for the flow cytometry experiments. For this 
reason THP-1 cells were used as the macrophage model for subsequent studies with 
the polymer-mannose conjugates.
The reduction in uptake caused by the competitive inhibitor mannan supports 
the conclusion that the uptake was mannose-specific. The data should indicate the 
non-specific and mannose-specific uptake as all the mannose binding sites should be 
blocked. This inhibition should be more pronounced at 4  °C, as at 37 °C there is 
constant replenishment by intracellular pools of MR (Stahl et al., 1980). The lack of 
inhibition in binding is contrary to most published studies (Linehan et al., 2000; Stahl 
& Gordon, 1982; Stahl et al., 1980), though the 4  °C binding is affected to a small
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degree. Also, most studies have found non-specific uptake to be about 20 % rather 
than 50 %. Higher concentrations mannan may give more accurate results, as all the 
MR’s may not be saturated. Still, these results are a good indication that mannose 
targeting should be able to increase uptake of conjugates significantly.
Corroboration of the uptake by endocytosis and visualisation of the 
distribution within the cell, fluorescent microscopy was used. The probes are clearly 
located in vesicles located throughout the cell. The brighter vesicles in the perinuclear 
region of the DQ ovalbumin-containing vesicles correlate with the increased 
fluorescence in the lysosomal compartments. However, presumably due to pH- 
dependent quenching along the endosomal pathway, FITC-BSA is brighter along the 
periphery of the cell. This did not occur when a chase time was included (fixed cells) 
and vesicular labelling was clear. FITC-BSA and FITC-BSA-Man was located 
primarily in the late endosome/lysosome (labelled with LAMP-1) and not endosomes 
(EEA-1). There is likely to be some bleed-through of the green channel into the red, 
which may account for the apparent co-localisation of some green EEA-1 with the 
probes. However the large amount of red labelled vesicles could not be bleed-through 
and the limited amount of non-colocalised red in the LAMP-1 labelled cells.
Finally, the specific anti-MR antibody has shown MR expression on the THP- 
1 cells. The previous data indirectly support the hypothesis of MR expression, 
showing receptor-specific uptake of mannosylated conjugates, but not the 
involvement of the MR itself. Direct visualisation of the MR in these cells showed a 
diffuse distribution, which correlates with previous studies showing that a large 
proportion of MR is located intracellularly, rather than on the cell surface (Diaz- 
Silvestre et al., 2005; Stahl et al., 1980). However, this can be rapidly deployed to the 
cell surface when needed, resulting in virtually continual uptake of mannosylated 
ligands. The non-reliance on de novo synthesis is of benefit to the design of 
mannosylated conjugates for uptake into macrophages. However, the MR antibody 
used only poorly stained the THP-1 cells, and did not stain the RAW 264.7 cells. 
Further studies with positive and negative controls would be necessary to confirm MR 
expression.
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There is evidence that when infected with Leishmania parasites the surface 
mannose receptor expression on macrophages is reduced (Basu et al., 1991). 
However, other studies have found no difference in MR-mediated uptake between 
infected and non-infected macrophages (Rabinovitch et al., 1985; Shepherd et al., 
1990). It would be interesting to determine whether in both our macrophage models 
and in the in vivo situation the mannose receptor show changes in receptor expression 
after infection. However, unfortunately these experiments were not undertaken.
3.5 Conclusions
From the data presented we can conclude that the THP-1 and RAW 264.7 cell 
lines are suitable models for use in these mannose-targeting studies. Use of probes has 
shown that binding and uptake are both temperature- and time-dependent. Mannose 
conjugation significantly increased both binding and uptake by both cell types. The 
results suggest that both RAW and THP-1 cells express MR, and in sufficient 
numbers to study receptor specific targeting of polymer conjugates. Also, MR ligands 
are trafficked to the endosome/lysosome as indicated by the DQ ovalbumin 
degradation and fluorescence, and the microscopy images. Specificity was further 
confirmed by competitive inhibition by mannan. It was decided for reasons of time to 
concentrate on one of the models for the bulk of the further studies. The THP-1 cell 
line was chosen for further studies as it has shown greater reproducibility, and is more 
representative of the intended target, the human macrophage.
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Chapter 4
Synthesis and Characterisation of OG-labelled HPMA 
Copolymer-Mannose Conjugates
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4.1 Introduction
The studies on the uptake o f model fluorescent probes in Chapter 3 confirmed 
that MR targeting could be achieved in both THP-1 and RAW 264.7 cells. The aim 
of these studies was to synthesise mannose-targeted polymer conjugates, and to 
investigate the mannose loading needed for MR targeting o f a polymeric carrier. In 
these studies HPMA copolymer with a GFLG linker ± mannose, with OG as a 
fluorescent marker, and THP-1 cells as a macrophage model, were used. As 
discussed in section 1.5.1, HPMA copolymers have been widely developed as drug 
carriers and for gene delivery (reviewed in Duncan, 2005). The design behind these 
conjugates will now be discussed in more detail.
4.1.1 History and development o f the HPMA polymer and HPMA-drug conjugates
HPMA polymers were first investigated as biomedical polymers in the 70’s 
(reviewed in Duncan, 2005; Kopecek, 1977). HPMA homopolymer was initially 
developed as a plasma expander. However, the subsequent studies during the 70's 
and 80's systematically developed HPMA copolymers as drug carriers. Kopecek and 
Bazilova (1973) developed methods for free radical polymerisation and 
copolymerisation o f the HPMA monomer with different co-monomers. 
Subsequently, Rejmanova et al. (1977) defined the polymerisation methods for 
incorporation o f methacrylic acid (MA) monomer bearing peptides terminating in 4- 
nitrophenol ester (ONp). The polymer intermediates prepared in this way can be 
easily reacted with amine groups by a process called aminolysis. This enables drugs 
or targeting residues that have an aliphatic amino group to be conjugated via an 
amide bond.
HPMA copolymer conjugates were originally designed for lysosomotropic 
drug delivery (reviewed in Duncan, 2005). The importance o f enzymatically 
cleavable side chains for intracellular drug release was apparent, and several studies 
led to the design o f appropriate peptide sequences, including GFLG, which is 
cleaved by lysosomal enzymes particularly cathepsin B (Duncan et al., 1983; Duncan 
et al., 1984; Duncan et al., 1980; Duncan et al., 1981; Rejmanova et al., 1985). An 
optimum HPMA copolymer structure for drug delivery, including molecular weight 
and optimum drug loading to retain solubility, was thus established. The synthetic
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methods, the biodistribution of the HPMA copolymer drug conjugates (with and 
without targeting ligands) and the use o f such conjugates are reviewed in the next 
sections.
4.1.2 Synthetic methods used to prepare HPMA copolymer conjugates
The synthesis o f HPMA copolymer-drug conjugates containing peptide side 
chains is now well established. It is commonly achieved by free radical 
copolymerisation o f HPMA monomer by either o f two methods (shown 
schematically in Figure 4.1):
i) Copolymerisation of HPMA monomer and MA-peptide (e.g. GFLG) 
terminating in reactive ONp. This polymeric intermediate can then be easily 
modified with drug or targeting ligand, providing they have an aliphatic amino group 
(Figure 4.1a). This is termed the polymer analogous reaction.
ii) Copolymerisation o f HPMA monomers and MA-peptide monomers 
terminating in the drug/ligand (Figure 4.1b).
Most HPMA copolymer conjugates have been prepared by the polymer 
analogous reaction and this technique was used to prepare the conjugates described 
here. This allows libraries to be made using a common intermediate o f specific 
molecular weight. This ensured reproducibility o f Mw and polydispersity and gives 
better control o f drug loading. Copolymerisation o f drug bearing monomers that can 
have different reactivities can lead to conjugates o f widely different molecular 
weight and/or polydispersity. One potential disadvantage o f the polymer analogous 
reaction is the possibility of free drug in the final conjugate. Also, there will 
inevitably be a random distribution o f drug and/or ligand along the polymer chain. 
Although copolymerisation using method (ii) would, also lead to a random 
distribution o f the drug-carrying monomer; and that carrying a targeting ligand.
Using an HPMA copolymer intermediate containing many reactive ONp 
groups it is possible to bind more than one drug or ligand at relatively high loadings. 
However, the highest practical loading is governed by the drug/conjugate solubility.
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CHUO®
(b)
Key
® Drug/targeting ligand
□  Amino acid side chain in polymeric precursor
□  Amino acid attached to the drug/targeting ligand to be conjugated
■ HPMA monomer 
T MA-drug/targeting ligand
Figure 4.1 Scheme showing synthetic m ethods for producing HPMA copolymer- 
drug conjugates. Panel (a) polymer-analogous reaction and panel (b) polymerisation 
of modified monomers. Taken from Duncan (2005).
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For example, the anti-cancer conjugate HPMA copolymer-GFLG-Dox (PK1) had a 
Dox loading o f around 8 wt %, and HPMA copolymer-GFLG-Dox-Gal (PK2) a Dox 
loading o f 7.5 wt %. The latter also had a Gal loading o f 4 mol %. The benefits of 
HPMA copolymers as carriers for drug delivery are discussed in section 1.5.1, but 
the high water solubility o f the HPMA copolymer is a particular advantage when 
binding to poorly water-soluble drugs. In the case o f Dox, solubility was increased > 
10 fold. However, higher loadings o f a hydrophobic drug may reduce solubility of 
the conjugate. When Dox loading was increased from ~ 5 to ~ 10 mol %, 
conformational changes actually resulted in reduced Dox release (Vicent et al., 
2005). This underlines the importance o f studying drug release and conjugate 
pharmacokinetics in order to optimise lysosomotropic conjugates. This is discussed 
further in the next section.
4.1.3 Pharmacokinetics and biodistribution o f HPMA copolymer conjugates
The biodistribution of any polymer-drug conjugate is governed by the 
polymer characteristics (chemistry and molecular weight), its drug payload, and 
whether or not a targeting ligand is included. HPMA copolymer conjugates have 
been systematically designed to optimise biodistribution. Early experiments 
investigated the body distribution o f HPMA copolymers o f different molecular 
weight using [14C] labelling and compared their retention and elimination (Sprincl et 
al., 1976). The higher Mw polymer (33,000 g/mol) displayed a longer retention time. 
The low Mw polymer (1, 000 g/mol) accumulated mostly in the kidneys, whereas the 
high Mw polymer (33,000 g/mol) had its highest levels in the spleen. The total body 
accumulation o f polymer was 5 times higher for the high Mw than the low Mw 
polymer. However, both were eliminated to below detectable levels after 6 months.
Using 125I-labelled HPMA copolymer fractions o f Mw 12,000 -  778,000 
g/mol, Seymour et al. (1987) further defined the effect o f polymer Mw on 
biodistribution and tumour targeting. The distribution o f polymers showed size- 
dependent accumulation, and higher Mw polymers were taken up by the RES. Also, 
the largest Mw polymer was retained at the site o f administration. The smallest was 
eliminated rapidly from the body. This study showed that the optimisation o f Mw 
could increase plasma circulation times and allow tissue and organ penetration.
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Rapid renal elimination o f HPMA copolymer conjugates without a specific 
targeting residue occurs below a Mw threshold o f 45,000 g/mol (Seymour et al., 
1987). The pharmacokinetic studies undertaken in phase I clinical trials o f PK1 
confirmed preclinical experiments and showed that > 50 % of the conjugate was 
excreted within 24 h, with a blood clearance o f ti/2a  o f 1-2 h, and a ti/2p of 93 h 
(Vasey et al., 1999). Drug access to areas such as the bone marrow and heart was 
limited by polymer conjugation, therefore reducing the non-specific Dox toxicity. 
The maximum tolerated dose was 320 mg/m2 Dox-equivalent; five times higher than 
that o f free Dox. Most anti-cancer polymer-drug conjugates tested clinically so far 
have relied on passive targeting. The altered pharmacokinetics o f polymer conjugates 
designed for cell-specific targeting will be discussed in the next section.
4.1.4 Targeting by HPMA copolymer conjugates
The studies described here build on previous work that has tried to establish 
targeted delivery o f HPMA copolymer conjugates. As discussed in section 1.5.3, a 
large number o f targeted HPMA copolymer conjugates have been described. 
Typically they contain antibodies, proteins, peptides and sugar residues to promote 
receptor-specific targeting (reviewed in Duncan, 2005) (see Table 4.1), however, the 
only targeted polymer conjugate to enter clinical trials to date is HPMA copolymer- 
GFLG-Dox bearing galactosamine (PK2).
PK2 was designed to target primary liver cancer as the ligand galactose 
(bound by the amino sugar) binds to the ASGPR found on both normal hepatocytes 
and hepatocellular carcinoma cells. This conjugate contained ~ 7.5 wt % Dox and ~ 
4 mol % galactose. In Phase 1 clinical trials < 5 % of the conjugate dose was 
excreted by 24 h, and achieved a 12-50 fold higher hepatoma-associated drug than 
equivalent free Dox (Seymour et al., 2002). PK2 had a maximum tolerated dose of 
160 mg/m2 Dox-equivalent. Although still approximately 3 fold higher than seen for 
free Dox, it was approximately half the value found for PK1, presumably due to the 
higher liver concentration. In PK2 a cleavable GFLG linker was used to bind 
galactose as well as Dox to the polymer backbone to prevent continuous uptake 
(recycling) o f polymer, as this would lead to accumulation of the polymer backbone 
rather than its hepatobiliary elimination.
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Table 4.1 Anticancer HPMA copolymer-drug conjugates with targeting residues in the literature.
Drug Linker Targeting Residue Indication References
Doxorubicin GFLG Tat Cancer Nori et al., 2003a ;2003b,
GFLG Hsp47/CBP2 binding peptide Cancer Tijerina et al., 2001; 2003
Hydrazone ATG antibody Cancer Nan et al., 2005
GFLG T ransferrin/CD71 antibody Cancer Ulbrich et al., 2004
GFLG Hyaluronan Cancer Kovar et al., 2002
GFLG Melanocyte stimulating hormone Cancer Luo et al., 2002 
O’Hare et al., 1993
Dox/Mce6 GFLG OV-TL16 antibody Ovarian cancer Shiah et al., 2001
Adriamycin GFLG OV-TL16 antibody Ovarian cancer Omelyanenko et al., 1998
Daunomycin/
puromycin
GFLG Fucose Cancer Duncan et al., 1987, 1988
Radiotherapy
P-emitter
Chelators GG-DPK for 99mTc 
CHX-A”-DPTA for 90Y
a vp3 integrin-targeting peptide Cancer
(angiogenesis)
Mitra et al., 2006
CHX-A”-DPTA Cyclohexyl derivative of Diethylenetriamine Pentaacetic acid; DPK = N-epsilon-bis(2-pyridylmethyl)lysine
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During the systematic design of PK2, HPMA copolymers bearing D- 
galactose, D-glucose and D-mannose, attached to the polymer via a GFLG linker 
were prepared. All these sugars were bound using the amino derivatives (e.g. 
galactosamine) to allow conjugation by aminolysis. To study their pharmacokinetics 
(and to allow gamma-camera imaging) copolymers were prepared additionally 
containing MA-Gly-Tyr to allow radio-iodination (Duncan et al., 1983). Both the 
galactose-targeted and the mannose-targeted conjugates were found to be 
predominantly in the liver after intravenous administration. The galactose-targeted 
conjugates were found predominantly in hepatocytes, whereas the mannose-targeted 
HPMA copolymers were found largely localised to the Kupffer cells (RES 
macrophages).
Subsequent studies used a library o f conjugates bearing 1-11 mol % galactose 
to investigate the minimum galactose loading necessary for increased hepatocyte 
targeting. Increased galactose content resulted in increased uptake, but a loading of 
only 4 mol % gave significantly increased targeting to liver cells (Duncan et al., 
1986). When using receptor-mediated approaches for drug targeting it is also 
important to define when receptor saturation occurs. In preclinical in vivo studies 
with PK2 it was found that liver targeting was dose-dependent and saturation 
occurred at > 0.68 mg/ml (Seymour et al., 1991). At higher doses the conjugates will 
simply distribute randomly around the body. Therefore in the phase 1 clinical trials, 
patient gamma-camera imaging was used to guide the dosing regime, moving from 
bolus injection to infusion at higher doses. There were no signs o f saturation or 
inhibition of hepatic targeting after intravenous administration with increasing drug 
doses (Seymour et al., 2002).
The various targeting residues that have been incorporated into HPMA 
copolymer-drug conjugates have mostly been directed at cancer (Table 4.1), 
however, ligands targeting other diseases, including leishmaniasis, have been 
proposed (Table 4.2). Ghandahari's group (Nan et al., 2004; Nan et al., 2001) 
synthesised a library o f HPMA copolymer-8-aminoquinoline conjugates with a 
mannose loading o f 2, 5, 10, 15 and 20 mol %. Increased uptake o f the conjugates 
into RAW 264 murine macrophages in vitro was evident at 5 mol % mannose. 
Further successive increases in mannose content above 5 mol % did not, however,
101
Table 4.2 HPMA copolymer-drug conjugates with targeting residues in the literature with non-cancer applications.
Drug Linker Targeting Residue Indication References
Dexamethasone Hydrazone D-aspartic acid octapeptide Rheumatoid
Arthritis
Wang et al., 2006
8-aminoquinoline GFLG Mannose Leishmaniasis Nan et al. 2004
Cyclosporin GFLG a-CD3 antibody Immunosuppression St’astny et al., 1997
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significantly increase uptake. Here, it was considered important to investigate the 
effect o f the mannose content o f HPMA copolymer-8-aminoquinoline conjugates on 
targeting to THP-1 cells as this had not been reported before in this cell type.
4.1.5 Synthesis and Characterisation o f  the HPMA copolymer ± Man Conjugates
Here, the same systematic approach used to develop PK2 was used to 
optimise the mannose loading o f the proposed HPMA copolymer conjugates. An 
HPMA copolymer precursor o f Mw 30,000 g/mol containing ~ 10 mol % GFLG side 
chains were used for this study (as for PK2). Again it was decided to use cleavable 
linkers for both drug and mannose binding to prevent accumulation of HPMA 
copolymer-Man in the macrophage.
In order to determine the minimum mannose content necessary for MR 
targeting in THP-1 cells, a library o f HPMA copolymer conjugates was prepared 
containing a range of loadings of D-mannosamine (2, 4, 6 and 8 mol %), and, in 
addition, OG-cadaverine as a fluorescent marker (1 mol %) to monitor cell uptake. 
OG was chosen as it has similar fluorescent qualities to FITC but is less susceptible 
to pH quenching (pKa = 4.7 Invitrogen). Use o f mannosamine and OG-cadaverine 
allows direct aminolysis o f the polymeric precursor to prepare the conjugates.
Chemical Characterisation o f  the Conjugates
The conjugates were first characterised in terms of total OG and free OG 
content. As they were used to monitor endocytic uptake, it was also important to 
determine the pH and concentration dependent fluorescence output.
Quantification of mannose content proved more difficult. Sugar 
quantification is complicated as it first involves hydrolysis of the sugar from the 
polymer backbone using harsh conditions, and then chemical modification of the 
sugar to allow indirect measurement. Previous studies with PK2 used hydrolysis 
conditions of 4M HCI at 100 °C for 4 h to release the galactosamine sugar. The sugar 
content in the hydrolysate was then quantified using an amino acid analyzer (Cheng 
& Boat, 1978; Duncan et al., 1986). This method, however, proved difficult due to 
degradation of the sugar before measurement.
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Elson and Morgan originally developed a method to determine free 
glucosamine by acetylation, transformation into a coloured solution by Erlich 
reagent, and measurement by UV (Elson & Morgan, 1933). Configliacchi et al. 
(1996) used this method to determine the total galactosamine content in PK2. 
Following its hydrolysis from the polymer using HC1 6N at 60 °C for 5 h, 
transformation of the sugar using a modified Elson Morgan method, it was measured 
by HPLC.
Here, the mannose content of the conjugates was determined using the 
Configliacchi method but the derivitised sugar was measured by UV, as this was 
quicker than HPLC and prevented degradation of the sugar. This method was 
developed by Salvatore Nicoletti (University of Dundee).
Biological Characterisation o f  the Conjugates
Flow cytometry was used here to investigate the effect o f mannose loading on 
the binding and uptake o f the conjugate library using THP-1 cells as a macrophage 
model. Derived cell association at 37 °C and 4 °C was used to distinguish binding 
and uptake, and to define the minimum mannose content necessary to promote MR 
targeting. The concentration dependence o f uptake o f the HPMA copolymer-OG- 
Man conjugates was also investigated, and effect o f the competitive inhibitor mannan 
on uptake.
4.1.6 Summary o f  aims
• To synthesise a library of HPMA copolymer conjugates bearing a range of 
mannose loading ( 0 - 8  mol %), and also OG (1 mol %) to enable measurement 
of derived cell association.
• To characterise the conjugates with respect o f mannose content by the modified 
Elson and Morgan method, the total and free OG fluorescence using PD10 
column chromatography and UV absorbance respectively.
• To measure the cell-association o f the library at 37 and 4 °C in THP-1 cells using 
flow cytometry and define the minimum mannose content necessary to promote 
MR targeting.
• To investigate the specific and non-specific cell-association o f HPMA 
copolymer-OG-Man by co-incubation with mannan as a competitor for the MR.
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4.2 Methods
The conjugation protocol for HPMA copolymer-GFLG-ONp and Man was 
initially adapted from Kopecek et al., (1986), and Salvatore Nicoletti (University of 
Dundee) provided help with modifications to the protocol.
4,2.1 Optimisation o f reaction time using TLC
To optimise the reaction times for mannose conjugation, first, reactions were 
carried out with HPMA copolymer precursor and mannosamine alone. HPMA 
copolymer containing GFLG-ONp side chains (9.03 mol %) was dissolved in DMSO 
(5 mg in 0.5 ml). To this solution, after stirring at room temperature for 30 min, a 
solution o f mannosamine.HC1 in dry DMSO (19.6 pi o f 12 mg/ml), along with 2 
molar equivalents (0.15 pi) of triethylamine. The reaction mixture was stirred at 
room temperature under nitrogen and monitored every hour using TLC.
The mannosamine aminolysis reaction was monitored by TLC using reverse 
phase silica gel plates in a solution of potassium orthophosphate and acetonitrile (9/1 
v/v). The plate was treated with ninhydrin reagent to visualise the amine group on 
the sugar (as a purple spot). The disappearance o f this spot showed that the 
mannosamine was reacting with the polymer. TLC was performed every hour from 
the start o f the reaction for 5 h, and then again after 16 h. After 4 h the spot had 
completely disappeared.
The same procedure was used to monitor OG-cadaverine binding. First, 
mannosamine was reacted as described above, and then, after 4 h, OG-cadaverine 
was added and the reaction left over night. Aminolysis by OG-cadaverine was 
monitored using silica gel plates in a mixture o f methanol and triethylamine (9.5/0.5 
v/v). The endpoint o f the reaction was taken as the point where the spot of free OG 
had disappeared and there was visible OG at the baseline (i.e. co-localised with the 
polymer). TLC was performed at the start o f the reaction and at 16 h to ensure the 
OG had bound to the HPMA copolymer.
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4.2.2 General method for preparation o f HPMA copolymer GFLG-OG conjugates
The method used to prepare the HPMA copolymer-OG conjugates is shown 
in Figure 4.2. Typically, 102.8 mg o f HPMA copolymer-GFLG-ONp (9.03 mol % 
side chains) was dissolved in DMSO (1 ml). After stirring at room temperature for 
30 min, 444 pi o f a solution of OG-cadaverine in dry DMSO was added (6.3 mg/ml) 
to this solution, estimated to give a final theoretical loading o f 1 mol %. The mixture 
was stirred in the dark for 16 h at room temperature under a nitrogen atmosphere and 
then an excess o f aminopropanol (2 pi) was added to remove any remaining ONp 
groups.
4.2.3 General method fo r  preparation o f HPMA copolymer GFLG-OG-Man 
conjugates
The method used to prepare the HPMA copolymer-OG-Man conjugates is 
shown in Figure 4.3. HPMA copolymer-GFLG-ONp (9.03 mol % side chains) was 
dissolved in DMSO (99.8 mg in 1 ml). To this solution, after stirring at room 
temperature for 30 min, a solution of mannosamine hydrochloride in dry DMSO (12 
mg/ml) was added (estimated to give theoretical final loadings o f 2 (98 pi), 4 (196 
pi), 6 (294 pi) or 8 (392 pi) mol % on the side chains) along with 2 molar 
equivalents (3.1 pi) o f triethylamine. The reaction mixture was stirred at room 
temperature for 4 h. Then, 430 pi o f a solution o f OG-cadaverine in dry DMSO (5 
mg/ml) was added to give final loading o f 1 mol %. The mixture was stirred at room 
temperature in the dark for 16 h under a nitrogen atmosphere and then an excess of 
aminopropanol (2 pi) was added to remove any remaining -ONp groups.
4.2.4 Purification o f HPMA copolymer-OG ± Man conjugates
The conjugates were then precipitated by pouring the reaction mixture into 50 
ml o f a rapidly stirring ice-cold acetone: diethylether solution (9/1 v/v), and stirring 
on ice for 10 min. The precipitate was then filtered off, thoroughly washed again 
with the acetone and ether solution, and dried. Acetone and diethyl ether fumes were 
trapped in a liquid nitrogen cold trap. The product was dissolved in water and then 
lyophilised before characterisation.
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Figure 4.2 Synthesis reaction scheme of HPMA copolymer-GFLG-ONp (Mw 37,000 
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4.2.5 Characterisation o f the conjugates in respect o f total and free OG
The OG content of the HPMA copolymer conjugates was estimated using the 
UV absorbance. A concentration curve of free OG-cadaverine was prepared (0.001 
to 1 pg/ml) in phosphate buffer at pH 7.4. Conjugate samples were also dissolved at 
in phosphate buffer (0.1 mg/ml). The absorbance was then measured at 494 nm and 
the amount of conjugated OG calculated using the calibration curve.
The free OG content of the conjugates was measured using a PD10 size 
exclusion column with PBS as the eluent. A sample of the conjugate (1 ml at 5 //g/ml 
OG-equivalent) was applied to the column and then 0.5 ml PBS added sequentially 
until 48 fractions (0.5 ml) were collected. A sample of each fraction (200 p\) was 
then assayed in a 96 well plate by measuring the UV absorbance at 494 nm. Free OG 
elutes separately from the conjugate, the conjugate elutes in the void volume (i.e. 
fraction 1 -  14), and therefore allows estimation of the free OG as a percentage of 
the total OG content. Those conjugates that contained a significant amount of free 
OG were re-purified using a PD10 column. Fractions 1 -  14 were collected and the 
remainder (containing free OG) was discarded. All the conjugates used in the 
biological assays contained less than 5 % free OG.
4.2.6 Determination o f mannose loading on HPMA copolymer conjugates
The measurements of mannose content in the HPMA copolymer-OG-Man 
conjugates were performed with an assay set up by Salvatore Nicoletti (University of 
Dundee). Analysis of conjugates 6 - 1 0  were performed with Salvatore Nicoletti at 
Cardiff University, but then subsequent analysis of conjugates 11 and 12 was 
performed by Salvatore Nicoletti at the University of Dundee. The method used is 
described below.
First, standards of D-mannosamine hydrochloride were prepared by dilution 
of the stock solution in water (0.63 mg/ml in 10 ml water) to give various 
concentrations between 0 and 16 pg /ml. To determine the mannose content of the 
conjugates, first the glycosidic linkage between the D-mannosamine and the glycine 
of the tetrapeptide was cleaved. A sample (1 ml) of the standard or conjugate (0.1 
mg/ml) was transferred to a 10 ml glass tube, and mixed with 1 ml of HCI (6 M). The
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tubes were capped and the solutions were stirred for 5 h at 60 °C, and then dried 
under vacuum.
The free mannose was then derivitised using acetylacetone and Ehrlich 
reagent. The dry residues were dissolved with 0.5 ml of water and 0.5 ml of acetyl 
acetone reagent (4.8 % (v/v) acetyl acetone in 1 M sodium carbonate buffer). The 
resulting mixtures were stirred for 20 min at 96 °C and then cooled on ice. 
Subsequently 2.5 ml of absolute ethanol and 0.5 ml of Ehrlich reagent (0.8 mg of p- 
dimethylaminobenzaldehyde dissolved in 30 ml of absolute ethanol and 30 ml of 
HC1) were added. The samples were then stirred for 10 min at 65 °C, and the UV 
absorbance measured at 530 nm. The mannose content was calculated from the 
calibration curve.
4.2.7 Absorbance and fluorescence characteristics o f  conjugates
The concentration and pH dependence o f the HPMA copolymer-OG ± Man 
conjugate fluorescence were measured as described in section 2.3.2.
4.2.8 Measurement o f binding and endocytosis o f  HPMA copolymer-OG ± Man in 
THP-1 Cells by flow  cytometry
The derived cell association o f HPMA copolymer-OG ± Man was determined 
using clear tissue culture media at an OG concentration of 1 pg/ml of OG-equivalent 
for all polymer conjugates in differentiated THP-1 cells with time. Derived cell 
association was measured using flow cytometry as described in section 2.3.3.
It should be noted that the PM A used to differentiate THP-1 cells from 
monocytes to macrophages can, at high levels, activate macrophages and this can 
lead to inhibition o f internalisation by the MR (Bozeman et al., 1988). However, the 
low levels o f PMA used here for differentiation would be unlikely to have this effect. 
Never the less, it was important to make sure all the PMA was removed.
First, the cell-association o f HPMA copolymer-OG and HPMA copolymer- 
OG-Man (with a theoretical 8 mol % mannose content) at 37 °C after 60 min 
incubation with THP-1 cells was compared. To determine the OG release the
111
Chapter 4
incubation media was retained and the free OG content was measured using a PD 10 
column as described in section 4.2.5.
To investigate the effect o f the presence of serum on the cell-association of 
HPMA copolymer-OG-Man, THP-1 cells were incubated with media containing 
HPMA copolymer-OG or HPMA copolymer-OG-Man, with or without serum 
present. Additionally, THP-1 cells were incubated overnight without serum to 
investigate the effect o f serum starvation.
The concentration-dependence o f conjugate uptake was measured by 
incubating THP-1 cells with increasing amounts o f HPMA copolymer-OG-Man (0 -  
1 mg/ml) for 60 min. To investigate the effect o f mannose competition cells were co­
incubated with and without mannan (10 mg/ml) as a competitive inhibitor. Cells 
incubated with mannan were also pre-incubated for 30 min with mannan before 
polymer solutions were added.
To define the minimum mannose content necessary to promote MR targeting, 
cell-association with time o f the HPMA copolymer-OG conjugates bearing a range 
of mannose loadings ( 0 - 8  mol %) was measured over 60 min at 37 °C. The cell- 
association at 4 °C was then measured to distinguish the cell binding from the cell 
uptake.
4.3 Results
4.3.1 Characteristics of HPMA copolymer-OG ± Man conjugates
Aminolysis of HPMA copolymer-GFLG-ONp with mannosamine was 
complete within 4 h. OG-cadaverine added at this time was found on the baseline i.e. 
polymer-bound, with no visible free OG after 16 h.
The HPMA copolymer-OG-Man conjugates synthesised using this protocol 
are summarised in Table 4.3.
For the preliminary biological experiments, a control HPMA copolymer 
conjugate was prepared with ~ 1 mol % OG (code number 3), and two batches of
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Table 4.3 Characteristics of HPMA copolymer-OG ± Man conjugates.
Code
n°
Conjugate Structure Total OG + 
(mol %) (wt %)
Free OG + + 
(% )
Mannose (mol 
% theoretical)
Mannose * (mol 
% measured)
3 HPMA copolymer-GFLG-OG 0.32 0.93 3.7 0 N/A
11 HPMA copolymer-GFLG-OG 1.05 2.8 4.2 0 N/A
6 HPMA copolymer-GFLG-OG 0.56 1.53 2.6 0 N/A
7 HPMA copolymer-GFLG-OG-Man 0.54 1.46 1.7 2 1.4
8 HPMA copolymer-GFLG-OG-Man 0.68 1.85 2.1 4 3.6
12 HPMA copolymer-GFLG-OG-Man 0.59 1.6 1.5 4 4.8
9 HPMA copolymer-GFLG-OG-Man 0.58 1.57 2.0 6 5.0
10 HPMA copolymer-GFLG-OG-Man 0.83 2.25 1.9 8 4.7
4 HPMA copolymer-GFLG-OG-Man 0.35 1.04 2.4 8 Not measured
5 HPMA copolymer-GFLG-OG-Man 0.98 2.89 1.1 8 Not measured
f Estimated by UV absorbance at 494 nm t f  Estimated by PD-10 chromatography * Estimated by Elson Morgon method
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HPMA copolymer conjugate with ~ 1 mol % OG and a theoretical loading of ~ 8 
mol % mannose (code number 4 and 5). This is the maximum amount that could be 
loaded on the HPMA copolymer precursor (9.03 mol % ONp groups).
Subsequently, a library of conjugates containing a range of mannose loadings 
(0, 2, 4, 6 and 8 mol %) was successfully synthesised (code numbers 6-10). Again 
conjugates contained ~ 1 mol % OG. A further batch of conjugates (HPMA 
copolymer-OG and HPMA copolymer-OG-Man containing 4 mol % mannose) was 
then synthesised.
Free OG-cadaverine (in phosphate buffer, pH 7.4) had an absorbance 
maximum of 494 nm (Figure 4.4a) and the calibration curve showed a linear 
dependence (r2 = 0.9996) of absorbance related to concentration over the range of 
concentrations tested (0 -  10 /^g/ml) (Figure 4.4b). The total OG content of all 
conjugates was in the range of 0.32 -  1.05 mol % (0.93 -  2.8 wt %) (Table 4.3). The 
HPMA copolymer-OG conjugates had an identical absorbance spectrum (Figure 
4.5).
The free OG content of the conjugates was determined using PD10 size 
exclusion chromatography. The conjugate eluted in the first 14 fractions (7 ml), 
whereas free OG eluted in fractions 14 - 48 (7 - 24 ml) (Figure 4.6). The free OG 
content was between 1.1 -  4.2 % of the total for all of the conjugates. The first 
conjugates (Table 4.3, code numbers 3 - 5) initially showed high free OG content (10 
-  12 %). However, it was decided for all biological experiments that only conjugates 
with levels less than 5 % free OG would be used, and therefore conjugates were re­
purified using the PD10 column. The library of conjugates containing 0, 2, 4, 6 and 8 
mol % mannose (code numbers 6 - 1 0 )  contained a similar amount of free OG (1.7 -
2.6 %) (Figure 4.7).
The calibration curve of mannose showed a linear dependence (r2 = 0.9996) 
of absorbance related to concentration over the range of concentrations tested ( 0 - 1 6  
pg/ml)  (Figure 4.8). The mannose content of conjugates 4 and 5 were not measured. 
The measured mannosamine content of the library of HPMA copolymer conjugates
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mean ± SD (n = 4).
115
A
bs
or
ba
nc
e 
Un
its
 
(a
.u
.)
0.35
0.3
0.25
0.2 HPMA copolymer- 
OG-Man
0.15 — - OG cadaverine
0.05
350 400 450 500 600550
Wavelength (nm)
Figure 4.5 Typical UV scan of HPMA copolymer-OG conjugate and OG 
cadaverine in phosphate buffer at pH 7.4.
116
1200 Bound OG
1000
800
</>4->
cD
600<l>uc<uu
V)<D Free OG400
OD
U_
200
0 5 10 15 20
Eluted Fraction (ml)
Figure 4.6 PD10 elution o f HPM A copolym er-O G  conjugates. HPMA copolymer-OG 
and free OG cadaverine were eluted in PBS through a PD10 column and fluorescence 
measured at 520 nm.
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eluted in PBS and the fractions collected were assayed for fluorescence measured (Abs 494 
nm Em 520 nm).
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( 0 - 8  mol %) correlated reasonably well with the theoretical values except at the 
highest value of 8 mol % containing between 0 - 5  mol % mannose (2 mol % 
theoretical gave 1.43 mol % measured, 4 measured 3.55, 6 measured 5.02, 8 
measured 4.71 mol %) (Table 4.3).
It was confirmed that pH had a relatively small effect on the fluorescence 
output of OG (Figure 4.9). A small reduction in fluorescence output was seen from 
PH 7 to pH 6.2 (about 16 % at 1 mg/ml), but not from 6.2 to 5.5. Concentration 
dependent quenching was seen at concentrations > 0.2 -  0.6 mg/ml, but this was 
minimal.
4.3.2 Comparison of the derived cell-associated fluorescence of HPMA copolymer- 
OG-Man conjugates in THP-1 cells
Incubation of cells with the HPMA copolymer-OG for 1 h at 37 °C showed a 
clear increase in derived cell-associated fluorescence with time when compared to 
cells incubated without conjugate (Figure 4.10a) (p < 0.05, students t-test). Derived 
cell-associated fluorescence was 3-fold greater for the HPMA copolymer-OG-Man 
conjugate (Figure 4.10b). When the cell culture media (collected after 1 h 
incubation) was subject to PD10 chromatography, there was no significant difference 
in the amount of free OG seen at the end of the incubation compared to the control (~ 
5 % to ~ 7 % free OG) (Figure 4.11).
When experiments were conducted to examine the effect of serum on derived 
cell association, greater uptake of HPMA copolymer-OG-Man was seen when the 
cells were incubated without serum; however, similar and significant differences 
were seen between HPMA copolymer-OG and HPMA copolymer-OG-Man derived 
cell association with and without serum present (Figure 4.12). Serum starving the 
cells overnight significantly reduced the difference in derived cell association 
between the targeted and the non-targeted conjugate.
There was an increase in concentration-dependent cell-association of HPMA 
copolymer-OG-Man compared to HPMA copolymer-OG after 1 h at 37 °C. This was
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not linear, the rate increasing with concentration, and did not plateau over the range 
studied (Figure 4.13).
When mannan was co-incubated with HPMA copolymer-OG-Man in the 
THP-1 cells, there was a reduction in derived cell-associated fluorescence at all 
concentrations (Figure 4.14). The derived cell-associated fluorescence of the cells at 
a concentration of 0.1 mg/ml HPMA copolymer-OG-Man was reduced by ~ 50 % 
when mannan was present, but at concentrations of 0.6 pg/m\ this had reduced by ~ 
20 %. This derived cell association reached a plateau at ~ 0.5 pg/m\. The derived 
cell-associated fluorescence measured in the presence of mannan was subtracted 
from the derived cell-associated fluorescence measured in the absence of mannan, to 
show the mannose specific cell-association. The specific derived cell association was 
~ 20 % of the total derived cell association.
The percentage of cells that were positive (i.e. had fluorescence above the 
autofluorescence of the control cells) was significantly increased for all mannose 
loadings (Figure 4.16a). The cells incubated with HPMA copolymer-OG did not 
increase above ~ 10 % positive. When the mean fluorescence was examined only the 
cells incubated with the conjugate containing 8 mol % mannose had significantly 
higher fluorescence compared to the control HPMA copolymer-OG (Figure 4.16b). 
The derived cell-associated fluorescence increased steadily with time over 1 h in 
cells incubated with all of the conjugates (Figures 4.15 and 4.17a). Cell-association 
of the 2 mol % mannose-loaded conjugate showed no significant difference 
compared to the non-targeted control overall (although there was a significant 
difference for the last two time points) (p > 0.05, ANOVA and Bonferroni post hoc 
test) (Figure 4.17b). However, at mannose loadings of 4 mol % mannose and above, 
the cells showed significant differences in derived cell association compared to the 
control. The uptake was rapid over the first 10 min, slowed after 10 min but did not 
reach a plateau. The increase in derived cell association correlated with mannose 
loading but it was not linear. The conjugates containing 2, 4, 6 and 8 mol % loadings 
showing a 2, 5, 6 and 18-fold increases in uptake at 60 min respectively. There was 
minimal derived cell association at 4 °C (Figure 4.18).
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Figure 4.17 Cell-associated fluorescence of HPMA copolymer-OG ± Man 
conjugates in THP-1 cells (37 °C). Panel (a) shows the cell-association o f a library of 
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association o f HPMA copolymer-OG-Man (2 mol%) compared to control on a larger 
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and HPMA copolymer-OG-Man (4, 6 or 8 mol%) was determined as p < 0.05 (ANOVA 
and Bonferroni post hoc test).
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4.4 Discussion
4.4.1 Conjugate synthesis and characterisation
The methodology for conjugation of galactosamine to HPMA copolymer- 
GFLG-ONp by aminolysis has been well established (Duncan et al., 1983; Kopecek, 
1986), but it was still necessary to determine the optimal reaction conditions for 
synthesis o f HPMA copolymer-Man conjugates. The initial reaction conditions and 
timings chosen here for mannosamine were based on PK2 synthesis and it was found 
that 4 h was optimal for mannose conjugation. This is much less than that used to 
bind galactosamine to HPMA copolymer precursor (16 h) (Kopecek, 1986). 
Subsequently, a library o f OG-labelled conjugates with a range of mannose loading 
( 0 - 8  mol %) was prepared.
The total OG content achieved was reproducible, with only a small batch-to- 
batch variation. The loading was kept low (< 1 mol % which equates to ~ 1 -  3 
pg/mg polymer). This was similar to that reported for other polymer conjugates (e.g. 
hyaluronic acid (3.4 pg/mg) (Duncan et al., 2008) and dextrin (5 pg/mg) (Richardson 
et al., 2008)). This low OG loading was used to allow higher mannose and drug 
loadings, and also to minimise the possibility that the OG fluorophore would itself 
would change the binding or uptake rate.
The PD10 column chromatography showed that the conjugates had only very 
low levels o f free OG (< 5 % of total fluorescence) and as this free OG level was 
similar for all conjugates, the impact on the measured total fluorescence would be 
minimal. Also, no significant pH-quenching o f OG fluorophore was observed with 
pH. Therefore, the measured cellular fluorescence would be expected to be 
independent o f the cellular compartment to which the conjugate was localised. 
Although higher concentrations (> 0.2 - 0.6 mg/ml) o f OG did show a small 
reduction in fluorescence output, the cell uptake experiments used a much lower 
concentration (1 pg/ml OG equivalent in the incubation medium). It is important to 
note that the concentration of fluorescent conjugate in endocytic compartments may 
be very high due to vesicle fusion. However, the intracellular concentrations were 
unlikely to reach 0.2 mg/ml.
130
Chapter 4
Although the total and free OG content o f the HPMA copolymer conjugates 
synthesised here was easy to determine, accurate Man quantification was much more 
difficult. The TLC showed no free mannosamine left after a 4 h reaction for any of 
the conjugates. However, the modified Morgan Elson method used here suggested 
that the maximum Man loading achievable was ~ 5 mol %, compared to a theoretical 
loading o f 8 mol % hoped for.
This discrepancy could have resulted from a low reaction yield. However this 
is unlikely, as PK2 has been prepared on an industrial scale without such problems. 
Alternatively, the values measured could be an artefact o f the quantification method. 
Configliacchi et al. (1996) optimised the hydrolysis conditions for PK2, which 
contained ~ 4 mol% galactose. They noted that higher temperatures and longer 
reaction times could lead to decomposition o f the sugar. The balance between 
hydrolysis and sugar decomposition is likely to vary for each sugar type. Possible 
issues here include the Man was not released optimally at this time and temperature, 
and/or the released sugar was subject is degradation. The solution conformation of 
polymer-drug conjugates has been shown to affect the drug release of drug from 
HPMA copolymer conjugates (Vicent et al., 2005). Perhaps this was also a factor 
here. It may have been better to further standardise the sugar analysis method for the 
Man conjugates but unfortunately time did not allow it. Another option that could 
have been used to accurately define Man content would have used [ l4C] 
mannosamine to prepare the conjugates. This would have had the added benefit of 
negating the need for fluorescence labelling, to measure cell uptake, which has 
inherent disadvantages, but these experiments were also not possible for various 
reasons. NMR of the conjugates could also have provided information on the 
conjugation o f mannosamine and OG. However, the 'H-NMR analysis identified the 
proton o f the polymer backbone and o f the protons o f the GFLG peptide chain, but 
the spectroscopic profile did not show any signal related to the protons o f the amino 
sugar or the fluorescent probe (not shown).
Never the less, as the synthetic methods used to prepare the HPMA 
copolymer-sugar conjugates have been well documented in the past and the TLC 
detected no free mannosamine in the reaction mixture, it was decided to progress to 
the biological experiments with these conjugates, assuming the theoretical loading to 
be correct.
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4.4.2 Cell uptake and evidence fo r MR-specific interaction
The biological experiments did provide indirect evidence to support the 
conclusion that the mannose had indeed been successfully bound to the polymer at 
the theoretical loadings. The derived cell association o f HPMA copolymer-OG 
conjugates with THP-1 macrophages measured using flow cytometry was 
significantly higher for the mannose-targeted conjugates. The percentage o f positive 
cells reached a maximum after 10 min for conjugates with 4, 6 and 8 mol % Man. 
The cells incubated with the conjugate loaded with 2 mol % Man had significantly 
more positive cells than the control but didn’t reach a maximum over the time course 
studied. The mean fluorescence didn’t show discemable differences except for the 
conjugate loaded with 8 mol % Man. Differences may have been seen more clearly if 
the cells were incubated with a greater concentration o f conjugate or for a longer 
time course.
When both the percentage o f positive cells and the mean fluorescence o f the 
cells was taken into account (as described in section 2.3.3) the differences were more 
clearly seen. Cell uptake was progressive with time, but not linear as a plateau of 
fluorescence was seen for all mannose loadings with time (Figure 4.17a). This may 
be due to the release o f free fluorophore or exocytosis o f the conjugate. Exocytosis 
rates were not measured, but the PD10 analysis o f the media after incubation with 
the cells showed no significant increase in free OG after 1 h (Figure 4.11), so release 
o f free OG is unlikely to account for the decreased rate o f uptake. Internalisation of 
surface MR with limited replacement from intracellular MR stores could be rate 
limiting. However, as no plateau was seen despite significantly increased conjugate 
concentration (~ 10 times more than used for time-dependent studies) (Figure 4.13), 
this is unlikely. The macrophage has massive intracellular MR stores, which can be 
mobilised rapidly (Stahl et al., 1980). Conjugates were clearly internalised as derived 
cell association was almost completely inhibited at 4 °C. However no concentration 
dependent specific uptake was seen at below 0.4 pg/ml. This might indicate a large 
amount o f non-specific uptake or that the MR were not adequately blocked by the 
mannan.
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The picture is complicated. Although the differences between the conjugates 
may be exaggerated using the derived cell-associated fluorescence, the results still 
indicate enhanced uptake o f the mannose targeted conjugates. The cells incubated 
with conjugates loaded with 2 - 6  mol % Man did not significantly different 
fluorescence values, however more cells took up the conjugates with 4 - 8  mol % 
Man and more rapidly (10 mins). The combined results showed that the derived cell 
association o f HPMA copolymer-OG-Man was enhanced when the mannose loading 
was at 4 mol % and above (Figure 4.17a). This is consistent with Nan et al. (2004) 
who reported that 5 mol %, but not 2 mol %, mannose was sufficient for targeting. 
These observations here were also comparable to the studies of Duncan et al. (1986) 
that found ~ 4 mol % galactosamine was able to target the ASGPR. The MR is 
expressed on macrophages at a similar level (5 x 105 receptors/cell) to the ASGPR on 
liver cells. The MR-targeting residue was bound to the conjugate by a GFLG linker 
and therefore conjugate would be expected to release Man, leaving just the 
polymeric carrier. This would then be excreted rather than continually being targeted 
to more macrophages.
It was found that doubling the Man content o f the conjugates produced more 
than a doubling o f uptake by THP-1 cells. These observations correlate with studies 
that have shown that multiple Man residues are necessary for MR interaction 
(Mammen et al., 1998). The MR has multiple binding sites, as discussed earlier 
(Section 1.6). Ligand interaction via individual saccharide groups is of low affinity, 
but high affinity binding is achieved through multivalent cooperative binding. When 
multiple ligands are incorporated into one macromolecule, biorecognition and 
binding should be enhanced (Mammen et al., 1998). This has previously been 
described as the ‘glycoside cluster effect’ - affinity enhancement over and above 
what was expected from the increased concentration o f sugar (Lee and Lee, 2000).
Oligomannosides with three branches have a greater inhibitory potency in 
preventing MR-mannan binding than linear oligomannosides or those with higher 
branching (Kery et al., 1992). It has also shown that the incorporation of trimannose 
residues stimulated endocytosis o f FITC-dextran as well as increasing expression of 
other adhesion molecules and co-stimulatory molecules (Kanbe et al., 2001). When 
investigating specificity of HPMA copolymer-Dox-galactose conjugates, multivalent
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‘TriGal’ targeting residues produced greatly increased biorecognition when 
compared to the galactose (David et al., 2004). Linking a trimannose residue to each 
HPMA copolymer-GFLG side chain may be a possible future method of increasing 
targeting efficacy.
When studying the uptake o f HPMA copolymer conjugates the THP-1 
derived cell-associated fluorescence was routinely measured in serum-free media. 
Serum has been shown to reduce uptake of mannose-targeted liposomes into mouse 
peritoneal macrophages in vitro, by competitively binding the mannose conjugate 
(Opanasopit et al., 2001). However, in these studies, serum competition for MR- 
specific binding was probably not important as there was no change in the relative 
difference between HPMA copolymer-OG and HPMA copolymer-OG-Man derived 
cell association when cells were incubated with or without serum. A general decrease 
in uptake o f both conjugates was seen in the presence o f serum but this was not 
specific to MR-mediated uptake. Reduced targeting via the MR was only seen after 
serum starvation, which is known to effect receptor expression, and may have 
reduced surface expression o f the MR. There was also greatly enhanced non-specific 
cell-association, which could be attributed to the induction o f apoptosis and loss of 
cell integrity rather than endocytosis.
4.5 Conclusions
In conclusion, a library o f HPMA copolymers containing OG and mannose 
loadings o f 2, 4, 6 and 8 mol % was synthesised and characterised. Although 
quantitative estimation o f the Man content proved difficult, the theoretical values did 
seem to correlate with the biological properties. A Man content threshold of 4 mol % 
seemed to be necessary to achieve reproducible targeting. For this reason the HPMA 
copolymer-Man (4 mol %) conjugate was chosen to study further the intracellular 
trafficking (chapter 5) and for AmB conjugation (chapter 6).
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Chapter 5
Intracellular fate of HPMA copolymer conjugates: Establishment of a 
subcellular fractionation method in THP-1 cells
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5.1 Introduction
When polymer-drug conjugates are designed for intracellular delivery, it is 
important to study their intracellular trafficking. The MR-targeted anti-leishmanial drug 
conjugate, once endocytosed by the macrophage, must be able to access the PV and not 
be routed to the recycling/secretory pathways (Figure 5.1). The precise intracellular 
localisation o f the conjugate and/or drug may also influence the choice o f drug and 
linker. This would also depend on the drug’s mode o f action. Therefore, the aim of this 
study was to establish a subcellular fractionation (SCF) method that could be used to 
investigate, and ideally quantify, the intracellular trafficking o f the MR-targeted HPMA 
copolymer-drug conjugates. Fluorescence microscopy was used to support these 
studies. The SCF method was set up in the uninfected THP-1 macrophage model, but 
with the aim o f transferring the technique to the infected model (at LSHTM). It was 
hypothesised that if  the conjugate was delivered to the PV, then it would directly access 
the parasite. However, if the conjugate was delivered to the lysosomal compartments, 
and the lysosomes did not fuse with the PV, it may then be necessary to include a linker 
that could release the drug here so it would diffuse to the PV.
5.1.1 Subcellular fractionation
Since the pioneering work in the 40’s and 50’s on cell fractionation, both cell 
fractionation and microscopy techniques have evolved side by side (De Duve & 
Beaufay, 1981). The first attempts to fractionate tissue or cells by applying 
sedimentation rates to separate organelles, used differential centrifugation (Bensley & 
Hoerr, 1934; de Duve, 1969; Hogeboom et al., 1948). Differential centrifugation 
involves homogenisation of tissue or cells in an isotonic solution (preventing vesicle 
ruption or changes in sedimentaion due to osmosis (Schneider, 1948)), and fractionation 
o f the homogenate by means o f successive centrifugations and washings. Increasing 
centrifugal force and centrifugation times can be used to yield fractions containing 
“nuclei”, “mitochondria”, “microsomes” and finally the cytosolic supernatant. Claude 
first investigated enzyme markers as a method to assess the purity each o f the fractions 
and developed a ‘quantitative’ fractionation method (Claude, 1946a; Claude, 1946b).
Hogeboom with Kuff pioneered the use o f density gradient centrifugation rather 
than differential centrifugation for quantitative fractionation of cells (Schneider &
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Figure 5.1 Potential intracellular fate of HPM A copolymer-drug conjugates.
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Hogeboom, 1951). Generally, density gradient centrifugation uses isopycnic or 
equilibrium centrifugation. The solution is placed on top o f the gradient and centrifuged 
at forces in excess o f 150,000 x g. The organelles move through the gradient until they 
reach the point in the gradient at which their density matches that o f the surrounding 
solution.
There are several advantages o f density gradients compared to differential 
centrifugation. Differential centrifugation requires differences in sedimentation 
coefficients as large as 1,000 fold for good separation (Hinton & Mullock, 1997) and 
therefore provides poor resolution o f organelle fractions. This is particularly true for 
those that are close in density such as the endocytic compartments. Density gradient 
centrifugation gives improved resolution as it allows the use o f buoyant density, as well 
as sedimentation rate, as a separation parameter. To investigate intracellular trafficking 
o f polymer conjugates in macrophage cells, it was necessary to separate the different 
compartments o f the endocytic pathway, so it was considered more useful to develop a 
density gradient centrifugation method.
5.1.2 Use o f SCF to investigate trafficking ofpolymer-drug conjugates
In recent years, fluorescence microscopy has been the principle method used to 
investigate the intracellular trafficking of drugs and drug conjugates (Watson et al., 
2005) (Table 5.1). SCF has not been widely utilised for drug delivery research, but 
several studies on the intracellular trafficking of HPMA copolymer-drug conjugates 
have used SCF methods (although often in conjunction with microscopy) (Table 5.2).
Trouet pioneered the use of fractionation methods to quantify trafficking of drug 
conjugates, beginning with DNA-daunorubicin/adriamycin complexes designed for 
lysosomotropic delivery (Trouet et al., 1972). Early studies on HPMA copolymer-drug 
conjugates used subcellular fractionation to investigate their intracellular fate. Duncan 
et al. (1986) first demonstrated the fate of HPMA copolymer-drug conjugates (PK2) in 
liver cells using density gradient fractionation. They showed that, with time, the 
radiolabelled conjugate was transported to lysosomes and then Dox was released and 
accumulated in the nucleus. More recently, Nori et al., (2003a; 2003b) and Tijerina et 
al., 2001; 2003) have used density gradient centrifugation to study the fate of peptide- 
targeted HPMA copolymer conjugates of Dox or monoethylenediamine (Mce6) in
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Table 5.1 Intracellular trafficking studies using microscopy to monitor HPMA copolymer drug delivery systems
Conjugate Methodology to investigate trafficking Cell line Reference
HPMA copolymer-ADR-GalN 
HPMA copolymer-ADR-OV-TL16
Live fluorescence microscopy and PFA fixed 
confocal microscopy (lysosomes labelled with 
neutral red or a 2-macrosialin)
HEP-G2
OVCAR-3
Omenyalenko et al., 
1998
HPMA copolymer-Mce6 -NLS Live fluorescence confocal microscopy A2780 Tijerina et al., 2003
HPMA copolymer-Dox-TAT 
HPMA copolymer-TAT
Live fluorescence confocal microscopy A2780 Nori et al., 2003
HPMA copolymer-Dox Fixed and live cell fluorescence and confocal 
microscopy (lysosomes labelled with FITC-Dextran)
B16F10 Seib et al., 2006
Table 5.2 Intracellular trafficking studies using SCF to monitor HPMA copolymer drug delivery systems
Conjugate Methodology Cell line Reference
HPMA copolymer-Dox-Gal Percoll density gradient, 26 fractions Rat liver Duncan et al., 1986
Cationic HPMA copolymer Percoll density gradient Rat Liver McCormick et al., 
1986
HPMA copolymer-Daunomycin-Gal Differential centrifugation Rat liver Wedge et al., 1991
HPMA copolymer-Mce6 -NLS 23 % Percol density gradient, 4 fractions A2780 Tijerina et al., 
2003
HPMA copolymer-Dox-TAT 
HPMA copolymer-TAT
23 % Percol density gradient, 4 fractions A2780 Nori et al., 2003
HPMA copolymer-Dox Differential centrifugation B16F10 Seib et al., 2006
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cultured A2780 ovarian carcinoma cells. These studies relied mainly fluorescence 
microscopy but they corroborated the results of cytosolic or lysosomal localisation by 
SCF. However, the fractionation method was limited as it only separated 4 fractions 
(lysosomal, plasma membrane, cytosolic and nuclear). Also, using these methods, they 
had poor resolution of the different endocytic compartments. Also, their studies used 
Percoll, a neutral, highly branched, high-mass, hydrophilic polysaccharide, which, 
although it can produce good purity of fractions, does not have good resolving power 
(Graham et al., 1994). A large overlap between mitochondria and lysosomes has been 
reported, with up to 50 % of the lysosomes being lost to the lower fractions (Arai et al., 
1991).
These early studies demonstrate the potential of using SCF to monitor the 
intracellular fate of drug conjugates. Our group have recently been developing 
improved differential centrifugation (Seib et al., 2006) and density gradient (Manunta, 
2007) methods with the specific aim of quantifying the intracellular distribution of 
polymer therapeutics.
Differential centrifugation of B16F10 cells showed quantitative and time- 
dependent accumulation of HPMA copolymer-Dox in lysosomes with subsequent 
transfer of free Dox to the nuclear fraction. The fractions were carefully characterised 
with high fraction purity (Seib et al., 2006). This study also underlined the unreliability 
of fluorescence microscopy due to both fluorescence quenching of Dox as a 
fluorophore, and the artefacts produced as a result of cell fixation. However, there was 
no separation of the endocytic compartments, the ‘lysosomal’ compartment likely also 
contained endosomes, mitochondria and peroxisomes. Subsequently, a novel density 
gradient centrifugation method was then developed in HepG2 cells as a means of 
gaining greater resolution of the endosomal compartments (Manunta, 2006). This 
density gradient subcellular fractionation, combined with fluorescence labelling of 
organelles, was also designed for characterisation of endocytic traffic of polymer 
therapeutics. However, it was clear from this study that further work was necessary to 
optimise separation of early endosomal and late endosomal/lysosomal compartments, 
and to apply the technique to polymer trafficking.
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5.1.3 Advantages and disadvantages of SCF and fluorescence microscopy for  
drug!conjugate trafficking studies
SCF has a number of advantages compared to fluorescence microscopy. The 
limitations of fluorescence microscopy are mainly related to the lack of resolution and 
fluorophore-associated artefacts. Well-characterised SCF methods have the advantage 
that they can be used to quantitate drug trafficking and fate. Also, the results obtained 
can be more representative of the whole cell population rather than just the few cells 
visualised with a microscope. SCF is however not without its disadvantages. The 
methods must be tailored to each specific cell line used and there is a need to carefully 
characterise the fractions obtained. It is almost impossible to purify each organelle type 
to complete homogeneity. There is also a danger of vesicle rupture and redistribution of 
the contents. As well as being technically difficult, SCF is very labour intensive, and 
requires large numbers of cells. Despite this, it is the most simple and quantitative 
method by which to measure intracellular localisation of drugs and conjugates, and their 
redistribution with time.
5.1.4 Establishment of an SCF method in THP-1 cells to study intracellular 
trafficking of HPMA copolymer conjugates
It was decided here to develop the SCF method of Manunta et al. (2007) for 
uninfected THP-1 cells. It was hoped that this could then be used to monitor the 
trafficking of HPMA copolymer-OG-Man and later the HPMA copolymer-drug 
conjugates. Uptake mechanisms and endocytic compartmentalisation are highly 
complex, so it was hoped that a better picture of the intracellular trafficking should be 
obtained. Confocal microscopy techniques were also established for THP-1 cells 
(reported in Richardson et al., 2008) to allow comparison of the SCF results and the 
visual images.
First it was necessary to optimise the cell breakage. It was essential to achieve a 
high breakage efficiency so that the lysate was representative of the whole cell 
population. This must be done without disrupting the organelle structure. A ball bearing 
homogeniser (cell cracker) was used to achieve a reproducible, standardised 
homogenate, the breakage efficiency measured by the release of cytosol (Aubry & 
Klein, 2006; Manunta, 2007; Seib et al., 2006). Iodinated media in conjunction with
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sucrose allows the required densities to be reached in media of lower viscosity and 
osmotic pressure than can be done with sucrose alone, resulting in good separation and 
little organelle damage. A density gradient of 5 -  20 % Optiprep (iodixanol solution) in 
a sucrose solution was chosen to allow sufficient separation of endosomes and 
lysosomes (Graham et al., 1994; Manunta, 2006).
It was essential to reliably identify the THP-1 fractions using organelle-specific 
markers. The enzyme assays chosen used here have been the standard for identifying 
subcellular fractions since the 50’s, and were previously validated for linearity by Seib 
et al. (2006). The marker enzymes used were N-acetyl-|3-glucosaminidase (lysosomes), 
alkaline phosphatase (plasma membrane) and lactate dehydrogenase (cytosol) as the 
assays are linear over a wide range of incubation times and protein content. There also 
appears to be little variation between different cell types (Seib et al., 2006; Tulkens et 
al., 1974). It was decided to use additional markers to label the endosomal 
compartments. Immunolabelling, common in fluorescence microscopy, can also be used 
to delineate the different endosomal compartments in the fractions.
The markers chosen were:
• Alkaline phosphatase (plasma membrane marker) (Graham, 1993).
• N-acetyl-(3-glucosaminidase (late endosome/lysosome marker) (Klemm 
etal., 1998).
• Immunolabelling using a LAMP-1 antibody (late endosome/lysosome 
marker).
• A 5 min incubation with Texas Red labelled-Transferrin (Tf-TxR) (early 
endosome marker).
• Immunolabelling using EEA-1 antibody (early endosome marker).
Once the subcellular compartments within the fractions have been characterised, 
the distribution of HPMA copolymer-OG-Man conjugates, as described in Chapter 4, 
was investigated.
143
Chapter 5
5.1.5 Establishment of a confocal fluorescence microscopy technique fo r  THP-1 cells 
to study intracellular trafficking of HPMA copolymer conjugates
The distribution of HPMA copolymer-OG-Man conjugates was then visualised 
using confocal fluorescence microscopy. Many fixation techniques that permeabilise the 
membrane to allow antibody labelling lead to movement or loss of linear structures such 
as HPMA copolymers. Therefore, Texas Red-labelled BSA was used here to label the 
endocytic pathway and confirmed using antibody labels. Using a protein marker that 
can be endocytosed negates the need for antibody markers (Richardson et al., 2008).
5.1.6 Summary o f aims
In summary, the specific technical aims were as follows:
• To establish a new density gradient SCF method for THP-1 macrophages
o To optimise cell breakage and to ensure minimal lysosomal 
rupture by measuring the lactate dehydrogenase release, 
o To characterise the fractions obtained for the early endosomal 
markers Tf-TxR and EEA-1 antibody; and also the late 
endosome/lysosome markers N-acetyl-p-glucosaminidase and 
LAMP-1.
• To investigate the time-dependent trafficking of HPMA copolymer-OG- 
Man conjugates in THP-1 cells after 5 min, 4 h (1 h pulse with a 3 h 
chase) or 24 h incubations using the SCF method.
• To investigate the effect of leupeptin protease inhibitor on the 
distribution of the HPMA copolymer-OG-Man conjugates, and released 
OG using the SCF method.
• To establish fixation and confocal fluorescence microscopy techniques 
for THP-1 macrophages using BSA-TxR to label the endocytic pathway, 
and to visualise the localisation of the HPMA copolymer-OG-Man 
conjugates after a 4 h incubation.
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5.2 M ethods
5.2.1 Subcellular fractionation o f THP-1 cells
5.2.1.1 Optimisation o f  cell breakage fo r  THP-1 cells
The methods has been developed by Manunta et al. (2007) and Seib et al., 
(2006) showed that a 8.008 mm ball giving a clearance o f 6 pm for the ball bearing in 
the cell cracker was ideal for cell breakage. It was decided to start with this and 
carefully validate it to ensure cells were broken, but organelles remained intact. The
o
same number o f cells ( 1 x 1 0 )  was used in each experiment. The THP-1 cell suspension 
was passed through the cell cracker (using the 6 pm gap ball) 1 -20 times.
After each pass, a 100 pi aliquot was taken and placed on ice until all passes 
were complete. Then, 50 pi was used to assess the degree o f cell breakage by measuring 
the lactate dehydrogenase release as described in section 2.3.5.1. Cell breakage was also 
assessed by eye using the light microscope coupled with a Trypan Blue exclusion assay 
(visible blue nuclei but no visible cells). Using the remaining 50 pi o f the sample, the 
lysosomal breakage was assessed by measuring N-acetyl-p-glucosaminidase activity as 
described in section 2.3.5.3. The optimum number o f passages through the cell cracker 
(10) was used in all subsequent fractionation experiments.
5.2.1.2 Gradient form ation
The continuous gradients (5 - 20 % w/v Optiprep) were prepared in advance 
using a gradient master and cooled to 4 °C. Two ultracentrifuge tubes were etched at 5 
ml using the marker block, one for the sample and one as a control. Solutions of 
Optiprep diluted in homogenisation buffer (HB) (comprising 250 mM sucrose, 6 mM 
EDTA, 60 mM HEPES, pH 7.4, and a 1 x protease inhibitor cocktail tablet) were made 
up at 5 % and 20 % Optiprep v/v. Then 5 ml o f the 20 % Optiprep solution was layered 
under 5 ml o f a 5 % solution using a syringe fitted with a long metal needle. The capped 
tubes were then placed into the automated gradient master which allows controlled 
mixing o f the low- and high-density solutions by rotation at a preset angle o f 80° at 17 
rpm for 2 min.
5.2.1.3 Homogenisation and fractionation
The general procedure used is summarised in Figure 5.2. THP-1 cells were 
seeded at 106 cells per ml in five 150 cm2 flasks and differentiated using PMA as
145
1. Cell harvest: washed with PBS (4°C), scraped in 50 ml PBS, 
centrifuged (1200 rcf5min 4 °C) and resuspended in 1 ml HB
2. Breakage of cells: 10 passes through cell cracker, centrifuged 
(2000 ref 2 min 4 °C) to remove nuclear pellet and obtain PNS
THP-1 cells
Wash 6 Mm gap
Y
Nuclear p ^ g  
pellet
3. Density gradient centrifugation: PNS layered on 5- 20 
% gradient (formed with Gradient Maker) and spun on 
ultracentrifuge
4. Fractionation: 24 fractions collected using fractionator
PNS
Optiprep
Gradient
Centrifugation 
(31000 ref 
16 h 4 °C) 
 ►
Analysis
Figure 5.2 Scheme for fractionation scheme of THP-1 cells.
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described previously (section 2.3.1.1). Cells were then washed three times with ice-cold 
PBS, leaving ~ 5 ml o f fresh PBS in each flask. Cells were scraped using a cell scraper 
(or rubber policeman) and the flasks washed with 5 ml fresh PBS. The cell suspension 
were transferred from the flasks and pooled in a 50 ml falcon tube and the total volume 
was made up to 50 ml with PBS. The cells were centrifuged at 1200 rpm at 4 °C for 5 
min, washed with 10 ml PBS and centrifuged again. The PBS was discarded and the 
pellet obtained was then washed in 0.5 ml HB. Cells were again pelleted by 
centrifugation (1200 rpm at 4 °C for 5 min) and resuspended in 1 ml HB.
The resulting cell suspension was then passed through the cell cracker 10 times. 
The cell homogenate was transferred to an eppendorf and the cell cracker washed with 
an additional 0.5 ml HB. This solution was then added to the total homogenate. A 
sample o f 200 pi was retained, and the rest centrifuged for 2 min, 2000 G at 4 °C to 
remove any intact cells. The resultant post nuclear supernatant (PNS) was transferred to 
a fresh eppendorf and the pellet washed a second time by adding 0.5 ml HB, 
centrifugation (1200 rpm at 4 °C for 5 min) and combining the supernatant with the 
PNS already collected leaving the nuclear pellet.
The PNS was then assayed for protein content using the Bradford assay. A 
sample o f 5 pi was placed in an eppendorf and diluted 1:10 in HB and 30 pi was used as 
described in section 2.3.4. A sample o f 2 mg protein in 1 ml HB was then layered onto 
the preformed gradient. The tubes were weighed to ensure balance, before 
ultracentrifugation using a swinging bucket Beckman SW 41 TI rota spun at 31,000 ref 
for 16 h at 4 °C. Fractions were taken from each tube using a piston gradient 
fractionator (speed 0.5 distance 3.41 mm). A total o f 23 fractions (~ 0.5 ml) were 
collected from the top. A 24th fraction was collected manually. These fractions were 
either immediately put on ice then assayed for protein, or they were frozen at -20°C 
overnight.
5.2.1.4 Incubation o f  Tf-TxR protein marker in THP-1 cells to label the early 
endosomes
THP-1 cells were seeded at 106 cells per ml in five 150 cm2 flasks and 
differentiated using PMA as described previously (section 2.3.1.1). Cells were washed 
with PBS, and then incubated with serum-free media with 0.2 % BSA for 20 min. To
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label the early endosomes, cells were again washed with PBS then incubated with Tf- 
TxR (7.5 pg/ml) for 5 min before placing on ice. Cell homogenisation and fractionation 
was performed as described in section 5.2.1.3.
5.2.1.5 Measurement o f  the gradient density o f  the fractions
To determine the density profile o f the gradient the blank gradient fractions 
(loaded with HB only) were measured using a refractometer. The refractive index, °Brix 
(which equates to % w/w sucrose) and the temperature o f each sample was recorded. An 
adjustment was made to standardise the refractive index measurements for the 
temperature differences using the following equation (correction factor according to 
manufacturer):
(temp -  20) x (7.8 x 10'6) + measured R.I. = r\
The density was then be calculated using the following calculation:
p=Ar]-B
p=density (g/ml), r|=refractive index (R.I.) and the value o f A and B constants 
depending on the nature o f the diluent used for preparing the solutions. In standard 
sucrose-iodixanol solutions A = 3.466 and B = 3.632 (Optiprep).
5.2.2 Characterisation o f THP-1 cell fractions
5.2.2.1 Measurement o f  total protein and enzyme marker distribution in THP-1 cell 
fractions
The total cell lysate, PNS and all the fractions obtained from the gradient were 
assayed for total protein and marker enzymes. The total cell lysate and the PNS was 
diluted 1:10 in HB before use in the protein and enzyme assays. Enzyme assays can be 
carried out in the presence of Optiprep (Ford et al., 1994) and the activity o f these 
enzymes in the presence of Tx-100 has been validated by Seib et al. (2006). Control 
samples (from the blank gradient) were included for each assay.
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Protein recovery and distribution was assayed using 30 pi of the fractions or 
diluted cell lysate/PNS, and using the Bradford method as described in section 2.3.4.
The distribution o f the cytosol marker lactate dehydrogenase was determined 
using 50 pi o f the fractions or diluted cell lysate/PNS, as described in section 2.3.5.1.
The distribution of the plasma membrane marker alkaline phosphatase was
determined using 25 pi of the fractions or diluted cell lysate/PNS, as described in
section 2.3.5.2.
The distribution of the lysosomal marker N-acetyl-P-glucosaminidase was
determined using 50 pi of the fractions or diluted cell lysate/PNS, as described in
section 2.3.5.3.
5.2.2.2 Measurement ofTf-TxR protein marker distribution in THP-1 cell fractions
The fractions (50 pi) were resolved by SDS-PAGE as described in section 2.3.6. 
Following separation, the gels were directly placed on a Typhoon 9410 variable mode 
imager to detect TxR-Tf using the 532 nm excitation laser with 610 BP30 filter.
5.2.23 Measurement o f  antibody marker distribution in THP-1 cell fractions
Antibody markers were used as secondary markers for early endosome and late 
endosome/lysosome compartments. The fractions were again resolved by SDS-PAGE 
as described in section 2.3.6, and then transferred to nitrocellulose and labelled with 
antibodies using the western blotting procedure described in section 2.3.7. Primary 
antibody incubation was performed with a-EEA-1 (1:3000) and secondary antibody 
incubations were with Alexa 488 (1:1000). Alexa Fluor 488 was monitored using a 488 
nm excitation with a 526 SP filter set on the Typhoon imager.
A semi-quantitative dot blot of the fractions was also performed as described in 
section 2.3.8 using 2 p\ of the fractions or PNS (diluted 1:10) and an a-LAMP-1 
antibody (1:1000 dilution). Secondary antibody incubations were with HRP conjugated 
anti-mouse antibodies (1:1000). HRP was monitored after incubation with ECL reagent 
for 5 min and exposure to film. The intensity of the band detected in each fraction was
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quantified using Image J software (Rasband, 1997-2007) and the results expressed as 
the amount of fluorescence in each fraction as a percentage of the total fluorescence 
intensity.
5.2.3 Intracellular localisation o f HPMA copolymer-OG-Man in THP-1 cells 
measured using SCF
THP-1 cells were seeded at 106 cells per ml in ten 150 cm2 flasks and 
differentiated using PMA as described previously (section 2.3.1.1). The cells were then 
washed with PBS, the culture medium was aspirated and replaced with 10 ml of fresh 
RPMI media (10 % serum) containing HPMA copolymer-OG-Man conjugate (0.1 
mg/ml). Cells were incubated for either 5 min (in 5 flasks) or a 4 h incubation (with 100 
pM  of the protease inhibitor leupeptin) (the remaining 5 flasks).
Following the incubation period, cells were placed on ice and cell 
homogenisation and fractionation was performed as described in section 5.2.1.3. The 
fractions obtained were immediately analysed for fluorescence. Samples of 100 p\ were 
placed in a 96 well plate and measured using a fluorescence plate reader (excitation 480 
nm and emission at 520 nm).
The above experiment was reproduced exactly, except the incubation times were 
adjusted to 24 h. The incubation was performed with (5 flasks) and without (5 flasks) 
100 pM  of leupeptin.
In addition, the cell culture media was collected after the 24 h incubation and 
free OG content was measured using a PD10 size exclusion column as described in 
section 4.2.5.
5.2.4 Confocal fluorescence microscopy imaging of HPMA copolymer-OG-Man in 
fixed THP-1 cells
A method was established to allow visualisation of HPMA copolymer-OG 
conjugates in fixed THP-1 cells that ensured retention of the water-soluble polymer 
with vesicles and avoided fixation artefacts (Richardson et al., 2008).
Cells were seeded at 5 x 105 cells/well on coverslips (ethanol immersed and 
washed in sterile PBS) in 6 well plates. To label the early endosomes and late
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endosomes/lysosomes, THP-1 cells were incubated with 1 mg/ml BSA-TxR for either 5 
min (to label the early endosomes) or a 1 h pulse with a 3 h chase (to label the late 
endosomes/lysosomes). The cells were subsequently washed 3 times with ice-cold PBS. 
Then the cells were fixed as described in section 2.3.9, and labelled with Tf-TxR 
(1:300), EEA-1 (1:600) and LAMP-1 (1:300) antibodies as described in section 2.3.10 
(simplified scheme in Figure 5.3).
THP-1 cells were co-incubated with 1 mg/ml BSA-TxR and 1 mg/ml HPMA 
copolymer-OG-Man or HPMA copolymer-OG conjugates for a 1 h pulse with a 3 h 
chase. The cells were then fixed by incubation for 20 min in 3% w/v paraformaldehyde 
in PBS, and then washed 3 times with PBS.
The coverslips were mounted on slides with 40 pi Vectashield, the edges sealed 
with clear nail varnish, and stored at 4 °C for imaging within 72 h. Imaging was 
performed as described in section 2.3.11.
5.3 Results
5.3.1 Optimisation o f cell breakage
Ten passes through the cell cracker gave a lactate dehydrogenase release of ~ 80 
% (range 60 -  100 %) (Figure 5.4). Based on these results all subsequent cell lysates 
were prepared with 10 passes through the cell cracker. To ensure the organelles 
remained intact during cell breakage, at each pass the cell lysate was assayed for the 
lysosomal marker, N-acetyl-p-glucosaminidase. Though a small increase in lysosomal 
enzyme release was seen at each pass (0 - 0.5 nmol 4-methyumbelliferyl formed per 
fraction), this was negligible (~ 7 %) when compared to the total release seen with 
Triton X-100 (~ 6.8 nmol) (Figure 5.5).
5.3.2 Optiprep gradient
There was very high reproducibility of the gradient profile with respect to 
refractive index values of each fraction (Figure 5.6). While there was a slightly sharper 
increase in density in fractions 1-5, the gradient showed a near-linear increase in 
density (from 1.035 - 1.11 g/ml). As the last fraction was taken manually and had a non-
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THP-1 cells incubated with 
HPMA copolymer-OG-Man 
and BSA-TxR
THP-1 cells incubated 
with BSA-TxR
1 h p u lse  + 
3 h c h a s e
5 min or
1 h p u lse  + 3 h c h a s e
Cells Fixed
Paraform aldehyde  
(20  min RT)
Cells Fixed
P araform aldehyde
(20  min RT)
Triton-X 100  extraction  
buffer (5 min RT)
▼
MeOH  
(5 min -20  °C)
Immunolabelling
1° a-EEA-1 a-LAM P-1
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Microscopy Microscopy
Figure 5.3 Scheme for confocal microscopy protocol. Incubation o f THP-1 cells 
with BSA-TxR and/or HPMA copolymer-OG-Man, then fixation and co-labelling 
with EEA-1 and LAMP-1 antibodies used to label endosomes and lysosomes.
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Figure 5.4 Optimisation of cell breakage of THP-1 cells. Effect of passage number 
through cell cracker on release o f lactate dehydrogenase as a marker for cytosol. Data 
represent average ± S.D. (n=3).
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Figure 5.5 Effect of homogonisation and fractionation on lysosomal integrity of THP-1 
cells. Lysosomal enzyme marker assay on homogenate after serial passes through cell cracker 
in the presence or absence o f 0.1 % v/v Triton X-100 (n = 1).
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Figure 5.6 Gradient density of fractions calculated from the measured 
refractive index. Panel (a) shows profile o f the total 24 fractions, panel (b) shows 
the profile with fraction 24 omitted. Data represent average ± S.D. (n=6).
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linear increase in density with a large standard deviation, it was decided to exclude this 
fraction.
5.3.3 Characterisation o f THP-1 subcellular fractions
The amount of total protein found in the PNS was between 2 -  5.2 mg/ml and 
the distribution between the fractions was reproducible. Tie gradient was loaded with 2 
mg protein in 1ml of HB. There was between 20-300 pg of protein in each fraction with 
a distinct peak of protein content in fractions 2 - 8  (Figure5.7).
The plasma membrane marker (alkaline phosphatase) was enriched in fractions 
12 and 19 (Figure 5.8). The lysosomal marker (N-acetyl-f-glucosaminidase) displayed 
one major peak at fractions 14-18, though this was fairly broad, and a smaller peak in 
the lighter fraction 7 (Figure 5.9a).
When the N-acetyl-j3-glucosaminidase content of the fractions was measured 
without Triton X-100, no enrichment was seen, with a basal level of about ~ 0.5 nmol 
(Figure 5.9b). With Triton X-100 was added the basal level was raised to about ~ 2 
nmol and showed enrichment of about 4 times in fraction 17 (8 nmol). The dot blot for 
the lysosomal marker LAMP-1 showed a very broad peak with particular enrichment in 
fractions 14-16, and a smaller one in fraction 7 (Figure 5.10).
Cells that had been incubated with Tf-TxR for 5 min to label the early 
endosomes showed fluorescence as a single band at 80kDa on the Typhoon imager 
after SDS PAGE. This was almost exclusively detected in fractions 4, 5 and 6 (Figure 
5.11a). Antibodies used to probe for EEA-1 after western blotting detected a band at 
180 kDa in fractions 4-10 (Figure 5.1 lb).
5.3.4 Intracellular localisation of HPMA copolymer-OGMan using SCF
SCF of THP-1 cells after incubation with HPMA copolymer-OG-Man showed 
no alteration in the protein distribution in the fractions compared to the control (Figure
5.12). After a 5 min incubation, fluorescence was detected mainly in fractions 1-6 (50 
% of the total fluorescence) with a small enrichment infractions 12-22 (13 % of the 
total) (Figure 5.13).
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Figure 5.7 Protein content of THP-1 fractions. Measured using the Bradford assay, 
and displayed as a percentage o f the total protein measured. Data represent average ± 
S.D. (n=5).
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Figure 5.8 Enrichment in THP-1 fractions of plasma membrane (alkaline 
phosphatase assay) (n=l).
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Figure 5.9 Enrichment in THP-1 fractions of lysosomes (N-acetyI-0- 
glucosaminidase assay). Panel (a) Lysosomal enzyme marker assay after 
fractionation. Data represent average ± S.D. (n = 3). Panel (b) shows the effect o f 
homogenisation and fractionation on lysosomal integrity o f THP-1 cells by 
performing the lysosomal enzyme marker assay after fractionation in the presence or 
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Figure 5.11 Labeling of the early endosomes in THP-1 fractions using Tf- 
TxR and EEA-1. Typical gels o f panel (a) Texas Red-transferrin incubated for 
5 min with cells and fluorescence visualised directly after SDS PAGE and (b) 
fractions transferred onto nitrocellulose, immunoblotted with a-EEA-1 
antibody and fluorescent secondary.
159
18
Blank
16
14
— -HPMA-OG-ManG
12
10
8
6
4
2
0
1 3 5 7 9 11 13 15 17 19  21  23
Fraction
Figure 5.12 Distribution of protein in THP-1 cell fractions after 1 h 
incubation with HPMA copolyraer-OG-Man. Protein measured in both 
control cell fractions (average ± standard deviation n = 3) and and those 
incubated with HPMA copolymer-OG-Man (n = 1) for 24 h using the 
Bradford assay and displayed as a percentage o f the total protein measured.
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Figure 5.13 Time dependence of HPMA copolymer-OG-Man distribution after 
incubation in THP-1 cells. THP-1 cells were incubated for 5 min, 1 h pulse with a 3 
h chase or for 24 h (with 100 pM leupeptin) before fractionation (n=l).
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However, after a 4 h incubation, this pattern was reversed and the fluorescence 
was shifted to the later fractions. There was a small enrichment in fractions 1-6 (15 % 
of the total), but fluorescence was mainly seen in fractions 12-22 (66 % of the total). A 
smaller peak was also seen in fraction 7. This distribution of HPMA copolymer-OG- 
Man correlated well with the lysosomal markers N-acetyl-|3-glucosaminidase and 
LAMP-1.
The distribution of fluorescence after a 24 h incubation showed a similar pattern 
to that seen in the cells after a 4 h incubation. There was enrichment in fractions 1 2 -2 2  
(71 % of the total), but showed a slightly greater accumulation in fractions 19 and 20, 
and a peak at fraction 7. However, when the cells were incubated with HPMA 
copolymer-OG-Man in the absence of leupeptin for 24 h, the fluorescence was mainly 
detected in the first 6 fractions (~50 % of the total) (Figure 5.14).
The amount of free OG in the media before incubation with THP-1 cells was 2.8 
%. After 24 h incubation in the presence of leupeptin this had increased to ~ 30 % free 
OG. After 24 h incubation of cells with HPMA copolymer-OG-Man in the absence of 
leupeptin there was ~ 60 % free OG (Figure 5.15). This indicates OG is released from 
the conjugate over 24 h.
5.3.5 Intracellular localisation o f HPMA copolymer-OG-Man using confocal 
fluorescence microscopy
When THP-1 cells were incubated with BSA-TxR the fluorescence was seen in 
distinct vesicular structures (Figures 5.16 and 5.17). After a 5 min incubation, BSA- 
TxR co-localised with EEA-1 and partially with Tf-TxR, but not with LAMP-1 (Figure 
5.16). After the 4 h incubation BSA-TxR co-localised with LAMP-1 but not with EEA- 
1 or Tf-TxR (Figure 5.17).
When THP-1 cells were incubated with HPMA copolymer-OG and HPMA 
copolymer-OG-Man conjugates and BSA-TxR for 4 h they had completely co-localised 
in the lysosomal structures (Figure 5.18). No evidence of plasma membrane, nuclear or 
cytosolic labelling was seen. There was no difference in localisation between the 
conjugates ± Man.
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Figure 5.14 Distribution of fluorescence in THP-1 cell fractions after 24 h 
incubation with HPMA copolymer-OG-Man (± leupeptin). The dotted line 
represents fluorescence o f fractions without leupeptin and solid line with 100 pM 
leupeptin (n=l).
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Figure 5.15 PD10 chrom atog raphy  of tissue cu lture m edia obtained a fte r a 24 h 
incubation o f HPMA-OG conjugates w ith THP-1 cells. PD-10 profiles of HPMA 
copolymer-OG-Man conjugate after 24 h incubation with THP-1 cells (± leupeptin) at 
37 °C were obtained by elution in PBS and the fractions collected were assayed for 
fluorescence measured (Abs 494 nm Em 520 nm).
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Figure 5.16 Representative confocal images of fixed THP-1 cells to dem onstrate 
BSA-TxR-labeled early endosomes. Cells were incubated with BSA-TxR for 5 min and 
co-labeled with endosome (EEA-1 and Transferrin) and lysosome (LAMP-1) markers. 
Examples o f co-localisation between compartment marker and BSA-TxR are indicated 
using white arrows.
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Figure 5.17 Representative confocal images of fixed THP-1 cells to dem onstrate 
BSA-TxR-labeled lysosomes. Cells were incubated with BSA-TxR for 1 h (plus 3 h 
chase) co-labeled with endosome (EEA-1 and Transferrin) and lysosome (LAMP-1) 
markers. Examples o f co-localisation between compartment marker and BSA-TxR are 
indicated using white arrows.
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Figure 5.18 Investigation of the effect of M an on the intracellular localisation of 
HPM A copolymer-OG ± Man conjugates after 1 h (plus 3 h chase) in THP-1 cells with 
BSA-TxR labeled lysosomes. Examples o f co-localisation between endocytic probe (BSA- 
TxR) and HPMA copolymer-OG are indicated using white arrows.
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5.4 Discussion
5.4.1 Establishment o f  an SC F  method fo r  THP-1 cells
A novel quantitative fractionation method has been developed for THP-1 cells, 
which can be used to investigate time-dependent trafficking of polymer conjugates and 
potentially other drug delivery systems. Knowing that liposomes, lipidic carriers and 
nanoparticles are being widely explored as drug delivery systems for anti-leishmanial 
drugs this method could provide useful comparisons.
The average cell breakage efficiency was > 80 % after 10 passes through the cell 
cracker. The apparent breakage decreased with greater than 10 passages. This may be 
due cell damage and/or to release of organelle contents and inhibition of enzyme 
activity, despite the presence of protease inhibitors in the medium. Also, the lysosomes 
were largely intact after 10 passes therefore this protocol was used for all further 
experiments.
The Optiprep density gradient was linear and reproducible (Figure 5.6). This 
was important as it is necessary to ensure a reproducible separation of the cell 
components. The density gradient used here was found to be different to that reported 
by Manunta et al. (2007). Even though the density range was similar (from 1.035 to 
1.11 g/ml compared to 1.045 -  1.11 g/ml), Manunta et al. (2007) reported a gradient 
profile that was steeper at higher density. This would be a limitation, as organelles of 
similar density (the early endosomal and late endosomal/lysosomal fractions) would not 
be easily separated. The linear gradient achieved here gives better separation of 
organelles at higher densities.
The protein content of the homogenate varied between ~ 2 and 5 mg/ml, 
therefore it was decided to use a constant amount of protein for the SCF (2 mg in 1 ml). 
This was applied to each gradient, and the distribution of protein subsequently obtained 
in the fractions was very reproducible, with the low-density fractions containing most of 
the protein (Figure 5.7). This was probably cytosolic. This protein distribution profile 
for THP-1 cells also differed from that reported by Manunta et al. (2007) for the HepG2 
cells. They found a second, higher, protein enrichment in the heavier fractions (16 - 18), 
close to the lysosomal marker (N-acetyl-|3-glucosaminidase) enrichment.
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The plasma membrane marker (alkaline phosphatase) mainly showed 
enrichment in the later fraction (19) (Figure 5.8). This did not correspond to the cytosol 
or early endosomes. The peak showed a similar distribution to, but at a slightly higher 
density than, the late endosomes/lysosomes. Previous studies have shown that larger 
fragments of plasma membrane, possibly reformed into vesicles can be present 
depending on the cell type and homogenisation method used (Tulkens et al., 1974). 
However, this assay was only performed on one fractionation experiment, and would 
need to be repeated to confirm the enrichment.
The LAMP-1 antibody staining and N-acetyl-P-glucosaminidase enzyme 
activity showed the same distribution throughout the fractions (Figures 5.9 and 5.10). 
They both co-localised in the higher density fractions. Importantly, the lack of 
enrichment when Triton X-100 was absent showed that the lysosomes were intact after 
homogenisation and fractionation.
The lysosomes were recovered over a broad banding density of 1.07-1.11 g/ml 
(Figures 5.9 and 5.10), in agreement with the pattern reported by Manunta et al. (2007) 
(1.07 -  1.12 g/ml). A broad banding density for lysosomes was also reported by 
Graham et al. (1994) when using mouse liver separated on self-generated Optiprep 
gradients (1.10 -  1.13). The recovery of lysosomes over a broad density range may be 
due to the fairly shallow gradient, and/or the heterogeneity of the vesicles. The second 
peak, seen with both lysosomal markers, was at a much lower density (fraction 6/7, 
~ 1.065 g/ml). However, this was at a higher density than early endosomal peak, and 
therefore unlikely to be cytosolic. Also, enrichment was seen in the same fractions using 
both the late endosome/lysosome markers, the membrane bound LAMP-1 and the 
intracellular enzyme N-acetyl-P-glucosaminidase.
The endocytic compartments are complex, with continuous fusion producing 
heterogeneity in the organelles population. For example, transient hybrid organelles, 
with intermediate densities between endosomes and lysosomes, have been reported, and 
may account for the apparent lysosomal enrichment in fractions of different densities 
(Mullock e tal., 1998).
Both the early endosome markers (Tf-TxR and EEA-1) were found in fractions 
of a low density (~ 1.05 g/ml) (Figure 5.11). Using the HepG2 cells Manunta et al.
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(2006) had reported EEA-1 localised in the same density fractions, but they had also 
found EEA-1 in higher density fractions. However Tf-TxR was found only in the lower 
density fractions. EEA-1 is cycled on and off the endosomal membrane, so a proportion 
will be cytoplasmic. In their study the lower density fraction was therefore attributed to 
the cytosolic portion of EEA-1, and the higher density fraction to the membrane-bound 
portion. In fact, two distinct, high and low density populations of early endosomal 
markers have been shown in previous studies (Chin et al., 2001; Hamasaki et al., 2004; 
Sheff et al., 1999). Surprisingly, in the present study using THP-1 cells, the Tf-TxR 
positive fractions co-localised with the EEA-1 positive fractions at low density, and no 
fluorescence was seen in the higher density fractions. Therefore, it was assumed that the 
low-density EEA-l/Tf-TxR positive fractions were not cytosolic and contained early 
endosomes.
Using the markers chosen, it was possible to clearly identify the early 
endosomes and the late endosomal/lysosomal compartments, and these were well 
differentiated.
5.4.2 Investigation o f  intracellular localisation o f  HPM A copolymer-OG-Man using 
SCF
The SCF method was able to show the time-dependent trafficking to lysosomes 
of the HPMA copolymer-OG-Man conjugates in THP-1 cells incubated with leupeptin. 
After a 5 min incubation, the conjugate was co-localised with the early endosomal 
markers, although there was also a small amount of conjugate found in the later 
fractions. It is unlikely that the fluorescence seen after 5 min was cytosolic as this 
would require free OG to have been released from the polymer. At this time it also did 
not co-localise with the plasma membrane enrichment. Therefore the conjugate 
appeared not to be surface bound. Consistent with the SCF, the microscopy also showed 
clear vesicular accumulation after 5 min.
After either a 4 h incubation, or a 24 h incubation, of THP-1 cells with the 
conjugate the distributions of fluorophore seen using SCF were very similar (Figure
5.13). The conjugate was transferred to lysosomes within 30 -  60 min. There was no 
change in distribution after 24 h compared to the 4 h, except there was a more
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pronounced peak in the higher density fractions (late endosomes/lysosomal 
compartments), as would be expected. The total accumulation of conjugate in the 
lysosomes would be expected to be much greater after the longer continuous incubation 
unless there was degradation and/or exocytosis occurring. As shown by the analysis of 
free OG in the incubation medium, ~ 30 % of the total OG was released from the cells 
after 24 h, indicating degradation and exocytosis. The uptake of the conjugates 
measured using flow cytometry (Fig 4.16), showing that uptake slowed over the 1 h 
incubation, although it did not reach a plateau, consistent with these SCF results.
Seib et al. (2006) reported that after incubation of B16F10 murine melanoma 
cells with PK1, using differential centrifugation, the lysosomal accumulation was 
calculated to show a 3-5 times enrichment of Dox. The uptake of HPMA copolymer- 
OG-Man is receptor-mediated and therefore showed greater accumulation than the 
studies on non-specific fluid-phase uptake. The lysosomal enrichment would therefore 
be highly significant.
To study cleavage of the HPMA copolymer-GFLG side chain, free OG could be 
viewed as a drug model. When THP-1 cells were incubated with HPMA copolymer- 
OG-Man without leupeptin in the medium, the distribution of fluorescence after a 24 h 
incubation was very different from the distribution when leupeptin was included (Figure
5.14). In fact, the distribution was almost indistinguishable from that seen after a 5 min 
incubation (thought to be early endosomal). There was however a reduction in 
fluorescence in the first fraction. As there was no chase time, there would presumably 
be some fluorescence (HPMA copolymer-OG-Man) in the early endosomes, as well as 
some free OG in the cytoplasm. However, the amount of OG fluorescence in the early 
endosomes would be expected to be relatively small in comparison to the total cellular 
fluorescence. Therefore it is suggested that the fluorescence found in the early fractions 
after 24 h incubation is mainly cytosolic. Using a pulse-chase in this experiment would 
have perhaps helped delineate the two from each other, however the measured free OG 
content of 60 % confirms that significant OG release has occurred. Together these 
experiments indicate that side chain cleavage occurred and resulted in OG escape from 
the lysosome into the cytoplasm and out of the cell.
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The results obtained here show trafficking of HPMA copolymer-OG-Man 
conjugates to lysosomes and this is consistent with previous studies on HPMA 
copolymers. As discussed earlier, Duncan and colleagues first demonstrated the time- 
dependent lysosomal transfer of l25I-labelled HPMA copolymer-galactose in rat liver 
cells using a density gradient fractionation method (Duncan et al., 1986). After 10 min 
radioactivity was recovered in fractions that contained the plasma membrane marker 
enzyme 5 ’-nucleotidase (densities of approximately 1.03-1.05 g/ml), thought to 
represent the early endosomal vesicles. After 60 min there was an obvious shift of 
radioactivity into heavier fractions (density of approximately 1.10 g/ml) that contained 
arylsulphatase and therefore thought to represent secondary lysosomes. Time-dependent 
delivery to lysosomes has also been demonstrated for HPMA copolymer-daunomycin 
conjugates in rat liver cells (Wedge et al., 1991).
Tijerina et al. (2001; 2003) and Nori et al. (2003a; 2003b) used SCF to study the 
fate and drug release from HPMA copolymer-Dox conjugates targeted with TAT 
peptide, and HPMA copolymer-Mce6 conjugates targeted with NLS, in A2780 ovarian 
carcinoma cells. They found that after 4 h, 90 % of the HPMA copolymer-GG-FITC 
conjugates without a targeting residue were endocytosed and localised to the lysosomes. 
However, the HPMA copolymer-GFLG-FITC conjugates were equally distributed 
between the lysosomal and cytosolic fractions, indicating lysosomal escape, somewhat 
in agreement with these studies. By comparison, the TAT-targeted HPMA copolymer- 
GG-Dox conjugates localised to the cytosol and the NLS-targeted HPMA copolymer- 
GG- Mce6 conjugates were delivered to the nucleus.
It should be noted that vesicle payload might alter the vesicle density. In fact, 
this property has been purposefully used in the past to modify the density of lysosomes 
and aid the purification (Arai et al., 1991). However, the distribution of the HPMA 
copolymer-OG-Man was shown to be almost identical to the lysosomal distribution, and 
so it might be concluded that the polymer conjugate does not cause a significant change 
in lysosomal density.
5.4.3 Comparison o f  SC F and confocal microscopy o f  HPM A copolymer-OG-Man
Fluorescence was clearly visible in vesicles, and co-localised with the late 
endosome/lysosome markers, when the HPMA copolymer-OG ± Man conjugates were
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incubated for 4 h with THP-1 cells (with leupeptin). There was no difference observed 
between the localisation of conjugates ± Man.
It was interesting to compare the semi-quantitative SCF results to the qualitative 
confocal fluorescence microscopy images. Cell fixation usually involves either 
detergent or solvent extraction that leads to permeabilisation of the intracellular 
membranes so that non-fixed material diffuses out. The method used here was 
developed to fix cells in a way that ensured retention of the water-soluble polymers in 
the intracellular vesicles (Richardson et al., 2008). It should be noted that there is likely 
to be some bleed-through of the green channel into the red, which could account for the 
apparent colocalisation. Using the appropriate antibody controls this could have been be 
ruled out. However, the SCF data and fluorescence microscopy images are in agreement 
and show that the HPMA copolymer-OG-Man conjugates co-localise to the late 
endosome/lysosome over the same time frame.
5.4.4 Transfer o f this SCF method to Leishmania-infected THP-1 macrophage cells
To really understand the fate of HPMA copolymer conjugates in Leishmania- 
infected macrophages it is necessary to set up the method for that model. However, a 
number of modifications may be needed. The density of the PV is unknown. It contains 
many of the same markers as lysosomes (LAMP-1, N-acetyl-|3-glucosaminidase), so 
will be needed to distinguish the endosomal, lysosomal and phagosomal (PV) 
compartments. Differences in trafficking in infected and non-infected cells might also 
be expected and this could impact on the ability of the conjugate to gain access to the 
PV.
The general nature of the PV is discussed in detail in Chapter 1. Ability of 
HPMA copolymer conjugates to access the PV will depend on fusion of endosomal or 
lysosomal vesicles with the PV. The PV is known to be a type of phagosome, which 
fuse with lysosomes (Geisow & Evans, 1984), but it does not express normal 
phagosomal characteristics, however it does contain LAMP-1, cathepsin B, D, H and L 
(Lang et al., 1994). There is a growing body of evidence showing considerable fusion 
between lysosomes and the PV for several Leishmania species (L. donovani in human 
monocyte-derived macrophages, L. mexicana in murine peritoneal macrophages and L. 
amazonensis in murine bone marrow-derived macrophages (Berman et al., 1979; Brazil,
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1984; Courret et al., 2002)). However, in the J774 macrophage cell line there is some 
evidence of reduced fusion of the L. donovani-infected PV with lysosomes (Holm et al., 
2001; Scianimanico et al., 1999), even though ultrastructural studies of L. donovani- 
infected macrophages from hamster liver incubated with liposomes have shown that the 
liposome-containing lysosomes fused readily with the PV (Weldon et al., 1983; Heath 
et al., 1984). Taken together, these studies strongly suggest that a polymer-drug 
conjugate delivered to the lysosome, as seen in the THP-1 cell model, should then be 
able to then enter the PV, and have direct access to the parasite.
Preliminary confocal microscopy studies on the uptake of the HPMA 
copolymer-OG-Man conjugates (2 h 30 min incubation) into L. donovani-infected THP- 
1 cells have shown some indication that the co-localisation of HPMA copolymer-OG- 
Man conjugates with the parasite (Seifert, 2007, unpublished, Figure 5.19). It must be 
stressed that these are only preliminary experiments, and this work is ongoing. 
However, this suggests that the HPMA copolymer-drug-Man conjugates will be able to 
enter the L. donovani-infected THP-1 cells in order to kill the parasite.
5.5 Conclusions
The aim of this study was to establish a SCF method that could be used to 
investigate the intracellular trafficking of MR-targeted HPMA copolymer-drug 
conjugates in subsequent studies. The results showed that this new SCF method could 
be used to investigate the time-dependent trafficking of HPMA copolymer-OG-Man 
conjugates and potentially of other polymer therapeutics in THP-1 cells (Wallom et al., 
2008). There was good linear separation of the intact components of the endocytic 
pathway, using a combination of markers (enzymes, endocytosed fluorescent ligands 
and antibody markers) and direct imaging. The lysosomal accumulation of HPMA 
copolymer-OG-Man conjugates was supported by the fluorescence microscopy images. 
This method was also carefully optimised to confirm localisation of the HPMA 
copolymers in the endocytic vesicles without the problem of artefacts (Richardson et al., 
2008).
Finally, these results have demonstrated the lysosomotropic delivery of HPMA 
copolymer-OG-Man and the release of OG as a model drug from the HPMA
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Figure 5.19 Prelim inary live cell confocal images of the intracellular localisation 
of HPM A copolymer-OG-M an conjugates with L. donovani-infected THP-1 cells.
L. donovani infected THP-1 cells were incubated with 0.1 mg/ml polymer solution in 
complete medium for 2 h 30 min. Examples o f the parasite (blue nuclear stain DAPI) 
and HPMA copolymer-OG-Man (green) in close proximity are indicated using white 
stars. Seifert, 2007, unpublished.
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copolymer-GFLG side chains as would been expected. There is clearly potential to 
develop a method for quantitative measurement of drug trafficking. Using this SCF 
method, in the next Chapter the synthesis, intracellular trafficking and toxicity of 
HPMA copolymer-Man-AmB conjugates will be studied.
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Synthesis of HPMA copolymer-AmB conjugates and determination of
activity and intracellular fate
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6.1 Introduction
The preceding studies have demonstrated that MR-targeted HPMA copolymer 
conjugates could be used to increase uptake into macrophages and also that these 
conjugates traffic to lysosomes (Chapters 3 - 5). In this study preliminary experiments 
were undertaken to evaluate a potential anti-leishmanial polymer-drug conjugate. As 
discussed in Chapter 1, AmB, a commonly used second line treatment for VL, was 
chosen as the model drug. The aim here was to synthesise and characterise a mannose- 
containing HPMA copolymer conjugate o f AmB, and determine its cytotoxicity in 
comparison to free AmB. The intracellular trafficking o f the HPMA copolymer-AmB 
conjugate was also investigated in uninfected THP-1 cells using the SCF method 
established in Chapter 5 to gain insight into the likely fate o f such conjugates.
Most novel AmB delivery systems have been investigated as antifungals. Those 
that have been tested against Leishmania have shown variable results though none have 
proved more effective than the commercial formulations. The ideal delivery system 
would solubilise AmB, have low cytotoxicity and haemolytic activity towards 
mammalian cells, actively target macrophages, achieve co-localisation with the 
Leishmania parasite and have high anti-leishmanial activity. HPMA copolymer-Man 
has shown macrophage targeting, endocytosis and delivery to the lysosome. The choice 
o f AmB and the properties o f AmB formulations, both the clinically available 
formulations and those in the literature, are discussed below.
6.L I Amphotericin B
AmB (Figure 6.1) and its mode o f action were described in section 1.4.2. It was 
chosen here because it is highly potent and it is the only anti-leishmanial drug not to 
have shown clinical resistance, although resistance has been demonstrated in vitro 
(Ouellette et al., 2004). The clinical use o f AmB is limited by problems such as 
insolubility, low selectivity for the parasite membrane, acute toxicity (primarily severe 
nephrotoxicity) and drug instability (Kleinberg, 2006).
AmB exerts its anti-leishmanial effect by binding to sterols and inserting into the 
membrane, forming pores. This quickly leads to cell death. It displays some selectivity 
for the parasite membranes as they contain ergosterol, however non-specific toxicity
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Figure 6.1 Chemical structures of amphotericin B and paromomycin
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occurs due to interaction with cholesterol in normal cell membranes (Gruszecki et al., 
2003). The aggregation o f AmB in aqueous solution is related to the membrane 
interaction and consequent toxicity. The behaviour of AmB in solution is discussed 
below and related to the possible benefits o f the various formulations.
AmB is very poorly soluble in aqueous solutions at physiological pH. It has 
better solubility at the pH extremes o f < 2 or > 7; however at these pHs it then becomes 
unstable. In aqueous solutions, at concentrations > 0.2 pg/ml, AmB self-associates due 
to its amphipathic nature, giving rise to a mixture o f water-soluble monomeric and 
dimeric structures and insoluble aggregates (Milhaud et al., 2002). The degree of 
aggregation depends on the AmB concentration, the solvent, the temperature, and the 
presence o f serum proteins. Previous studies have examined the effect o f the AmB 
aggregation state on the bioactivity following entrapment o f AmB in albumin 
microspheres (Ordonez-Gutierrez et al., 2007). Preparations o f free and encapsulated 
AmB in monomeric, dimeric and multi-aggregated forms were prepared and their 
activity against Leishmania infantum-infected J774 macrophages and against the free 
promastigotes was compared. Free AmB (in any form) did not kill the extracellular 
promastigote, however all the albumin microsphere encapsulated forms did. Free AmB 
in its monomeric and dimeric form was most toxic to the intracellular amastigote, but 
only the encapsulated drug was able to completely eliminate infection. The free AmB in 
multi-aggregated form was most toxic to host J774 macrophage cells, but interestingly, 
none o f the encapsulated forms showed toxicity against these macrophages.
This study highlights both the affect o f the AmB aggregation state and the 
ability o f a drug delivery system to modulate AmB toxicity and activity (therapeutic 
index). It is thought that AmB binding to low-density lipoproteins (LDL) actually leads 
to the non-specific cellular toxicity, and that it is the aggregated form that causes non­
specific haemolysis (Legrand et al., 1992; Ridente et al., 1999). Thus, encapsulation can 
reduce protein binding and consequently non-specific toxicity (Croft et al., 2006). This 
is also one potential mechanism by which liposomal encapsulation reduces the non­
specific toxicity o f  AmB. Polymer conjugation o f AmB could also potentially reduce 
toxicity by this mechanism.
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6.1.2 Commercially available AmB products
A variety o f AmB delivery systems have shown improved clinical benefit 
compared to free AmB. This is almost always due to reduced toxicity allowing 
administration o f higher doses, rather than higher activity. Some delivery systems are 
actually less active. The commercially available AmB formulations are summarised in 
Table 6.1.
Since 1958 Fungizone® has been second line treatment for leishmaniasis, after 
the antimonials. Fungizone® is AmB solubilised with deoxycholate and it is delivered as 
an infusion, However this often leads to infusion-related reactions, and as the AmB 
dissociates quickly, it causes acute toxicity. Amphotec® and Abelcet® are lipid 
formulations primarily used for treatment o f fungal infections. The liposomal AmB 
Ambisome® (see Section 1.5) is not in general use for leishmaniasis due its high cost. 
However, it is increasingly used for the treatment of fungal infections, particularly in 
Europe. A recent in vitro study compared the activity o f Fungizone®, Amphocil®, 
Ambisome® and Abelcet®, against Leishmania donovani and it was found that their 
activity depended on the cell model used (Yardley & Croft, 2000). In the peritoneal 
macrophage (PEM) model Fungizone® and Amphocil® had higher activity than 
Ambisome® and Abelcet®. In contrast in THP-1 cells Amphocil® and Abelcet® had 
higher activity than Ambisome®, with Fungizone® showing the lowest activity. 
However, Ambisome® clearly showed higher clinical activity compared with 
Fungizone®, and this has been attributed to higher plasma concentrations, and slower 
elimination times compared to AmB (Bekersky et al., 2002). Liposomal AmB allows an 
administration o f 5 times higher dose than conventional AmB (Fungizone®) in vivo due 
to the greatly reduced side effects (Lemke et al., 2005).
The disadvantages o f liposomes (summarised in section 1.5) means that there is 
still scope for improved, cheaper AmB therapies, particularly those targeted to 
Leishmania-infected macrophages, rather than disseminated fungal infections, which 
require very different pharmacokinetic design. Reduced uptake into macrophages means 
that the drug is not removed from the circulation. This is advantageous for fungal 
infections. The drug either needs to be slowly released from the delivery system in the 
circulation or at the site o f fungal infection (e.g. exploiting lowered pH). In contrast
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Table 6.1 Characteristics of different drug delivery systems designed for AmB that are on the market.
Name Delivery method/formulation Indication Dose
mg/kg/day
Plasma half life 
(h)/Cmax(p,g/ml)
AmB
W t%
Reference
Fungizone Micellar colloidal complex 
with sodium deoxycholate 
(oligomeric)
Fungal
infections
Leishmaniasis
0 .6 - 1 24-48/ 1.4 12.5 Cheron et al., 
2003
Abelcet
(ABLC)
Ribbon-like lipid complex 
(Intralipid)
Fungal
infections
5 20-24/1.7 50 Wingard et al., 
2 0 0 0
Amphotec/
Amphocil
(ABCD)
Disk shaped cholesterol 
sulphate colloidal dispersion
Fungal
infections
3 - 4 22/3.1 65 Bowden et al., 
2 0 0 2
AmBisome Unilamellar liposome 
(monomeric) (60-70nm)
Fungal
infections
Leishmaniasis
2 - 5 24 / 23-83 12.5 Bekersky et al., 
2 0 0 2
macrophage uptake is essential for activity against Leishmania. Ideally the drug should 
be released specifically inside the macrophage in the vicinity o f the parasite.
6.1.3 Novel AmB formulations in pre-clinical development
Ongoing studies on alternative AmB formulations and delivery systems have shown 
varying degrees o f success (Table 6.2). They have been primarily been designed for 
controlled release or for better targeting o f disseminated fungal infections, but some 
have also shown activity against leishmaniasis.
6.1.3.1 Heat aggregated Fungizone®
Second generation formulations o f Fungizone® have been developed. Heated 
Fungizone® produces ‘super-aggregated’ AmB which showed lower toxicity but similar 
activity against L.donovani compared to conventional Fungizone® (Petit et al., 1999). 
Also, it has shown increased uptake into J774 macrophages (Cheron et al., 2003). 
However, results have suggested it is actually less kinetically stable and dissociates into 
monomers more quickly than Fungizone® (Baas et al., 1999).
6.1.3.2 Targeted Am B liposomes
Liposomes exploit Am B’s high affinity for lipids (sterols and phospholipids). 
However, none o f these lipid formulations have yet surpassed Ambisome®, which is 
still considered the gold standard anti-leishmanial formulation.
To further increase the anti-leishmanial activity, macrophage-targeted AmB 
liposomes have been explored. In fact, the only targeted delivery systems to incorporate 
AmB have been MR-targeted liposomal vesicles (Vyas & Sihorkar, 2000). Recently, 
multilameller vesicles (MLVs) containing AmB with macrophage-specific ligands, 
employing p-aminophenyl-mannopyranoside (PAM) and O-palmitoyl mannan (OPM), 
have been designed (Vyas et al., 2000). After intravenous administration to rats, PAM 
showed liver and spleen targeting, and OPM, in comparison, resulted in alveolar 
macrophage accumulation. The same group also designed an OPM targeted MLV for 
aerosolised delivery (Vyas et al., 2005) and a trilaurin-based nanoparticle targeted with 
OPM for liver targeting (emulsome) (Gupta et al., 2007; Gupta & Vyas, 2007).
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Table 6.2 Characteristics of different drug delivery systems designed for AmB against Leishmania that are in the literature.
Delivery
method/formulation
Specifications Targeting Reference
Heated deoxycholate 
complex
Superaggregated Fungizone - Petit et al., 1999
Liposomes Fungizome - Kshirsagar et al., 2005
PEGylated liposome - Moribe et al., 1999
PC and cholesterol liposome OPM/PAM Vyas et al., 2005; 2000
Polymer conjugates PEG - Sedlak et al., 2007 a+b; Conover et al., 2003
Dendrimer - Gupta et al., 2007
Arabinogalactan - Falk et al., 1999; Ehrunfreund-kleinman et al., 
2004; Nishi et al., 2007
Nanoparticle/micelle/ Chitosan/Dextran nanoparticle - Tiyaboonachai and Limpeanchob, 2007
other Polyaxomer 188 coated poly(epsilon- 
capolactone)
- Espuelas et al., 2003
Emulsomes OPM Gupta et al., 2007
PVP - Charvalos et al., 2006
Albumin/PLGA/poly(sebacic 
anhydride) microspheres
- Sanchez-Brunete et al., 2005
Lipid nanosphere
- Otsubo et al., 1999
Table 6.2 continued Characteristics of different drug delivery systems designed for AmB against Leishmania 
that are in the literature.
Delivery
method/formulation
Specifications Targeting Reference
Nanoparticle/micell Egg lecithin-bile salt micelle - Brajtburg et al., 1994
e/other Sucrose ester - Gruda et al., 1991
Block copolymer micelle - Lavasanifar et al., 2002
Poly(ethylene oxide)-block-poly(L- 
amino acid) micelle
• Adams et al., 2003
PEG-block-poly(£-caprolactone-co-
trimethylenecarbonate)micelle
“ Vakil et al., 2005 
Vandermeulen et al., 2006
PEG micelle - Moreno et al., 2001, 2003;
Lecithin based oil-in-water emulsion - Brime et al., 2004
Cochleate lipid cylinder - Zarif et al., 2005
Carbon nanotube - Wu et al., 2005
However, these targeted AmB preparations have not been tested specifically against 
Leishmania.
6.1.3.3 Polymer-AmB conjugates
Several PEG conjugates o f AmB have been designed and have demonstrated 
reduced toxicity in comparison to conventional AmB in vivo, but have not yet been 
tested against Leishmania. The first PEG-AmB conjugate contained two molecules o f 
AmB attached to PEG (Mw 40,000 g/mol) by a labile carbamate linkage (Conover et 
al., 2003). Though this conjugate achieved a 6  times reduction in toxicity in vivo, the 
relatively fast rate o f hydrolysis o f 1 -3 h and release in blood plasma could lead to fast 
accumulation in the kidneys, and this is a potentially serious disadvantage as 
nephrotoxicity is a primary concern with AmB. A second PEG-AmB conjugate with a 
pH sensitive imine linkage was then investigated (Sedlak et al., 2007b). The conjugate 
was designed for site-directed drug release at pHs is 5.5, either in the intracellular 
compartments or at sites o f localised fungal infection. PEG molecular weight did not 
affect the rate o f drug release but a notable disadvantage of the PEG conjugates is their 
low drug carrying capacity. Subsequently, a AmB-PEG-6 -poly(L-lysine) conjugate was 
designed, again using an imine linkage, containing 12 AmB molecules per polymer 
conjugate (Mw 26,700 g/mol) (Sedlak et al., 2007a). This conjugate was 5 times less 
toxic in vivo than AmB delivered as Fungizone®, with a maximum tolerated dose 
(MTD) o f 45 mg/kg, whilst maintaining in vivo antifungal effectiveness against 
Candida albicans.
Conjugates o f AmB bound to arabinogalactan (an oxidised polysaccharide, Mw 
23,000 g/mol) via an amine or imine bond have demonstrated reduced toxicity in vivo 
(Ehrenfreund-Kleinman et al., 2002; Falk et al., 1999; Falk et al., 2004). Only one has 
been tested against Leishmania (major) and had similar activity to Fungizone®, 
however it contained potentially toxic contaminants from the synthesis. An AmB 
conjugate o f gum arabic (90% arabinogalactan, Mw ~ 250,000 g/mol) showed good 
activity against L. donovani, but only against the promastigotes (Nishi et al., 2007). 
Also, the MTD was 20 mg/kg in comparison to 45 mg/kg for PEG and arabinogalactan 
conjugates, most likely to the large size, and show slow release of AmB in plasma.
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Succinylated dextrin ( a - 1,4 polyglucose) has also been developed as a drug carrier 
as it is degraded by a-am ylase slowly in the blood plasma (Hreczuk-Hirst et al., 2001). 
Dextrin-AmB conjugates showed similar haemolytic activity to fungizone and greater 
non-specific cytotoxicity (against B16F10 cells) compared to Fungizone®. Also, these 
conjugates had a very low loading o f AmB (0.006 wt %) (German et al., 2000).
The potential o f polymers as AmB-delivery systems is clear, however the optimal 
conjugate should have a high carrying capacity with the ability to target the AmB 
conjugates to the macrophages and optimal release kinetics for intracellular delivery.
6.1.4 Techniques used to study HPMA copolymer-AmB-Man conjugates
6.1.4.1 Chemical characterisation o f  the conjugates
It was decided in Chapter 4 to use conjugates containing 4 mol % mannose for the 
drug conjugates. AmB could be conjugated via the amino group on the mycosamine 
sugar o f AmB, therefore the methods described in Chapter 4 were modified and used 
here to prepare HPMA copolymer-AmB, HPMA copolymer-AmB-Man and HPMA 
copolymer-OG-AmB-Man conjugates. It was decided to load 4 mol % of AmB onto the 
conjugate, making full use o f the available side chains to try and achieve a high drug 
loading. The conjugates were characterised for AmB content using UV absorbance.
The unusual absorbance properties o f AmB have been used to study the aggregation 
state and the stability o f AmB (Hargreaves et al., 2006). The absorbance peak at 415 nm 
is related to the monomeric form o f AmB, and the peak at 348 nm related to the 
aggregated form. Therefore, the aggregation state can be assessed by using the ratio of 
A348/415 (a higher ratio = greater aggregation). The aggregation state o f the conjugate 
was measured using the ratio o f A348/415 in comparison with free AmB, Also, AmB 
displays thermal instability. The absorbance decreased by 50% over 24 h when 
incubated under physiological conditions at 37 °C (Ehrenfreund-Kleinman et al., 2002; 
Ehrenfreund-Kleinman et al., 2004). Therefore, the UV absorbance was used to monitor 
the stability o f  the conjugates over time under physiological conditions (pH 7.4, 37 °C) 
as this may affect the drug release and activity o f the conjugates.
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6.1.4.2 Biological characterisation o f  the conjugates
An important factor was the cytotoxicity o f the conjugates. The AmB formulations 
discussed previously have all been shown to significantly reduce the cytotoxicity and 
haemolytic activity o f AmB. The cell viability of THP-1 cells incubated with the 
HPMA copolymer-AmB and HPMA copolymer-AmB-Man conjugates was compared 
to free AmB using the MTT assay. The haemolysis assay was used to see if  the degree 
o f RBC lysis was reduced by conjugation to HPMA.
To show whether HPMA copolymer-OG-AmB conjugates ± Man showed different 
degrees o f uptake (in THP-1 cells), flow cytometry was used. Also, preliminary studies 
to investigate the intracellular distribution o f the HPMA copolymer-AmB-Man 
conjugates in THP-1 cells, the SCF method developed in Chapter 5, together with 
confocal fluorescence microscopy, were used. The protease inhibitor leupeptin was used 
to prevent linker degradation and therefore investigate the fate o f the HPMA 
copolymer-OG conjugates without release o f free OG.
6,1.5 Summary o f  aims
The specific technical aims were as follows:
• Synthesis o f HPMA copolymer-AmB, HPMA copolymer-AmB-Man and 
HPMA copolymer-OG-AmB-Man.
• Characterise the conjugates for free and total AmB content using the 
measured UV absorbance and high performance liquid chromatography 
(HPLC).
• To study the aggregation state o f the conjugate and the stability at 37 °C in 
comparison to free AmB measured using the UV absorption spectra.
• To determine the cell viability o f THP-1 cells incubated with the HPMA 
copolymer-AmB-Man conjugates compared to free AmB using the MTT 
assay.
• To measure the RBC lysis caused by HPMA copolymer-AmB-Man 
conjugates compared to free AmB using the haemolysis assay.
• To study the cell association o f the HPMA copolymer-OG-AmB and 
HPMA copoly mer-OG-AmB-Man conjugates using flow cytometry.
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• To visualise the intracellular fate of the HPMA copolymer-OG-AmB-Man 
conjugates using confocal FM.
• To apply the SCF method developed in Chapter 5 to investigate the 
intracellular localisation o f HPMA copolymer-AmB-Man conjugate.
6.2 M ethods
The general methods for used in these studies have already been described in 
chapter 2. The RAW 264.7 and THP-1 cells were maintained as in section 2.3.1.1. The 
MTT assay, flow cytometry and confocal fluorescence microscopy methods were 
performed using the methods described in sections 2.3.1.3, 2.3.3, 2.3.9, and the SCF 
procedure as described in sections 5.2.1, 2 and 3. The TLC reactions to monitor 
conjugation o f mannose and OG to HPMA copolymer-GFLG was performed as 
described in section 4.2.1.
6.2.1 Synthesis and characterisation o f HPMA copolymer-AmB ± Man conjugates
General method fo r  preparation o f  HPMA copolymer-AmB conjugates
HPMA copolymer-AmB conjugates were synthesised as shown in Figure 6.2 
Typically, HPMA copolymer-GFLG-ONp (9.03 mol % side chains) was dissolved in 
DMSO (63.7 mg in 1 ml). After stirring at room temperature for 30 min, a solution of 
AmB in dry DMSO (248 pi, 32 mg/ml) was added to this solution. This reaction 
mixture was then stirred at room temperature in the dark for 16 h under a nitrogen 
atmosphere. Then an excess o f aminopropanol (2 pi) was added to remove any 
remaining ONp groups.
General method fo r  preparation o f  HPMA copolymer-AmB-Man conjugates
Typically, HPMA copolymer containing GFLG-ONp side chains (9.03 mol %) 
was dissolved in DMSO (63.7 mg in 1 ml). To this solution, after stirring at room 
temperature for 30 min, a solution o f mannosamine.HCl in dry DMSO (130 pi, 24 
mg/ml), along with 2 molar equivalents (2 pi) o f triethylamine was added. This reaction 
mixture was stirred at room temperature for 4 h. A solution o f AmB in dry DMSO (248 
pi, 32 mg/ml) was then added. This reaction mixture was stirred in the dark for 16 h at 
room temperature under a nitrogen atmosphere and then an excess of aminopropanol (2 
pi) was added to remove any remaining -ONp groups.
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Figure 6.2 Reaction scheme for the conjugation of AmB to HPMA copolymer- 
GFLG-ONp (Mw 37,427 g/mol, Mw/Mn 1.58). x = 90.07 mol %; y + x = 9.03 mol %.
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General method fo r  preparation o f  HPMA copolymer-OG-AmB ± Man conjugates
OG labelled HPMA copolymer-AmB ± Man conjugates were also prepared 
using the methods described above. However, immediately after the 16 h incubation 
with AmB, a solution o f OG-cadaverine in dry DMSO (340 pi, 5 mg/ml) was added. 
The mixture was again stirred at room temperature in the dark for 16 h under a nitrogen 
atmosphere and then an excess o f aminopropanol ( 2  pi) was added to remove any 
remaining -ONp groups. Subsequently all conjugates were purified as described in 
section 4.2.4.
6.2.2 Characterisation o f  the conjugates in respect o f  total and free OG, and total 
AmB
Conjugates were characterised for total and free OG content using the methods 
described in section 4.2.5. It was decided not to measure the total mannose content of 
these conjugates due to the limitations o f the method found in chapter 4, and the time 
limitations on developing an alternative method.
The total AmB content o f the conjugates was measured by UV. A calibration 
curve of AmB was prepared over a concentration range o f 0 - 200 pg/ml and the 
absorbance at 300 -  600 nm measured. The absorbance at 420 nm was plotted to create 
a calibration curve. Each conjugate was also dissolved in MeOH and the absorbance at 
300 -  600 nm was measured. HPMA copolymer in MeOH was used as a background 
control. The absorbance o f the conjugates at 420 nm was then used to determine the 
total AmB content from the calibration curve.
6.2.3 Determination o f  free AmB using HPLC
A HPLC method was set up to determine the free AmB content of the HPMA 
copolymer-AmB-Man conjugate. A calibration curve o f AmB (2 -  80 pg/ml) was made 
up in DMSO. Samples (100 pi) containing the internal standard l-amino-4- 
nitronaphthalene (1 pg/ml) were injected into a pBondpak reverse phase C18 column, at 
a flow rate o f  1 ml/min using 40:28:32 methanol:acetonitrile:5mM EDTA as eluent, and 
a UV detector wavelength set at 407 nm.
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To determine the amount o f free AmB in the HPMA copolymer-AmB-Man 
conjugate, a solution o f the conjugate in DMSO was injected (100 pi, 250 pg/ml). To 
assess the sensitivity the injection was repeated with a spike o f AmB (20 ng/ml).
6.2.4 Characterisation o f the HPMA copolymer-AmB-Man conjugate aggregation 
state and stability
The absorbance spectra o f free AmB and o f the HPMA copolymer-AmB-Man 
conjugates was determined in MeOH and media (0.1 mg/ml) and an absorbance 
spectrum measured for each (300 -  500 nm). Then the absorbance spectra o f free AmB 
and o f the HPMA copolymer-AmB-Man conjugates was determined in MeOH/water 
mixtures over the range o f 300 -  500 nm. Solutions were prepared by diluting a 0.6 
mg/ml stock solution o f AmB or HPMA copolymer-AmB-Man conjugate in varying 
ratios o f MeOH to water (0 - 100 % v/v MeOH) at 0.1 mg/ml. The aggregation state 
was assessed by determining the ratio o f A348/415.
The change in absorbance o f HPMA copolymer-AmB conjugates was used to 
investigate the stability under physiological conditions. The conjugates and free AmB 
were dissolved in clear media at 37 °C, and the absorbance spectra (300 -  500 nm) was 
measured every hour for 5 h. Again the ratio o f A 338/415 was calculated and plotted with 
time.
6.2.5 Measurement o f  the cytotoxicity o f  AmB, paromomycin and the HPMA 
copolymer-AmB ± Man conjugates against THP-1 cells using the MTT assay
Preliminary cytotoxicity experiments were performed using both differentiated 
THP-1 and RAW 264.7 cells with paromomycin and AmB.
Cells were seeded at 105 cells (100 pi) per well, and then were incubated for 24 
h before the media was removed and replaced with fresh media. Stock solutions of 
drugs were made up at 20 mM (AmB in DMSO and paromomycin in media). Solutions 
o f drugs were then made up at 81 pg/ml o f AmB and 210 pg/ml of paromomycin in 
complete media. To the first row o f wells 50 pi of each drug solution was added (3 
wells for each drug). Serial dilutions were then made by pipetting 50 pi o f the top 
solution to the next row, mixing and taking 50 pi to the next well. The 50 pi taken from 
the last well was discarded. The final concentration ranges were 1 - 7 0  pg/ml of
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paromomycin and 0 - 2 7  pg/ml o f AmB in 100 pi per well. One row of blank wells was 
filled with 100 pi o f complete media only.
The plates were then incubated for 67 h before adding the MTT and the cells 
were incubated for a further 5 h (total 72 h) and the MTT assay was performed as 
described in section 2.3.1.3. Data was expressed as a percentage o f the control (blank 
wells).
The same assay was used to investigate the cytotoxicity o f the conjugates in 
comparison to free AmB. Stock solutions o f HPMA copolymer-AP, HPMA copolymer- 
AmB, HPMA copolymer-AmB-Man and free AmB were dissolved in DMSO at 20 
mg/ml. Solutions were then made up at an AmB equivalent o f 1 mg/ml in complete 
media. These solutions were added to the first wells and the method described above 
repeated exactly. The final AmB equivalent concentrations were 0.46 pg/ml -  1 mg/ml.
The effect o f leupeptin on the cytotoxicity o f the conjugates on THP-1 cells was 
also investigated. Solutions o f HPMA copolymer-OG-Man and free AmB were made 
up at AmB-equivalents of 0.1, 0.5 and 1 mg/ml in complete media, with and without 
leupeptin (100 pM) and the assay performed as described above. The results were then 
used to decide the concentration used for the subcellular fractionation experiments.
6.2.6 Measurement o f  the haemolytic activity o f AmB and the HPMA copolymer- 
AmB ± Man conjugates
The haemolytic activity o f the HPMA copolymer, HPMA copolymer-AmB, 
HPMA copolymer-AmB-Man conjugates and free AmB was assessed using isolated rat 
red blood cells (RBCs) in vitro (Duncan & Spreafico, 1994). Samples were dissolved in 
DMSO before being made up at appropriate concentrations in clear media in a 96 well 
plate (100 pi). The conjugates were diluted in clear media to give an AmB equivalent 
concentration o f 0.46 pg/ml -  1 mg/ml. A control o f PBS with Triton X-100 (0.5% v/v) 
was also included on the plate for each conjugates/drug tested. Plates were stored in the 
dark at 4 °C whilst the RBCs were prepared.
Healthy male Wistar rats (250 to 300 g) were killed by vertebral dislocation, and 
whole blood was taken immediately by cardiac puncture. Blood was placed into heparin 
bead-containing tubes on ice, and resupsended in 2 ml ice-cold PBS. The RBC’s were
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then prepared by washing three times. Tubes were washed by centrifugation (10 min, 
1500 RCF at 4 °C), removal o f the PBS, and addition o f 2 ml fresh cold PBS and 
centrifugation, two more times. The RBCs were then weighed and finally resuspended 
in a PBS solution at 2 % w/v.
To start the assay, the RBC solution (100 pi) was added to each well and the 
plates were incubated at 37 °C for 1 h in the dark. The plates were then centrifuged 
(1500 x g for 10 min) and the supernatant (100 pi) was carefully pipetted into a new 96 
well plate without disturbing the cells debris layer. The haemoglobin release from the 
RBCs was measured using the absorbance at 550 nm against a PBS blank measured 
using a microtitre plate reader. Data were expressed as the percentage haemolysis 
observed compared with total haemolysis induced by Triton X-100, adjusted to take 
into account the background observed with the PBS blanks.
6.2.7 Derived cell association and studies on the intracellular fate o f HPMA 
copolymer-AmB ± Man
Flow cytometry
Differentiated THP-1 cells were seeded at 5 x 105 cells per ml per well in clear 
media in 6 well plates overnight. The derived cell association o f HPMA copolymer-OG- 
AmB-Man and HPMA copolymer-OG-AmB was measured by incubation of the THP-1 
cells with solutions o f the conjugates in clear media (at 1 pg/ml of OG-equivalent) over 
60 min. Derived cell association was measured every 10 min for 60 min by flow 
cytometry as described in sections 2.3.3. A total o f 10 000 cells were counted, and data 
expressed as (the % o f positive cells x geometric mean o f the fluorescence)/100.
Subcellular fractionation
The intracellular localisation of the HPMA copolymer-AmB-Man in THP-1 
cells was then investigated using subcellular fractionation. Differentiated THP-1 cells 
were seeded at 106 cells per ml in clear media in five 150 cm2 flasks overnight. The cells 
were then washed with PBS, the culture medium was aspirated and replaced with 10 ml 
of fresh RPMI media (containing 10 % serum and 100 pM  leupeptin) containing HPMA 
copolymer-OG-Man conjugate (100 pg/m\ AmB-equivalent). Cells were incubated for 
24 h.
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Following the incubation period, cells were placed on ice and cell 
homogenisation and fractionation was performed as described in section 5.2.1.3. The 
fractions obtained were then immediately analysed for UV absorbance. Samples of 
standards (0 -  2.5 pg/ml free AmB in HB solution) and fractions (100 pi) were placed 
in a 96 well plate and measured using a microtitre plate reader (420 nm).
A dot blot o f the fractions was performed using the protocol described in section 
2.3.8, with an a-A m B primary antibody (1:50 dilution/0.028 pg/ml). A semi- 
quantitative calibration curve was made using standards of free AmB and AmB 
conjugates in HB over a concentration range of 0 -  100 pg/ml AmB equivalent. 
Samples o f 2 pi o f the standards, fractions or PNS (diluted 1:10) were used. Secondary 
antibody incubations were with HRP conjugated anti-mouse antibodies (1:1000). HRP 
was monitored after incubation with ECL reagent for 5 min and exposure to film. The 
intensity o f the band detected in each fraction was quantified using Image J software 
(Rasband, 1997-2007) and the results expressed as the amount o f fluorescence in each 
fraction as a percentage o f the total fluorescence intensity.
Confocal microscopy
Confocal microscopy was used to visualise the intracellular localisation of 
HPMA copolymer-OG-AmB ± Man. Differentiated THP-1 cells were seeded at 5 x 105 
cells per ml per well on coverslips as described in section 2.3.9. Cells were then co­
incubated with BSA-TxR (1 mg/ml) and HPMA copolymer-OG-AmB or HPMA 
copolymer-OG-AmB-Man conjugates (1 mg/ml) in clear media containing leupeptin 
(100 pM ) for either 4  h or 24 h. The cells were then fixed by incubation for 20 min in 
3% w/v paraformaldehyde in PBS, and then washed 3 times with PBS (as described in 
section 5.2.4). The coverslips were mounted on slides with 40 pi Vectashield, the edges 
sealed with clear nail varnish, and stored at 4 °C for imaging within 72 h. Imaging and 
analysis was performed using the protocol described in section 2.3.11.
6.3 Results
6.3,1 Characteristics o f  HPMA copolymer-OG-AmB-Man conjugates
The characteristics o f the HPMA copolymer-AmB conjugates synthesised are 
summarised in Table 6.3.
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Table 6.3 Characteristics of HPMA copolymer-AmB conjugates.
Code
number
Conjugate structure AmB content+ 
mol % wt %
Mannose content 
(theoretical mol %)
OG content+ f 
mol % wt %
AC1 HPMA copolymer-GFLG-AP NA NA NA NA NA
AC2 HPMA copolymer-GFLG-Man NA NA 4 NA NA
AC3 HPMA copolymer-GFLG-AmB 3.5 17.7 NA NA NA
AC4 HPMA copolymer-GFLG-AmB-Man 3.1 15.8 4 NA NA
AC5 HPMA copolymer-GFLG-OG-AmB 3.7 18.8 NA 0.62 1.68
AC6 HPMA copolymer-GFLG-OG-AmB-Man 3.2 16.4 4 0.54 1.47
f Estimated by UV absorbance at 415 nm + + Estimated by UV absorbance at 494 nm
The total OG content o f the OG-labelled conjugates (AC5 and 6) was 0.62 and 
0.54 mol % (1.68 and 1.47 wt %). It was not possible to measure the free OG content 
using PD10 columns as the AmB conjugates stuck to the column (as a visible yellow 
band), and could not be eluted with aqueous solutions.
Free AmB in DMSO had an absorbance maximum of 415 nm (Figure 6.3a) and 
the AmB calibration curve had a linear dependence (r2 = 0.9989) over the range of 
concentrations tested (0 -  200 pg/ml). The sensitivity was 1 pg/ml (Figure 6.3b). The 
AmB content o f the conjugates was in the range o f 15.8 -  18.8 wt % (3.1 -  3.7 mol %).
After HPLC elution, free AmB had a retention time (tr) of ~ 7 min. A smaller 
peak was also visable at ~ 4 min (Figure 6.4a). The internal standard l-amino-4- 
nitronaphthalene eluted too close to the solvent front and so was not used in further 
studies. The calibration curve for AmB was linear (r2 = 0.999) up to concentrations of > 
80 pg/ml with a maximum sensitivity (3 x baseline) of 2 ng (20 ng/ml) (Figure 6.4b).
When HPMA copolymer-AmB conjugates were injected into this system, no 
peak was seen, however when the conjugate solution was spiked with free AmB (20 
ng/ml), the drug could be detected (Figure 6.5). The peak o f the spiked HPMA 
copolymer-AmB was greater than the peak for the free AmB alone, equating to 90 
ng/ml.
6.3.2 Conjugate aggregation state and stability
The UV spectra o f AmB and HPMA copolymer-AmB did not significantly 
differ (Figure 6.6). In MeOH, the peak maxima o f AmB and conjugate are identical 
(348, 370, 390 and 415 nm), though the 415 nm peak is slightly reduced. The AmB 
peaks in media (345, 363, 385 and 419 nm) showed the conjugate peaks were identical 
except for the first peak, which had shifted to 352 nm. The ratios of A348/415 were found 
to be 0.28 (AmB) and 0.74 (conjugate) in MeOH indicating a monomeric state; and 3.3 
(AmB) and 2.9 (conjugate) in media indicating an aggregated state.
The spectra o f both AmB and HPMA copolymer-AmB-Man showed a clear but 
gradual change in spectra with increasing MeOH concentration. The absorbance
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Figure 6.3 C alib ra tion  curve for AmB. Panel (a) shows the absorbance spectra of 
AmB in DMSO (0.1 mg/ml). Panel (b) calibration curve measured in MeOH at 415 
nm. The data represent the mean ± SD (n = 3) and where the error bars are not 
visible they fall within the data points.
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maxima was 407 nm in MeOH shifting to 330 nm in water (Figures 6.7 and 6 .8 ). The 
minimum MeOH concentration to give the completely monomeric form of AmB was 
50% (Figure 6.7b). However, the change in absorbance spectra o f the conjugate was 
less rapid and did not reach complete monomeric form until the MeOH concentration 
was > 70 % (Figure 6 .8 b).
There was no change in the A 348/415 ratio o f free AmB measured over 5 h at 4 °C, 
with the value remaining constant at ~ 3.9 (Figure 6.9a). However, the A348/415 ratio 
measured at 37 °C decreased significantly. Compared to AmB, the HPMA copolymer- 
AmB values measured at 37 °C were relatively stable at ~ 3.9 (Figure 6.9b).
6.3.3 Cytotoxicity o f AmB, paromomycin and the HPMA copolymer-AmB conjugates
Preliminary studies with AmB indicated IC50 values of ~ 2 pg/ml in THP-1 
cells, and 5 pg/ml in RAW 264.7 cells (Figure 6.10). Paromomycin however was not 
very cytotoxic over the concentration range tested, however, it caused a greater 
reduction in cell viability in THP-1 cells (~ 20 % at 80 pg/ml).
The HPMA copolymer-AmB ± Man conjugates were significantly less toxic 
than AmB (p < 0.05, students t-test) (Figure 6.11). AmB was toxic at concentrations 
above 0.001 mg/ml and had an IC 50 value o f 0.01 mg/ml. Both conjugates showed no 
toxicity at < 0.004 mg/ml AmB-equivalent, but cell viability was reduced by ~ 40 % at 
1 mg/ml AmB equivalent (as opposed to > 80 % by free AmB). Therefore it was not 
possible to estimate IC50 values. There was no difference in toxicity seen between 
HPMA copolymer-AmB and HPMA copolymer-AmB-Man.
The cell viability o f HPMA copolymer-AmB-Man after incubation with THP-1 
cells for 4 h at 1 mg/ml AmB-equivalent was reduced by > 30 % (Figure 6.12). 
However, when the incubation media contained leupeptin there was no cytotoxicity. 
After 24 h the cell viability had also reduced in the 0.5 mg/ml incubation, by ~ 10 %. 
Leupeptin had no effect after 24 h. Incubation with 0.1 mg/ml HPMA copolymer-AmB- 
Man had no effect on cell viability at either time point. It was therefore decided to use 
this non-toxic concentration (0.1 mg/ml AmB-equivalent) for incubation of THP-1 cells 
with HPMA copolymer-AmB-Man in the subcellular fractionation studies.
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203
0
5% MeOH 
10% MeOH 
20% MeOH 
30% MeOH 
40% MeOH 
50% MeOH 
60% MeOH 
70% MeOH 
80% MeOH 
90% MeOH 
100% MeOH
300 350 400
Wavelength (nm)
450
=j
os
£c
o
©
CO
CO
<A.Q<
O
50 75 100250
% MeOH
Figure 6.8 Effect of MeOH concentration on the absorbance of HPMA 
copolymer-AmB-Man. Panel (a) the UV absorbance scans of conjugate in different 
ratios o f H20:M eO H , panel (b) the ratio monomeric/aggregate peak as a measure o f 
aggregation.
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6.3.4 Haemolytic activity o f  the HPMA copolymer-AmB conjugates
AmB showed a high degree o f haemolysis (~ 40 % at 0.03 mg/ml) after 1 h, but 
the HPMA copolymer-AmB ± Man conjugates did not show any haemolytic activity up 
to a concentration o f 1 mg/ml AmB-equivalent (Figure 6.13). Therefore, no Hbso values 
(concentrations at which there was 50 % Hb release) could be determined. The PBS 
blank gave a value o f ~ 20 % haemolysis, though this differed greatly between 
experiments and between individual microtitre plates. The blank values were therefore 
subtracted as background from the sample values.
6.3.5 Cell accumulation o f  HPMA copolymer-AmB-Man in THP-1 cells
THP-1 cells showed a clear increase in THP-1 derived cell-associated 
fluorescence with time when incubated with the HPMA copolymer-OG-AmB and 
HPMA copolymer-OG-AmB-Man conjugates for 1 h (Figure 6.14a). This uptake was 
rapid over the first 10 min and then slowed, but it did not reach a plateau. Derived cell- 
associated fluorescence was 2-fold greater for the HPMA copolymer-OG-AmB-Man 
conjugate compared to HPMA copolymer-OG-AmB and statistically significant at all 
time-points (p < 0.05, paired t-test) (Figure 6.14b).
When compared with the derived cell association o f HPMA copolymer-OG ± 
Man (4 mol %), discussed in chapter 4, there was no difference in derived cell 
association o f HPMA copolymer-OG-Man ± AmB in TH P-ls (Figure 6.15). However 
there was a two-fold increase in derived cell association o f HPMA copolymer-OG-AmB 
compared to HPMA copolymer-OG.
6.3.6 Intracellular fa te  o f HPMA copolymer-AmB-Man in THP-1 cells
When the cell were visualised using confocal microscopy the conjugates showed 
a high degree o f co-localisation (yellow) with the BSA-TxR-labelled lysosomes after a 
4 h incubation with HPMA copolymer-OG-AmB and HPMA copolymer-OG-AmB- 
Man (Figure 6.16). The amount o f OG-fluorescence was greater but still largely co­
localised after 24 h (Figure 6.17). No difference could be seen in distribution o f the 
HPMA copolymer-OG-AmB conjugates with and without Man. Also, no change in cell 
morphology was seen at these concentrations and time points.
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(a) HPMA copolymer-OG-AmB
(b) HPMA copolymer-OG-AmB-Man
Figure 6.16 Confocal fluorescent microscope images of THP-1 cells incubated for a 24 
h with AmB conjugates. Panels represent cells labelled with BSA-TxR and co-labelled 
with (a) HPMA copolymer-OG-AmB and (b) HPMA copolymer-OG-AmB-Man. Examples 
o f co-localisation between compartment marker and BSA-TxR are indicated using white 
arrows.
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(a) HPMA copolymer-OG-AmB
(b) HPMA copolym er-O G -A m B -M an
Figure 6.17 Confocal fluorescent microscope images of THP-1 cells incubated for a 1 h 
pulse and a 3 h chase with AmB conjugates. Panels represent cells labelled with BSA- 
TxR and co-labelled with (a) HPMA copolymer-OG-AmB and (b) HPMA copolymer-OG- 
AmB-Man. Examples of co-localisation between compartment marker and BSA-TxR are 
indicated using white arrows.
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After incubation o f THP-1 cells with the HPMA copolymer-AmB-Man 
conjugate and SCF, the UV absorbance was used to measure the AmB distribution in 
the fractions. The measured absorbance was at the lower end o f the calibration curve (~ 
0.05 mg/ml close to the limit o f detection 0.01 mg/ml), so results were shown as % of 
total absorbance (Figure 6.18). After 24 h incubations the AmB UV absorbance was 
found predominantly in two groups o f fractions, ~ 15 % in 3-5, and ~ 35 % in 14-22. A 
smaller peak was also seen in fraction 10. This distribution correlated somewhat with 
the lysosomal enrichment, however a larger proportion was in fractions correlating with 
the early endosomal compartments.
The AmB dot blot was used to gain better resolution of the intracellular 
distribution. The method was able to detect < 1 pg/ml free AmB or AmB-equivalent on 
the conjugates, and had a linear increase up to 50 pg/ml (Figure 6.19). However, it was 
not possible to measure the AmB in the fractions due to problems with detection. An 
example o f a dot blot o f the fractions shows dark spots in fractions 4 - 8 ,  and clear spots 
in fractions 1 6 - 2 0  (Figure 6.20). The possible reasons for this and possible solutions 
will be discussed in the next section.
6.4 Discussion
The primary aim o f these preliminary studies was to synthesise and characterise 
the HPMA copolymer-AmB-Man conjugates and evaluate them for the biological 
compatibility and potential for targeting macrophages.
Synthesis and chemical characterisation o f  the conjugates
These studies show preliminary results on HPMA copolymer-AmB-Man 
conjugates, but greater characterisation o f the conjugates is needed before further 
development is possible.
A high loading o f AmB was achieved (~ 17 wt%) in comparison to both 
Fungizone and Ambisome (~ 12 wt %). Importantly, improved solubility was shown, 
which would be essential for safe delivery of a therapeutic, and appropriate for IV 
administration. If  a higher loading was necessary, then this could be achieved by using a 
HPMA copolymer with higher number o f GFLG side chains. However, aqueous 
solubility may be reduced with higher AmB loadings. The solubility was not tested due
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distribution of HPM A copolymer-AmB-M an conjugates.
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to lack of product but the conjugate was clearly soluble in cell culture media at the 
concentrations used.
The sensitivity o f the HPLC method (20 ng/ml) compared well with the 
published sensitivity values, which vary between 1 and 100 ng / ml in plasma and 
tissues (Table 6.4). The unknown peak seen at about 4 min (Figure 6.4) probably 
corresponds to impurities (other polyene compounds) that are found in all commercial 
preparations o f AmB, such as amphotericin A (Cleary et al., 2007).
When the HPMA copolymer-AmB conjugate was applied to the column no free 
AmB was detected, but in the spiked sample the AmB detected was greater than the 
amount spiked (Figure 6.5). This could possibly indicate the presence of free AmB, 
however the results indicate the amount would be minimal in any case (>1% of total). 
This discrepancy may be due to measuring at the limit o f sensitivity o f the method. Had 
more time been available, the amount o f free drug would be measured using a more 
robust method, such as using a different column to separate the free AmB, and the drug 
release from the conjugates would have been investigated using this method.
The Man content o f these conjugates was not measured due to the problems with 
the method (discussed in section 4.4.1), and the limited time available to develop a new 
method. However, the theoretical Man contents were supported by the biological results 
in chapter 4.
For further development o f the HPMA copolymer-AmB-Man conjugates, it 
would be necessary to better characterize the conjugates for the total Man, the free OG, 
and most importantly the free AmB content. The time limitation on these studies and 
the length o f time needed to validate new methods meant that only preliminary 
characterisation could be performed. Had more time been available, the free AmB 
content would have been measured using an LH20 chromatography column, and then 
using either UV or HPLC analysis. However, the latter studies (the different stability 
and cytotoxicity profiles o f the conjugates compared to free AmB) support the 
assumption that AmB was bound to HPMA copolymer and there was limited free AmB.
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Table 6.4 Methods for AmB extraction and measurement by HPLC reported in the literature.
Reference
Granich et al., 
1986
Wang et al., 
1992
Lopez-Galera et 
al., 1995
Extraction method Recovery HPLC method Sensitivity
Cells homogenised and extracted 92% HPLC + N-acetyl AmB standard, 0.04-10
with MeOH. SPE C l8 column, A382, 1.5ml/min, C l8 RP column, Ug/ml
conditioned with acetonitrile, mobile phase acetonitrile:0.01 M
sodium acetate buffer (pH7.2), EDTA (40:60 v/v pH4.2),
200pl sample, washed with retention time 4.9 min
MeOH-sodium acetate buffer (1:1),
eluted with MeOH
Blood/ tissues homogenised and 92, 69, HPLC + N-acetyl AmB standard, 5 ng/ml (P)
extracted with MeOH. SPE C l8 76% A382, lOOpl sample injected, 25 ng/ml (B)
column conditioned with MeOH, (plasma, lml/min, C l8 RP column, mobile 2.5 ng/ml (U)
water, lOmM phosphate buffer blood phase acetonitrile:2.5mM 50 ng/ml (T)
pH7.4; washed with MeOH:phos tissues) Na2EDTA (45:55 v/v pH4.2),
buf (40:60 v/v); elution retention time 6-7 min
acetonitrile:2.5mM Na2EDTA
Serum samples diluted 200:600pl 90.2% HPLC + A405, lml/min, short 50 ng/ml
in MeOH, 10500g 5 min, 80 pi C l8 RP column, mobile phase
supernatant injected directly acetonitrile :2.5mM Na2EDTA
(30:70 v/v), retention time 1.5 min
Table 6.4 continued Methods for AmB extraction and measurement by HPLC reported in the literature.
Reference Extraction method Recovery HPLC method Sensitivity
Lambros et al., Serum or tissues homogenised and 91.5,74, HPLC + A383, lml/min, C l8 RP 100 ng/ml
1996 extracted with MeOH-acetic acid (9:1 70% column, mobile phase
v/v), the supernatant filtered and 100 (plasma, acetonitrile:acetate buffer (37:63 v/v
pi injected directly lungs,
liver)
pH 4), retention time 15 min
Walsh et al., as Granich et al. 90% as Granich et al. 25 ng/ml
2000
Campanero et J774.2 cells lysed with TnXlOO (1%) ~ 99 % HPLC at A408, lml/min, C8 RP 1 ng/ml
al., 2000 then diluted 2:1 v/v with MeOH and 
150 pi samples injected directly
column, mobile phase 
acetonitrile:water:0.05 M 
ammonium acetate, 0.02 M 
triethylamine, 4% acetic acid buffer 
(40:14.5:45.5 v/v pH6.6), retention 
time 4.01 min
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Table 6.4 continued Methods for AmB extraction and measurement by HPLC reported in the literature.
Reference Extraction method Recovery HPLC method Sensitivity
Eldem & 
Arican-Cellat, 
2001
Plasma diluted 1:1 in PBS. SPE C l8 
column conditioned with MeOH, 
water, phosphate buffer; 1 ml sample; 
washed with MeOH-phosphate buffer 
(40:60 v/v); eluted with acetonitrile- 
disodium edetate (2.5mM, 60:40 v/v, 
pH 4.2)
98% HPLC at 407 nm, lOOpl sample, 
lml/min, C8 RP column, mobile 
phase acetonitrile :disodium edetate 
45:55 v/v pH5), retention time 6.27 
min
10 ng/ml
Bekersky et 
a l , 2002
Plasma samples < 2 mg/ml, extracted 
with MeOH and supernatant injected
66-77 % HPLC at 405 nm, lml/min, RP 
column, mobile phase 
acetonitrile:0.05 N sodium acetate 
(34:66 v/v), retention time 4.9 min
Espanuelas et 
al., 2003
as Campanero et al. - J774.2 cells as Campanero et al. but 1 OOpl 
injected and mobile phase pH3
1 ng/ml
Vogelsinger et 
al., 2006
Tissue homogenised, extracted with 
MeOH. SPE C l8 column conditioned 
with MeOH, 45% MeOH; 0.5 ml 
sample; washed with 45 % MeOH; 
eluted with 60% acetonitrile.
55.2±4% Reversed-phase HPLC using a RP 
C8 column, 405 nm, mobile phase 
acetonitrile-MeOH 10 m M NaH2P 0 4 
buffer (41:10:49, v/v). Retention 
time 6.7 min.
5 ng/ml
As the toxicity o f AmB is related to the aggregation state o f the drug, the UV 
absorbance under different conditions could reveal information about the conformation 
o f the conjugates, in relation to free AMB and other delivery methods, such as 
Ambisome®. In MeOH the conjugate spectrum was typical of monomeric AmB and of 
aggregated AmB in aqueous media (Figure 6.6). AmB aggregated in a solution o f s  50 
% MeOH (Figure 6.7), as previously demonstrated by Adams & Kwon (2004). 
Although there was no large difference between the absorbance spectra in aqueous 
solution, the MeOH concentration at which the HPMA copolymer conjugate bound 
AmB aggregated was lower (70 -  100 % MeOH) (Figure 6.8). This and the altered 
stability profile suggested there was a different product, and that AmB was covalently 
bound rather than free AmB associated with the polymer.
Therefore, the hydrophobic interaction o f AmB in aqueous solution was not 
impaired by the conjugation to the polymer. In agreement with studies on other polymer 
conjugates such as PEG-AmB and gum Arabic-AmB conjugates (Nishi et al., 2007; 
Sedlak et al., 2007a; Sedlak et al., 2007b). The structure o f the HPMA copolymer is 
postulated to be a dynamic unimolecular micelle and the hydrophobic AmB could cause 
a change in conformation allowing the AmB to aggregate and may effect drug release. 
This has been proposed for HPMA copolymer-Dox, which showed a reduced rate o f 
drug release with increased drug loading due to the effect o f the hydrophobic interaction 
of Dox (Vicent et al., 2005).
It was important that therapeutics were stable at 37 °C, but free AmB has little 
stability in aqueous solutions at this temperature. The problems of AmB instability may 
be amplified in preparations of AmB designed to have an increased plasma half-life. 
However, the reduction in absorbance o f the HPMA-conjugated AmB occurred at a 
slower rate and to a lesser degree than that o f free AmB (Figure 6.9). Similar results 
were observed with arabinogalactan-AmB conjugates (Ehrenfreund-Kleinman et al., 
2002; Ehrenfreund-Kleinman et al., 2004). These data suggest that the covalent binding 
o f AmB to the polymer leads to stabilisation o f the drug in aqueous solution. The 
increased stability shown by the HPMA copolymer-AmB conjugates should mean a 
greater percentage o f the drug delivered to the parasite would still be active.
Biological characterisation o f  the conjugates
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The success o f these delivery methods is dependent on the mechanism of action, 
e.g. the state of aggregation, and this may influence the choice o f delivery method. 
These preliminary studies have shown that HPMA copolymer conjugation produced a 
stable AmB therapeutic with reduced haemolytic activity and reduced cytotoxicity 
against human macrophage cells. Methods to investigate the intracellular fate o f the 
AmB conjugates were also set up and demonstrated the potential o f these methods to 
study the intracellular trafficking o f other polymer-drug conjugates.
The haemolysis assay is most commonly used to assess the non-specific toxicity 
o f AmB. However, the toxicity o f AmB to macrophages has been attributed to a 
different mechanism than that for the RBCs, and involves binding to serum LDL and 
uptake via the LDL receptor, therefore it was considered important to also assess the 
toxicity in the THP-1 cells (in the presence o f serum).
First, the cytotoxicity o f AmB and paromomycin was investigated. AmB was, as 
expected, much more toxic to both THP-1 and RAW 264.7 cells than paromomycin In 
fact, paromomycin did not show toxicity against the RAW 264.7 cells, although a small 
amount o f cytotoxicity was seen against the THP-1 cells (Figure 6.10). Clinical trials of 
paromomycin (at 11 mg/kg/day for 21 days) have shown it to have activity against VL 
equal to AmB (at ~ 1 mg/kg/ every other day for 30 days) though required higher doses 
(Sundar et al., 2007). It may be possible to achieve greater activity with lower doses 
when delivered to the specific site o f action (the PV). Therefore, paromomycin was 
considered a possible alternative drug for conjugation if AmB proved not feasible, or in 
combination with AmB.
The cytotoxicity o f the HPMA copolymer-AmB ± Man conjugates was 
significantly lower than the free AmB against the THP-1 cells (Figure 6.11). At AmB 
concentrations found in the blood o f Fungizone-treated patients (~ 2 pg/ml) 95 % is 
bound to plasma proteins (Bekersky et al., 2002). In studies in renal cells, inhibition of 
LDL-AmB formation decreased toxicity (Barwicz et al., 1992), as did inhibition o f LDL 
receptor expression (Wasan et al., 1994). Similar to other polymer-drug conjugates, 
HPMA copolymer conjugation significantly reduced toxicity to THP-1 cells. Therefore, 
it could be that binding to LDL is inhibited. The reduction in non-specific toxicity 
should increase the anti-leishmanial specificity.
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The reduction in toxicity could also be due to polymer-bound AmB being 
sufficiently well hidden within the polymer coil to minimize membrane interaction. 
However, this does not prove that the AmB does not retain any activity when bound. 
Different mechanisms are thought to be responsible for cytotoxicity and anti- 
leishmanial activity. However activity is likely to be inhibited, as the amino group on 
the sugar to which the polymer is bound has been found to be essential to activity 
(Brajtburg et al., 1990). A rotatable p-glycosidic bond links the macrolide ring and the 
sugar, and the sugar orientation strongly affects the ergosterol selectivity and 
permeabilisation o f the membrane (Matsumori et al., 2005). Although there was still 
some toxicity seen with the conjugate, this was completely prevented when leupeptin 
was added to the incubation medium (Figure 6.12). Leupeptin had no effect after 24 h, 
but this is likely to be due to degradation of the leupeptin. Therefore, this indicates that 
drug release is essential for activity.
Toxicity o f AmB and its formulations is normally assessed in RBCs with no 
serum present. In studies on human RBCs, only the self-associated form of AmB caused 
K+ leakage and subsequent haemolysis (Legrand et al., 1992). Therefore the haemolysis 
caused by AmB was probably due to this aggregation rather than LDL binding and 
uptake. The absence o f haemolytic activity when incubated with the HPMA copolymer- 
AmB-Man conjugates further supported the conclusion that no free AmB was present. 
Although the UV absorbance studies showed the conjugates were in an aggregated state, 
this did not lead to toxicity. This property o f the conjugated drug may lessen the risk of 
severe hepatic toxicity. Next it was important to investigate the uptake, to see if the 
AmB conjugates retained the increased derived cell association in macrophages seen in 
HPMA copolymer-Man conjugates espite possible changes in conformation (Chapter 
4).
Increased cell surface binding o f the AmB conjugates was considered a 
possibility due to the high loading o f AmB. Also, the conformational change that may 
be induced by AmB conjugation may change the MR binding, the non-specific cell 
association and therefore the uptake. The conjugate solutions were standardised to 
contain the same amount o f OG, rather than the amount of AmB. However the actual
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amount o f AmB used was almost identical (18.8 wt % in HPMA copolymer-AmB 
compared to 18.7 wt % in HPMA copolymer-AmB-Man). When the derived cell 
association in TH P-ls was compared to that o f the conjugates studied in chapter 4 
(Figure 6.15), there was no difference between HPMA copolymer-OG-Man ± AmB, 
however there was a difference between HPMA copolymer-OG ± AmB. This would 
suggest that there was some enhanced non-specific binding or uptake due to the AmB, 
but this was not significant in comparison to the MR-specific uptake.
Specific uptake is likely to be related to efficacy. Heated Fungizone® showed 
higher uptake into macrophages, and was 2.5 times more effective against Leishmania 
donovani (but showed no difference in activity against fungal infections) (Cheron et al., 
2003). Interestingly, Ambisome® actually has lower uptake into J774 macrophages than 
other liposomal AmB formulations (Legrand et al., 1996). Therefore it is hoped that MR 
targeting can increase uptake in comparison to Ambisome® without increasing non­
specific toxicity, and result in greater activity.
Ambisome® is the gold standard o f anti-leishmanial treatment, where cost is not 
a factor. The prolonged circulation times mean Ambisome is passively targeted to the 
macrophages. However, AmB is also slowly released in the blood plasma over time 
(Bekersky et al., 2001). Therefore its activity is not constrained to inside the 
macrophage. Specific targeted release o f the drug from the HPMA copolymer-AmB- 
Man conjugates in the macrophage/PV may reduce the dose needed and result in even 
lower toxicities. However, further studies are needed on the pharmacokinetics of these 
conjugates before conclusions can be drawn.
The results from the cytotoxicity studies were used to determine concentrations 
and timings used for the SCF and confocal FM studies (0.1 mg/ml for 24 h). When 
Fungizone is administered in vitro only a small amount o f AmB administered actually 
gets to the lysosome after 1 h (Vertut-Doi et al., 1994). This is dependent on 
concentration as high concentrations can block endosome-lysosome fusion. This further 
emphasises that a specific delivery method is needed. The high localisation o f the 
HPMA copolymer-AmB-Man conjugate in lysosomes demonstrates the advantage of 
this system. Though the AmB was only partly found in the lysosomes using the SCF
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method (Figure 6.18), the microscopy showed there was a high concentration of 
conjugate in the lysosomes. If more time were available, further studies including a 
pulse-chase incubation with HPMA copolymer-AmB-Man would have been performed 
to try to further investigate the trafficking. Also, if a shorter time frame had been used 
e.g. 4 h, this would eliminate the possibility that the leupeptin was degraded.
As AmB acts on surface it might not need to be released as long as it is 
delivered to PV. However, if  there was inhibited fusion between the PV and the 
lysosome, then the drug must be able to diffuse across the vesicle membranes. For AmB 
this may lead to increased toxicity to the lysosomal membrane and lead to rupture of 
lysosomes. The studies with lysosomes discussed in section 5.1.1, and the microscopy 
studies showing HPMA copolymer-OG in close proximity to the parasite in the THP-1 
cells in chapter 5, suggest fusion would allow direct access to the PV for the conjugate. 
However, the intracellular trafficking of the HPMA copolymer-drug conjugates must be 
carefully examined, and highlights the need for studies in infected cells.
One o f the main difficulties of this study was that an accurate method for 
quantifying AmB was not available. Several attempts were made to measure AmB using 
dot blotting with an antibody against AmB. When calibrating the antibody, the method 
was found to be very sensitive, detecting both free AmB and HPMA copolymer-AmB- 
Man conjugates from - 0 . 1 - 5 0  pg/ml. However, difficulties arose when the fractions 
were blotted, giving a negative image on the film (clear spots rather than dark) (Figure 
6.20). If  more time were available, this method would be further investigated. 
Alternatively, the ideal quantitative method would have been to degrade the linker to 
then extract the free AmB and use the HPLC method to determine exact amounts of 
conjugate/AmB in each fraction.
Following this work, studies on efficacy would be needed, as well as studies on 
the intracellular trafficking in Leishmania-infected macrophages. A preliminary study 
on anti-leishmanial activity has been performed using these conjugates (by Karin 
Seifert, 2007, LSHTM). HPMA copolymer-AmB and HPMA copolymer-AmB-Man 
had significant anti-leishmanial activity (reduced infection completely at 0.56 pg/ml, 
and to -  20 % at 0.19 jug/ml) (Figures 6.21 and 6.22). The MR-targeted conjugate had
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• THP-1 cells differentiated
• Promastigotes at late stage (infective)
• Infected ration 10:1
• After 24h infection control checked
• Cells washed and AmB/Conjugate 
added (0.19-5 Mg/ml)
• After 72 h cells washed, MeOH fixed 
and stained with Giemsa (10% for 10m)
• Amastigote infected cells counted compared to 
negative control (100 %) and AmB-treated positive 
control (100 macrophages in quadruplate)
Figure 6.21 Scheme for investigation of efficacy of HPMA copolymer-AmB 
conjugates against Leishmania donovani-infected THP-1 cells.
I
I
\
228
100 n
AmB HPMA-AmB HPMA-AmB- HPMA-AP
M
Figure 6.22 Efficacy of HPM A copolymer-AmB conjugates against Leishmattia 
donovani-iniected  THP-1 cells. The amastigote infection level o f the THP-1 s was 
~ 50 %. 100 cells were counted per quadruplate and the data expressed as a 
percentage o f the control.
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slightly higher activity, possibly supporting the idea of greater uptake and therefore 
drug release. These studies were only preliminary and ongoing, further work is needed 
to confirm these results and explore these effects in more detail. For comparison, the 
ED50’s of Fungizone and Ambisome against Leishmania donovani against THP-1 cells 
were similar at 0.18 and 1 pg/ml (Yardley & Croft, 2000). However, it should be noted 
that these values differ depending on the cell line, and are also different in vivo (in PEM 
0.13 and 1.5; in vivo 0.21, 0.73).
6.5 Conclusions
In conclusion, HPMA copolymer-AmB-Man conjugates have been synthesised 
with enhanced solubility and stability in comparison to free AmB. These conjugates 
have reduced the haemolysis and the non-specific toxicity against the human 
macrophage model THP-1. Enhanced MR-specific derived cell association and 
macrophage uptake, as well as subsequent trafficking to lysosomes have been shown. In 
order to develop the HPMA copolymer-AmB-Man conjugates for treatment of 
leishmaniasis further characterisation of the conjugates is required. However, these 
preliminary results have demonstrated the potential o f these conjugates to provide a 
specific and potent treatment for leishmaniasis.
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7.1 Perspective and recent developments
Although the field o f polymer therapeutics is relatively new, there has been an 
exponential increase in research in this area over the last few years (Duncan et al., 
2006). This is presenting new opportunities to design novel, more therapeutically 
effective treatments for a number o f diseases including intracellular infections such as 
leishmaniasis. The original idea behind this project was the need for new anti- 
leishmanial therapies. The main drugs currently in use are more than 50 years old and 
the therapeutic scenario has actually worsened over this time due to emerging 
resistance. The number o f new drugs entering the pipeline is very low, mainly due to 
the lack o f funding. Despite tropical diseases such as malaria, trypanosomiasis, 
leishmaniasis and tuberculosis accounting for 5% of the global disease burden, they 
accounted for only 0.1 % drugs brought to market between 1996 and 2006 (Date et 
al., 2007). However, according to the WHO, leishmaniasis remains a major health 
problem, and the distribution if not the actual number o f cases has been on the 
increase since this study began (Boelaert, 2004).
Despite the numerous efforts to advance the diagnosis and treatment of 
Leishmania, there have been no significant advances. This situation has led to the 
formation o f several not-for-profit product-development partnerships (Drugs for 
Neglected Diseases initiative (DNDi), The Medicines for Malaria Venture the 
Institute for One World Health, and the WHO Tropical Diseases Research Programme 
(TDR)). Specific initiatives include the clinical trials platform being organized by the 
DNDi in the Horn o f Africa; and the draft agreement between the Bill and Melinda 
Gates Foundation and One World Health to carry out phase III/IV trials of 
paromomycin in India (Sundar et al., 2007). In 2005 health ministers formulated an 
ambitious VL elimination programme in the Indian subcontinent (Bhattacharya et al.,
2006), spurred by the fact that, in this area, humans are the only reservoir and 
phlebotomus argentipes the only vector. However, the situation is less favourable in 
other areas and all these drugs have significant drawbacks.
A further boost to the anti-leishmanial effort came when some pharmaceutical 
companies agreed to reduce the prices o f their drugs. An agreement between the 
WHO and Vestar in 2007 led to preferential pricing o f Ambisome for VL patients of 
10 GBP per 50 mg vial (as opposed to 96.69 GBP (BNF 2006)). However this price is 
valid for VL patients treated by not-for-profit organisations in East Africa only. The
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Medecins Sans Frontieres (MSF) claims that this is not enough to make Ambisome a 
cost effective alternative: “This is a significant and welcome reduction o f the current 
private market price. However, treatment o f VL with L-AMB according to WHO is 
done with a total dose o f 20 mg/kg, with a flexible dosing schedule but an initial dose 
o f at least 5 mg/kg. With the reduced price, for a patient of 35 kg, a full course with a 
total dose o f 20 mg/kg still costs US$280. This price is too high for implementation in 
treatment programmes in developing countries.”
Although considerable progress has been made in basic research into the 
biology o f Leishmania, for example the Leishmania Genome Network has recently 
mapped the genome o f Leishmania major (Ivens et al., 2005), the research in the area 
o f therapeutics has not been so productive. However, the fact that since this study 
began, in 2004, no new anti-leishmanial therapies have been introduced to the market, 
makes polymer-drug conjugates o f existing drugs a very interesting option for 
investigation. Since 2004, the number o f polymer therapeutics entering clinical trials 
has increased greatly, and the continued clinical trials o f HPMA copolymer-drug 
conjugates, including the targeted polymer drug conjugate PK2, have encouraged 
further research into novel therapeutics including for infectious agents.
7.2 Critical evaluation of study and future work
The design o f the novel HPMA copolymer conjugates able to target anti- 
leishmanial drugs to the macrophage could contribute significantly, and provide 
improved therapeutics, less toxic than existing drugs and also better able to overcome 
resistance. One aim o f this study was to design the HPMA copolymer-AmB-Man 
conjugates with increased macrophage targeting and reduced non-specific toxicity, 
and to eventually produce a candidate for clinical trial. A second objective was to 
investigate the in vitro intracellular trafficking o f the conjugate and drug in uninfected 
macrophages. Therefore, a large amount o f the work was establishing methods that 
could be used to study polymer therapeutics, specifically setting up the macrophage 
models, and the fluorescence microscopy and SCF methods.
Initial studies demonstrated that the THP-1 cell line was a suitable model for 
use in these mannose-targeting studies; expressing MR in sufficient numbers to study 
receptor specific targeting of polymer conjugates (Chapter 3). HPMA copolymer-Man
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endocytosis was proportional to sugar content with a threshold o f 4 mol % needed to 
achieve reproducible targeting to the THP-1 macrophages over the control conjugate 
(Chapter 4). A novel quantitative fractionation method was developed for THP-1 
cells, along with a confocal microscopy method, which could be used to investigate 
time-dependent trafficking o f HPMA copolymer conjugates (Richardson et al., 2008; 
Wallom et al., 2008) (Chapter 5). Using this SCF method, the lysosomotropic delivery 
o f HPMA copolymer-OG-Man and the release of GFLG bound OG could be 
demonstrated. The established methods have the potential to be applied to the study of 
a variety o f polymer therapeutics.
Finally, the first HPMA copolymer-AmB-Man conjugates were synthesised 
and investigation into their activity demonstrated reduced haemolysis and toxicity 
against the human macrophage model THP-1 (Chapter 6). Uptake and trafficking 
studies showed enhanced cell association, macrophage uptake and trafficking to 
lysosomes. However, one o f the challenges o f this method was achieving truly 
quantitative analysis o f drug trafficking. The difficulty in measuring fluorescence or 
absorbance in a biological situation was a disadvantage. Had more time been 
available, methods would have been established to measure the absolute amounts o f 
conjugate or AmB in the fractions. These studies have, though, begun to demonstrate 
the potential o f these conjugates to provide a highly specific and effective treatment 
for leishmaniasis.
These results have underlined the advantages o f using polymer-drug 
conjugates for the treatment o f leishmaniasis, but have also highlighted a number of 
remaining questions. Further studies are needed to investigate the trafficking o f the 
conjugates in infected cells to establish the localisation in relation to the parasite. The 
SCF method established in THP-1 cells here would have to be further optimised for 
infected cells, and the PV distinguished from the lysosomes. Although the current 
studies have demonstrated trafficking to the lysosomes in uninfected cells, in infected 
cells the likely altered trafficking o f the conjugates could have a drastic effect on the 
original hypothesis. Few studies have attempted to study subcellular fractionation o f 
Leishmania-infected macrophage cells (Kima & Dunn, 2005). None, to the author’s 
knowledge, have studied intracellular trafficking o f polymer drug conjugates in 
infected macrophages. However, current work at the LSHTM is developing this 
method in infected cells.
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This research was necessarily informed by the success o f Ambisome®, the 
current gold standard o f treatment when cost is not a factor. AmB was a good choice 
for conjugation to HPMA copolymer, achieving a high loading o f 16 - 19 wt%, in 
comparison to 12.5 wt% in Ambisome®. It is highly potent; preliminary activity 
studies showed that HPMA copolymer-AmB-Man conjugate (AmB dose o f 0.56 
pg/ml) produced almost 100 % parasite inhibition in Leishmania donovani-mfQctzd 
THP-1 cells, yet no non-specific toxicity against the macrophage at this dose. These 
results compare favourably with in vitro studies on Ambisome®, which had an IC50 o f 
1 pg/ml (Yardley & Croft, 2000) and show that HPMA copolymer-Man conjugates 
could provide a viable alternative. Whether activity could be increased beyond that of 
Ambisome® is beyond the scope o f this study. Further studies on the in vivo activity 
are needed, as in vitro studies are limited as they do not take into account the different 
whole-body pharmacokinetics associated with polymer-drug conjugates.
To fully characterise the HPMA copolymer-AmB-Man conjugates and obtain 
a potential clinical candidate, pharmacokinetic studies would be needed to optimise 
the conjugate in vitro. Firstly, investigation of the polymer-drug linker to ensure 
optimal rates o f intracellular release within the vacuole would be essential. Secondly, 
in vivo studies would be needed to ensure 4 mol % was still enough for targeting, and 
to establish pre-clinical activity and dosage data particularly in comparison to 
Ambisome®.
7.3 Potential applications for future development
Even if  the afore-mentioned studies showed that HPMA copolymer-AmB- 
Man was highly effective against leishmaniasis, the potential for future development 
as an anti-leishmanial therapy will depend on a variety o f factors such as the cost and 
patient compliance. Although formulated for IV administration, polymer drug 
conjugates are designed for long plasma circulation times, hence less frequent 
injections are needed. Interestingly, trials o f single dose Ambisome® treatment with a 
90 % cure rate have been reported (Sundar et al., 2001). A similar single dosage o f the 
HPMA copolymer-AmB-Man conjugates could ensure high patient compliance and 
greatly reduce cost. Also, specific MR targeting reducing non-specific uptake could 
further reduce the required dose. Together, polymer-drug conjugates have the
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potential advantage o f reduced side effects, shorter treatment cycles and reduced dose, 
therefore increasing patient compliance and significantly reducing costs. The 
important comparison is against Ambisome®. Whether HPMA copolymer conjugates 
will be cheaper is difficult to calculate, however the active targeting could potentially 
decrease the dose needed in comparison to Ambisome®.
MSF suggest combination therapy could bring the price per treatment down 
but there is little data on combination therapies with Ambisome®. Combination 
therapy is desirable when resistance is a problem and this can be achieved neatly with 
a polymer conjugate. Indeed, recent studies have shown the potential breast cancer 
therapeutic HPMA copolymer-Dox-AGM conjugate has markedly enhanced 
cytotoxicity in vitro compared to HPMA copolymer-Dox, although mixtures o f the 
two single drug conjugates did not have a synergistic effect (Greco et al., 2007; 
Vicent et al., 2005).
The choice o f drug will be very important. The drug release rates o f HPMA 
copolymer conjugates with a GFLG linker vary considerably depending on the drug 
conjugated and can greatly affect the activity. Combinations o f drugs in simple 
mixtures may not necessarily improve the therapeutic effectiveness. Indeed the 
activity when mixed is likely to be very different to the activity when administered on 
the same polymeric chain. Miltefosine and AmB have shown synergy (Jha, 2006).The 
long Vi life (150h) o f miltefosine means it needs careful regulation to prevent 
resistance developing (Chappuis et al., 2007). However, combination may reduce the 
treatment duration and prevent resistance (Bryceson, 2001). Paromomycin is 
attractive due to its low cost (US$10-20 per course), though side effects such as 
nephrotoxicity may limit its use. VL patients often have additional bacterial 
infections, and paromomycin has the advantage o f being active against a number of 
bacterial infections. The current emerging problem of co-infection with HIV would 
benefit from intracellular delivery as well as combination therapy. Alternatively, the 
emergence o f several new classes of drugs, for example dihydrofolate reductase 
inhibitors that have lower efficacy in vivo, presents an opportunity to generate several 
novel therapeutics.
Possible alternative applications of HPMA copolymer-Man’s macrophage 
targeting, and the ability to tailor the intracellular trafficking and release o f this sort of
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system, are numerous. As discussed earlier, macrophages play a critically important 
role in host defence against many infectious agents, including bacteria, virus and 
parasites (Ahsan et al., 2002). Macrophages are also host’s frontline defense against 
tumour cells. Therefore, targeting o f drugs to macrophages could be an effective 
strategy for treatment o f a variety o f infectious diseases including schistosomiasis, 
leishmaniasis, brucellosis, salmonellosis, cancer, HIV, tuberculosis, influenza, herpes 
simplex e.g. in transplant patients, as well as rheumatoid arthritis, systemic lupus 
erythematosus, multiple sclerosis, enzyme replacement therapy e.g. gaucher disease. 
Since this study began, Ghandahari et al. have begun to develop the HPMA 
copolymer-Man platform for imaging, conjugating gadolinium for enhanced MRI of 
macrophages (Zarabi et al., 2006).
In conclusion, the presented work has advanced the methods needed for the 
design and the development o f the ideal anti-leishmanial therapy. MR-targeted 
HPMA copolymer-AmB conjugates have shown potential for macrophage targeting 
and delivery to specific intracellular compartments. In addition, novel methods for 
investigating polymer therapeutics have been developed.
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